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ABSTRACT 
 
Mutations of the WFS1 gene are responsible for most cases of Wolfram syndrome (WS), a 
rare, recessively inherited neurodegenerative disorder characterised by juvenile-onset non-
autoimmune diabetes mellitus and optic atrophy. Variants of WFS1 are also associated with 
non-syndromic hearing loss and type-2 diabetes.  
 
Understanding the function of the WFS1 protein-product wolframin, would enable 
developments in targeted therapy for WS patients and important insights to its possible 
contribution to type-2 diabetes pathogenesis. This study was aimed at expanding the 
spectrum of WS-associated genetic mutations and clinical data, and investigating the 
molecular mechanisms responsible for phenotypic variation associated with WFS1-
mutation.  
 
The mutational and phenotypic spectrum of WS is broadened by our report of novel WFS1 
mutations and a case of WFS2-associated WS. New perspectives on the molecular 
mechanisms linking mutation to disease manifestation are also taken by characterisation of 
representative WFS1 mutations specific to phenotype, identification of potentially novel 
WFS1 interacting partners, and the first evidence linking WFS1 with the exocrine pancreas. 
Our data suggests that some WFS1-mutations may allow residual protein function and these 
findings lay the groundwork for future functional investigation of mutated wolframin to 
explore this hypothesis further.   
 
  
This thesis is dedicated to the memory of 
 
 
 
 
 
Mark Anthony Pallas 
12th November 1970 - 28th January 2010 
 
 
 
 
 
Thank you for sharing your wonderful father with us x 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
I would like to acknowledge my supervisor Professor Tim Barrett without whom this work 
would not have been possible. Many thanks for all the patience and support. 
Special thanks also go to Dr Malgosia Zatyka, who has been an invaluable mentor in the 
laboratory throughout my time in Birmingham. She is a meticulous, hard-working person 
and a fine example of the kind of scientist I’d like to be. 
The rest of the Medical and Molecular Genetics laboratory members are also acknowledged 
not only for their technical expertise and help, but also for their friendship, humour and 
oftentimes emotional support. A particular mention must go to: Dr Christopher Ricketts, Dr 
Mark Morris, Dr Dewi Astuti, Dr Christopher Bruce, Dr Ania Straatman-Iwanowska and Dr 
Stephen Jacques. 
Outside of the laboratory I have had the tremendous support and camaraderie of my pals in 
the Molecular Neuroscience Group with whom I’ve shared some memorable times and 
some great laughs. I’m happy to say I have gained some life-long friends.  
I would like to extend my eternal gratitude to my family and partner Robert. I am lucky 
enough to have the most supportive and loving parents and an inspirational step-father who 
has always had faith in me. I would not have gotten through the last year without Robert to 
hold my hand and my little angels Maggie and Brooke.  
Finally, I would like to acknowledge the Medical Research Council for providing funding for 
this work 
CONTENTS 
CHAPTER 1 
INTRODUCTION 
 
1.0.0. Diabetes mellitus…………………………………………………………………………………………………………………………………....1                  
1.0.1. Prevalence and burden of diabetes mellitus………………………………………………………………………………….………..2 
1.1.0. Aetiology of diabetes mellitus………………………………………………………………………………………………………………….2 
1.1.1. Type 1 diabetes mellitus…………………………………………………………………………………………………………..……………..4 
1.1.2. Type 2 diabetes mellitus…………………………………………………………………………………………………..……………………..4 
1.1.3. Other types of diabetes…………………………………………………………………………………………………………….…………….5 
1.2.0. Diabetes prevention and treatment ……………………………………………………………………….……………………………….6 
1.3.0. Wolfram syndrome………………………………………………………………………………………………………….…………………….10 
1.3.1. Genetics of Wolfram syndrome…………………………………………………………………………………………….……………….11 
1.3.2. WFS1…………………………………………………………………………………………………………………………..…………………………12 
1.3.3. Wolframin…………………………………………………………………………………………………………………………………….……….13 
1.4.0. Wolframin function……………………………………………………………………………………………………………………………….15 
1.4.1. Wolframin, insulin secretion and Ca2+ homeostasis………………………………………………………………………………16 
1.4.2. Wolframin and cell proliferation………………………………………………………………………………………………..………….19 
1.5.0. Endoplasmic reticulum stress………………………………………………………………………………………………………….…….19 
1.5.1. ER stress sensors……………………………………………………………………………………………………………………………..…….20 
1.5.2. ER stress and apoptosis………………………………………………………………………………………………………………………….24 
1.5.3. ER stress and diabetes……………………………………………………………………………………………………………….………….26  
1.5.4. Wolfram syndrome and ER stress………………………………………………………………………………………………………….28 
1.6.0. WFS2……………………………………………………………………………………………………………………………………………….…….31 
1.7.0. Understanding Wolfram syndrome pathogenesis and the role of WFS1 in type 2 diabetes……………………33 
 
 
CHAPTER 2 
MATERIALS AND METHODS 
 
2.0.0. Suppliers of laboratory materials………………………………………………………………………………………………………..…37 
2.0.1. Patient DNA samples and clinical data……………………………………………………………………………………………………37 
2.0.2. Cell lines…………………………………………………………………………………………………………………………………………………38 
2.1.0. DNA amplification………………………………………………………………………………………………………………….………………38 
2.1.1. Genomic DNA PCR…………………………………………………………………………………………………………………………………39 
Components, conditions, optimisation, primers 
2.1.2. Reverse-transcription PCR…………………………………………………………………………………………………..…………………42 
 Promega Reverse Transcription System… 
Applied Biosystems High Capacity cDNA Reverse Transcription kit 
2.1.3. Real-time PCR/Quantitative PCR (Q-PCR)………………………………………………………………………….……………………43 
2.2.0. Restriction Digestion………………………………………………………………………………………………………………………………46 
2.3.0. Agarose gel electrophoresis……………………………………………………………………………………………..………..…………46 
2.3.1. Agarose gel extraction……………………………………………………………………………………………………..……………………47 
2.4.0. Sequencing…………………………………………………………………………………………………………………………….………………48 
DNA cleanup, sequencing reaction, ethanol precipitation, sequencing analysis 
2.5.0. Microsatellite marker analysis………………………………………………………………………………………………….……………50 
2.6.0. Site-directed mutagenesis……………………………………………………………………………………………………………………52 
Mutagenic primer design, mutagenesis reaction, Dpn1 digestion, Transformation of XL1- Blue Supercompetent 
Cells 
2.7.0. Microbial cell culture and manipulation…………………………………………………………………………………..……………55 
2.7.1. Long-term storage and revival of bacteria………………………………………………………………………………………..……56 
2.7.2. Preparation of Luria-Bertani (LB) broth and agar plates…………………………………………………………………………57 
Selection additives, antibiotics, X-Gal, IPTG 
2.7.3. General culture and selection of bacterial cells………………………………………………………………………………………59 
Growth on agar plates and selection of clones, growth in liquid culture 
2.7.4. Transformation of bacterial cells (cellular cloning) ……………………………………………………………..…………………60 
Chemical transformation, electroporation 
2.7.5. Extraction of plasmid DNA from bacterial cells………………………………………………………………………………………63 
QIAprep Spin Miniprep Kit, QIAgen Plasmid Maxi Kit 
2.8.0. Yeast cell culture and manipulation………………………………………………………………………………………….……………66 
2.8.1. General cell culture and selection of yeast cells………………………………………………………………………….…………66 
2.8.2. Preparation of YPD broth and agar plates………………………………………………………………………………………………67 
Selective drop-out media (SDM), X-α-Gal/IPTG indicator plates 
2.8.3. Long-term storage and recovery of yeast………………………………………………………………………………………………68 
2.8.4. Transformation of yeast…………………………………………………………………………………………………………………………69 
2.8.5. Isolation of DNA from yeast…………………………………………………………………………………………………..………………70 
2.9.0. Mammalian cell culture and manipulation…………………………………………………………….………………………………71 
2.9.1. General tissue culture……………………………………………………………………………………………………………………………71 
Cell maintenance and propagation 
2.9.2. Freezing cells for long-term storage………………………………………………………………………….……………………………72 
2.9.3. Reviving frozen cells………………………………………………………………………………………………………………………………74 
2.9.4. Cell counting………………………………………………………………………………………………………………………………….………74 
2.9.5. Transfection……………………………………………………………………………………………….……………………….…………………74 
2.10.0. Harvesting cells for protein and RNA extraction………………………………………………..…………………………………75 
2.10.1. Protein extraction…………………………………………………………………………………………………………..……………………75 
2.10.2. RNA extraction…………………………………………………………………………………………………………………….………………77 
Harvesting with TRIzol, RNeasy 
2.11.0. Protein quantification……………………………………………………………………………………………………………….…………80 
2.12.0. RNA/DNA quantification………………………………………………………………………………………………………………………81 
2.13.0. Polyacrylamide gel electrophoresis and Western-blotting……………………………………………………………………81 
2.13.1. Preparation of polyacrylamide gel……………………………………………………………………….………………………………82 
2.13.2. Loading samples and running gel…………………………………………………………………………………………………………82 
2.13.3. Western blotting……………………………………………………………………………………………………………………….…………83 
2.13.4. Developing western blots………………………………………………………………………………………………………….…………86 
2.13.5. Quantitative analysis of protein expression values………………………………………………………………………………87 
2.14.0. Co-Immunoprecipitation……………………………………………….……………………………………………………….……………87 
2.14.1. Pre-clearing cell lysates……………………………………………………………………………………………………….………………88 
2.14.2. Immunoprecipitation…………………………………………………………………………………………………………………..………89 
2.14.3. Eluting ‘pulled-down’ protein………………………………………………………………………………………………………………90 
2.14.4. Detection of precipitated protein-complexes………………………………………………………………………………………90 
2.15.0. Immunocytochemistry………………………………………………………………………………………………………………..………91 
2.15.1. Cell culture……………………………………………………………………………………………………………………….…………………91 
2.15.2. Fixation……………………………………………………………………………………………………………………………….………………91 
2.15.3. Staining…………………………………………………………………………………………………………………………………….…………92 
2.15.4. Mounting……………………………………………………………………………………………………………………………..…….………93 
2.16.0. Immunohistochemistry………………………………………………………………………………………………..…………….………93 
2.16.1 Tissue preparation…………………………………………………………………………………………………………………..…….……93 
2.16.2 Fixation and staining……………………………………………………………………………………………………………..……….……94 
2.17.0. Fluorescent microscopy………………………………………………………………………….………………………….………….……95 
2.18.0. Measuring protein stability with cyclohexamide………………………………………………………………………………….95 
2.19.0. Molecular cloning………………………………………………………………………………………………….…………………..….……97 
2.19.1. Obtaining and verifying starting material……………………………………………………………………………………………97 
2.19.2. PCR amplification of DNA fragments/genes………………………………………………………………..………………………98 
2.19.3. Restriction digestion/ligation……………………………………………………………..………………………..……………………101 
2.19.4. Intermediate vectors…………………………………………………………………………………………………………….……………102 
pGEM-T, blunt-end ligation, cloneJET, sticky-end ligation 
2.19.5. Transformation, selection and small-scale culture plasmid extraction…………………….…………………………105 
2.19.6. Verification of clones…………………………………………………………………………………………………………………………105 
2.19.7. Re-transformation, selection and large-scale culture plasmid extraction……………………………..……………106 
2.20.0. Bioinformatics……………………………………………………………………………………………………………………………………108 
CHAPTER 3 
MUTATION ANALYSIS OF WOLFRAM SYNDROME PATIENTS 
 
3.0. Introduction……………………………………………………………………………………………………………………………………………109 
3.1.0. Specific aims and approach……………………………………………………………………………….…………………………………111 
3.2.0. Mutation analysis of WFS1………………………………………………………………………………………..…………………………111 
3.2.1. Novel WFS1 mutations…………………………………………………………………………………………………..……………………116 
3.2.2. Patient Clinical Data…………………………………………………………………………………………………………….………………117 
3.3.0. Mutation analysis of WFS2 (Zcd2) …………………………………………………………………………………….…………………119 
3.3.1. Clinical information …………………………………………………………………………………………….………………………………123 
3.3.2. Haplotype analysis ………………………………………………………………………………………………………..….…………………125 
3.4.0. Mutation analysis of ATP1B1………………………………………………………………………………………………….……………125 
3.5.0. Mutation analysis of SLC19A2 …………………………………………………………………………………………………..…………126 
3.5.1. Confirmation of inactivating SLC19A2 mutation in patient with TRMA phenotype………………………………128 
3.6.0. Sequencing analysis summary………………………………………………………………………………………………..……………130 
3.7.0. Genotype-phenotype correlation……………………………………………………………………………..…………………………132 
3.8.0. Summary and discussion……………………………………………………………………………………………………..………………137 
3.8.1. Further work……………………………………………………………………………………………………………..…………………………139 
 
CHAPTER 4 
CHARACTERISATION AND FUNCTIONAL ANALYSIS OF SELECTED WFS1 VARIANTS 
 
4.0  Introduction and aims…………………………………………………………………………………………….………………………………141 
4.1.0  Selection of WFS1 gene mutations………………………………………………………………………………………………………144 
4.1.1 Clinical information……………………………………………………………………………………………………………….………………145 
4.1.2  Physio-chemical properties of WFS1 missense mutations……………………………………………………………………149 
4.1.3 Bioinformatic analysis of WFS1 missense mutations…………………………………………………………….………………153 
4.2.0 Cloning and site-directed mutagenesis of WFS1……………………………………………………………………………………157 
4.3.0 Steady-state expression of WFS1 mutants……………………………………………………………………………………….……160 
4.3.1 Specific aims and methods……………………………………………………………………………………………………………………160 
4.3.2  Steady-state expression of WFS1 mutants harvested in RIPA buffer…………………….………………………………161 
4.3.3  Antibody specificity……………………………………………………………………………………………………………..………………164 
4.3.4  Quality of plasmid DNA preparations…………………………………………………………………………………………..………165 
4.3.5  Differences in wolframin solubility………………………………………………………………………………………………………167 
4.3.6  Crude measures of WFS1 solubility in RIPA buffer……………………………………………………………….………………168 
4.3.7  Steady-state expression of WFS1 variants harvested in Laemmli buffer………………………………………………171 
4.3.8  Summary and discussion………………………………………………………………………………………………………………………175 
4.4.0  Comparative stability of wild-type and selected WFS1 variants……………………………………………………………177 
4.4.0  Background and aims………………………………………………………………………………………………..…………………………177 
4.4.1  Specific methods and approach……………………………………………………………………………………………………………178 
4.4.2  Pilot experiments and method development……………………………………………………………………………….………180 
4.4.3  Pilot Results…………………………………………………………………………………………………………………………………………181 
4.5.0  Relative stability of WFS1-variants……………………………………………………………………………………………..………..186 
4.5.1  There are no significant differences in stability between wild-type wolframin, WFS1-L511P and WFS1-
R611H…………………………………………………………………………………………………………………………………………….………..……186 
4.5.2  Summary and discussion………………………………………………………………………………………………………………………192 
4.6.0  Comparative mRNA levels of wild-type-WFS1 and WFS1-L511P……………………………………………………..……195 
4.6.1  Background and aims…………………………………………………………………………………………………………………..………195 
4.6.2  Specific methods and approach……………………………………………………………………………………………………………195 
4.6.3  Results……………………………………………………………………………………………………………………………………….……..…196 
4.6.4  Summary/conclusions………………………………………………………………………………………….………………………………200 
4.7.0  Localisation of WFS1 variants………………………………………………………………………………………………………………201 
4.7.1  Background and aims………………………………………………………………………………………………………………….………201 
4.7.2  Specific methods…………………………………………………………………………………………………………………………………202 
4.7.3  Pilot experiments…………………………………………………………………………………………………………………..……………202 
4.7.4  Choice of cell line…………………………………………………………………………………………………………………………………203 
4.7.5  Antibody optimisation and transfection……………………………………………………………………….………………………205 
4.7.6  Detection of endogenous and over-expressed WFS1……………………………………………………………………………206 
4.7.7  Negative control experiments………………………………………………………………………………………………………………208 
Severely truncated WFS1 products do not localise correctly to the ER membrane 
4.7.8  Localisation of WFS1 variants………………………………………………………………………………………………………………214 
The WFS1-L511P variant appears to cause a degree of protein aggregation in vitro whereas other selected 
WFS1 missense variants have the capacity to co-localise correctly to the ER.  
4.7.9  Summary and discussion………………………………………………………………………………………………………..……………220 
4.8.0  Chapter summary…………………………………………………………………………………………………………………………………221 
 
CHAPTER 5 
IDENTIFYING WFS1 MOLECULAR PARTNERS 
5.0.0 Introduction………………………………………………………………………………………………………………………………….…..…224 
5.0.1  The yeast two-hybrid system……………………………………………………………………………………….………………………225 
5.0.2  Molecular partners of wolframin…………………………………………………………………………………………………………227 
5.1.0  Specific aims and methods…………………………………………………………………………………………..………………………229 
5.2.0  Isolation and identification of DNA from positive yeast two-hybrid clones…………………………………………..232 
5.3.0  Confirming protein interactions in yeast………………………………………………………………………………………………237 
5.4.0  Expression of WFS1 in exocrine tissue……………………………………………………………………………………….…………240 
5.4.1  Analysis of WFS1 mRNA and protein in rat Acinar cells……………………………………………………….……………….241 
5.4.2 Immunohistochemical analysis of rat pancreata……………………………………………………….…………………...…….244 
5.5.0  Cloning genes for proposed WFS1-partners to mammalian expression vectors……………………………………249 
5.6.0  Transfection and over-expression of WFS1 and candidate partner-proteins in mammalian cells…………251 
5.6.1  Method Development………………………………………………………………………………………………………………….………251 
5.6.2  Over-expression of WFS1 and proposed molecular partners (CLPS, PNLIP, REG1A, CPB1) …………..………253 
5.7.0  Co-immunoprecipitation of over-expressed WFS1 and proposed molecular partners …………………………262 
5.7.1  Specific methods……………………………………………………………………………………………………………….…………...……262 
5.7.2  Co-IP of WFS1-CLPS………………………………………………………………………………………………………………………………264 
5.7.3  Co-IP of WFS1-REG1A………………………………………………………………………………………………………………………..…268 
5.7.4  Co-IP of WFS1-CPB1………………………………………………………………………………………………………………………..……270 
5.8.0  Ongoing and further work ………………………………………………………………………………………………………………..…271 
5.8.0  Protein solubilisation……………………………………………………………………………………………………………………………271 
5.8.1  Optimising Co-IP conditions ……………………………………………………………………………………………………………..…271 
5.8.2  Alternative approaches for confirming protein interactions in mammalian systems……………………………273 
5.9.0  Summary and discussion………………………………………………………………………………………………………………………274 
 
CHAPTER 6 
GENERAL DISCUSSION 
 
6.0.0  Thesis summary…………………………………………………………………………………………………………………………………..278 
6.1.0  Future directions…………………………………………………………………………………………………………………..……………..283 
6.1.1  Wolframin depletion………………………………………………………………………………………………………………….………..284 
6.1.2 Testing the model………………………………………………………………………………………………………………….……………..286 
6.1.3  Wolframin functional assays………………………………………………………………………………………………………………..287 
6.2.0  Conclusions……………………………………………………………………………………………………………………………………..…..289 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES 
 
CHAPTER 1 
1.0. Etiological classification of diabetes…………………………………………………………………….……………………………………..3 
1.1. Genetic loci associated with type 2 diabetes predisposition……………………………………………………….………………9 
1.2. Natural history of Wolfram syndrome………………………………………………………………………………………………………10 
1.3. Hypothetical structure of the wolframin protein………………………………………………………………………………………15 
1.4. Glucose-stimulated insulin secretion………………………………………………………………………………………………..………18 
1.5. ER stress pathways……………………………………………………………………………………………………………………………………22 
CHAPTER 2 
2.0. Essential steps for storage and handling of E. coli strains…………………………………………………………………………56 
2.1. Primer design for insertion of restriction sites during PCR.…………………….………………………………….……………100 
2.2. Intermediate cloning vector maps for pGEM-T (Promega) and pJET1.2 (Fermentas) ………..………….……..…103 
2.3. Principle steps in molecular cloning.………………………………………………………………………………………………....……107 
 
CHAPTER 3 
3.0-2. Electropherograms illustrating WFS1 mutations …………………………………………………………………………113-115 
3.3. Location of mutations across the wolframin protein. ………………………………………………………………….…………116 
3.4. Conservation of WFS1 residues across species…………………………………………………………….…………………………118 
3.5. Mutation of WFS2………………………………………………………………………………………………………………..…………………119 
3.6. Abolition of Xmn1 restriction site by WFS2-mutation……………………………………………………………………..………120 
3.7. Splicing aberration caused by WFS2-mutation………………………………………………………………………………..………122 
3.8. Mutation of SLC19A2………………………………………………………………………………………………………………………………128 
3.9. Summary of WS mutation analysis………………………………………………………………………….………………………………131 
3.10. Proportions of mutation-types found in the West Midlands cohort (n=93) ……………….…………………………133 
3.11. Genotype-phenotype correlation in WS…………………………………………………………………………………..……………136 
 
 CHAPTER 4 
4.0. Dot diagram showing the predicted amino acid configuration of the wolframin protein and location of 
selected sequence variants……………………………………………………………………………………………………………………………150  
4.1. Conservation of selected WFS1 amino acids across species ……………………………………………………………………154 
4.2. Cloning of human WFS1 into mammalian expression vector pcDNA3.1(+)………………………………………………158 
4.3. Site-directed mutagenesis of human WFS1……………………………………………………………………………….……………159 
4.4 Steady-state expression WFS1 variants harvested in RIPA buffer…………………………………………………….………162 
4.5. Mean steady-state expression WFS1 mutants relative to wild-type (set 1) ………………………….…………………163 
4.6. Mean steady-state expression WFS1 mutants relative to wild-type (set 2) ………………………………….…………166 
4.7. Relative steady-state expression of WFS1 mutants in both soluble and insoluble fractions of RIPA buffer 
lysates……………………………………………………………………………………………………………………………………………………………169 
4.8. Steady-state expression WFS1 variants in the soluble and insoluble fractions of RIPA buffer lysate………171 
4.9. Steady-state expression WFS1 variants harvested in Laemmli buffer………………………………………………..……172 
4.10. Mean steady-state expression WFS1 variants relative to wild-type………………………………………………………174 
4.11-13. Cyclohexamide pilot experiments over a 48 hour chase period……………………………………………….……181-4 
4.14. Pilot data (n=2/3) of relative stability of WFS1 variants 6 hours following 100µM cyclohexamide 
treatment………………………………………………………………………………………………………………………………………………………185 
4.15. Relative stability of endogenous and over-expressed WFS1 following 100µM cyclohexamide 
treatment………………………………………………………………………………………………………………………………………………………187 
4.16. Relative stability of wild-type WFS1 and WFS1-N term only mutant following 100µM cyclohexamide 
treatment………………………………………………………………………………………………………………………………………………………188 
4.17. Relative stability of wild-type WFS1 and WFS1 variants following 100µM cyclohexamide treatment……189 
4.18. Immunoblot analysis of the stability of WFS1 variants following 100µM cyclohexamide 
treatment………………………………………………………………………………………………………………………………………………………190 
4.19. Relative expression of WFS1 variants 6 hours following cyclohexamide treatment (n=3/4).  
………………………………………………………………………………………………………………………………………………………………………191 
4.20. Relative mRNA expression of wild-type and mutated WFS1 (n=12) measured by Real-time 
PCR……………………………………………………………………………………………………………………………………..…………………………198 
4.21. Relative mRNA expression of WFS1 variants (n=12) measured by Real-time PCR. …………..……………………199 
4.22. Cells fixed and stained with anti-PDI or anti-WFS1 Ig…………………………………………….………………………………204 
4.23. COS7 and HEK293 cell lines fixed and stained with anti-WFS1………………………………………………………………205 
4.24. COS7 cells stained with anti-WFS1 Ig……………………………………….……………………………………………………………207 
4.25. Co-staining of COS7 cells with anti-WFS1 and anti-PDI Igs………………………………………………………….…………209 
4.26. COS7 cells over-expressing tagged (myc) or untagged WFS1…………………………………………………………………211 
4.27A-B. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs…………………….………………………………212 
4.27C-D. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs……………………….……………………………213 
4.28. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (wt-WFS1, E158K) ……………………….……215 
4.29. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (R558H, R611H) ………..………………………216 
4.30. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (G736A, E737K)…………………………………217 
4.31. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (R818C) …………….………………………………218 
4.32. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (L511P) ….…………………………………………219 
 
CHAPTER 5 
5.0. Principles of the yeast two-hybrid assay…………………………………………………………………………………………………226  
5.1. Methods workflow……………………………………………………………………………………………………………………………….…231 
5.2. MATCHMAKER GAL4 Two-Hybrid System 3………………………………………………………………………………….…………238 
5.3. Re-testing positive interactions in yeast…………………………………………………………………………………………….……239 
5.4. Expression of WFS1 RNA in exocrine cells…………………………………………………………………………………….…………242 
5.5. Qualitative analysis of WFS1 expression in exocrine cells………………………………………………………….……………243 
5.6. Histology of the pancreas……………………………………………………………………………………………………………………….245 
5.7-8. Immunohistochemical analysis of rat pancreas sections………………………………………………………….……247-248 
5.9. Cloning methods for selected WFS1-partner candidates…………………………………………………………………………250 
5.10. Method development………………………………………………………………………………………………………………………..…252 
5.11. Method development - Testing different post-transfection incubation times……………………………….………254 
5.12. Method development – Comparison of expression in host cell lines………………………………………………….…255 
5.13. Expression of WFS1 and CLPS in HEK293 cells………………………………………………………..…………………………..…256 
5.14. Method development- Comparison of REG1A expression in lysate supernatant and pellets…………………258 
5.15. Method development – Expression of CPB1-HA in HEK293 cells…………………………………………………..………259 
5.16. Method development - Expression of PNLIP-HA and WFS1-Myc in HEK293 cells………………………………..…260 
5.17. Principles of indirect co-immunoprecipitation………………………………………………………………………………..……263 
5.18-21. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and colipase (CLPS-HA) ………………..265-268 
5.22. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and pancreatic stone protein (REG1A-
HA)………………………………………………………………………………………………………………………………………………………………..269 
5.23. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and carboxypeptidase B1 (CPB1-HA)...………270 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF TABLES 
 
CHAPTER 2 
2.0. Culture conditions for mammalian cell lines……………………………………………………………………………..………………73 
2.1. Cell lysis and IP wash buffer recipes……………………………………………………………………………………………….…………77 
2.2. Comprehensive list of antibodies………………………………………………………………………………………………………………85 
2.3. Bioinformatics resources…………………………………………………………………………………………………………………………108 
CHAPTER 3 
3.0. WFS1 mutations identified. ……………………………………………………………………………………………………………………112 
3.1. Predicted phenotypic effects of WFS1 mutations……………………………………………………………………………………117  
3.2. Genetic data for WFS2 mutation…………………………………………………………………………………………….………………120 
3.3. Age of onset (years) of clinical features in a patient with WFS2-associated WS………………………………………123 
3.4. Median age (and range) of onset in years of clinical features in WFS2-associated WS families…….…………124 
3.5. Age of onset (years) of clinical features in a patient with SLC19A2-associated TRMA…………………………..…128 
3.6. Genetic data for SLC19A2 mutation……………………………………………………………………………………………..…………129 
3.7. Age of onset (years) of clinical features associated with SLC19A2-R162X. ………………………………………………129 
3.8. Proportions of mutation-types found in the West Midlands cohort (n=93) ……………………………………………133 
3.9. Genotype-phenotype correlation in WS………………………………………………………………………………………….………134 
CHAPTER 4 
4.0. Selected WFS1 missense variants and associated clinical features……………………………………….…………………147  
4.1 WFS1 missense variants – Genetic and physiochemical data……………………………………………………………………151 
4.2 Bioinformatic analysis of selected WFS1 variants using SIFT and Polyphen………………………………………………156 
4.3. Site-directed mutagenesis of human WFS1……………………………………………………………………………………….……160 
4.4. Mean steady-state expression WFS1 mutants relative to wild-type (set 1) …………………….………………………164 
4.5. Mean steady-state expression WFS1 mutants relative to wild-type (set 2) ……………………………….……………167 
4.6 Mean steady state expression of WFS1 variants in soluble and insoluble fractions relative to wild-type 
WFS1……………………………………………………………………………………………………………………………………………………………..170 
4.7. Mean steady-state expression WFS1 variants relative to wild-type (Laemmli buffer) ………………………….…173 
CHAPTER 5 
5.0. Clones identified from initial yeast-two hybrid screen……………………………………………………………………….……234 
5.1. Cloning methods for selected WFS1-partner candidates…………………………………………………………………………250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
A 
AD 
Adenine 
activating domain 
APS ammonium persulphate 
ASK1 apoptosis signal-regulating kinase 
ATF4 activating transcription factor 4 
ATF6α  activating transcription factor 6α  
ATP adenosine triphosphate 
BAX Bcl2-associated X protein 
Bcl2 
BiFC 
B-cell lymphoma 2 
bimolecular fluorescence complementation 
BiP immunoglobulin binding protein/GRP78 
bp base pairs 
BSA bovine serum albumin 
C 
CaM 
CdFYP 
Cytosine 
calmodulin 
chaperone-dependent yellow fluorescent protein 
cDNA complementary deoxyribonucleic acid 
cfu colony forming units 
CHOP C/EBP homologous protein 
cm centimetre 
cm3 
CX 
cubic centimetres 
cyclohexamide 
CO₂ carbon dioxide 
DAPI 
DBD 
4'-6-Diamidino-2-phenylindole 
DNA-binding domain 
ddH2O  
DIDMOAD 
double-distilled dihydrogen monoxide/water 
diabetes insipidus, diabetes mellitus, optic atrophy and deafness 
DMEM Dulbecco's modified eagle media 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs 
ECACC 
deoxyribonucleotide triphosphate 
European Collection of Cell Cultures 
EDTA 
eIF2 
ethylenediaminetetraacetic acid 
eukaryotic initiation factor 2 
ER endoplasmic reticulum 
ERAD ER-associated protein degradation 
ERIS endoplasmic reticulum intermembrane small protein 
ERO1α endoplasmic reticulum oxidoreductin 1 
EtBr ethidium bromide 
eIF2 
FACS 
eukaryotic initiation factor 2 
fluorescence-activated cell sorting 
FRET 
g 
fluorescence resonance energy transfer 
grams 
G guanine 
GADD 
GDM 
GWAS 
HRD1 
growth arrest and DNA-damage-inducible 
gestational diabetes mellitus 
genome wide association studies 
HMG-CoA reductase degradation protein 1 
HRP 
HSP90 
horseradish peroxidise 
heat shock protein 90 
H2O  dihydrogen monoxide/water 
ICC 
Ig 
Immunocytochemistry 
immunoglobulin 
IHC Immunohistochemistry 
IMAGE Integrated Molecular Analysis of Genomes and their Expression 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IRE1α inositol requiring enzyme 1α 
JNK c-Jun N-terminal kinase 
kb 
kDa 
kilobase 
kilo dalton 
LB 
LCM 
Luria-Bertani 
laser-capture microdissection 
MAPK mitogen-activated protein kinase 
MCS multiple cloning sites 
ml millilitre 
mm millimetre 
mM millimolar 
MODY maturity onset diabetes of the young 
ng nanograms 
NO nitric oxide  
P58IPK P58 inhibitory protein kinase 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDI protein disulphide isomerise 
PERK PKR-like ER kinase 
pM 
PPI 
Picomolar 
protein-protein interactions 
QDO quadruple drop-out 
RIDD regulated IRE-1 dependent decay  
RNA ribonucleic acid 
rpm revolutions per minute 
SDM spray dried barley malt extract 
SDS-PAGE sodium dodecyl sulfate polyacrylamide electrophoresis 
SERCA 
SNP 
sarco-endoplasmic reticulum Ca2+-ATPase 
single nucleotide polymorphism 
SOC super optimal broth 
SOD superoxide dismutase 
T thymine 
TBE tris/borate/EDTA 
TEMED tetramethylethylenediamine 
Tm melting temperature 
TRAF2 TNF-receptor-associated 2 
U 
UAS 
units 
upstream activating sequences 
UPR unfolded protein response 
UV ultraviolet 
WF wolframin 
WFS1 Wolfram syndrome 1 gene 
wfs1 Wolfram syndrome 1 gene mouse homolog 
WFS2 Wolfram syndrome 2 gene 
WS Wolfram syndrome 
XBP1 X-box-binding protein 1 
YPD yeast-extract, peptone, dextrose 
µl microlitre 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 INTRODUCTION 
 
1 
 
CHAPTER 1 
  INTRODUCTION 
 
1.0.0  Diabetes mellitus 
Diabetes mellitus is a metabolic disorder, characterised by intolerance to glucose. 
The hormone insulin is required to maintain blood glucose homeostasis, and 
diabetes mellitus can be due to defects in insulin secretion or insulin action. 
 
Acute hyperglycaemic episodes are a medical emergency. The consequences of 
excessive blood glucose include an osmotic diuresis, which may cause severe 
dehydration and electrolyte imbalance. In addition, the lack of glucose entry into 
cells means that they have to rely on alternative energy sources derived from fatty 
acid metabolism. This is a relatively inefficient process and leads to the production of 
toxic by-products, ketones. Without treatment a state of diabetic ‘ketoacidosis’ can 
result in loss of consciousness, renal failure and ultimately death. 
 
Chronic hyperglycaemia is associated with long-term micro and macro vascular 
complications (Fowler, 2008). These include; nephropathy, retinopathy and 
peripheral/autonomic neuropathies, that can lead to permanent organ damage or 
failure and cardiovascular disease, ending in disability and premature mortality. 
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1.0.1  Prevalence and burden of diabetes mellitus 
 
Diabetes is the fifth largest cause of death worldwide, affecting an estimated 285 
million people; a figure that is projected to double by 2030 (Diabetes UK, 2010). The 
vast increase in the number of people with diabetes is particularly pronounced in 
developing countries, and is correlated with population growth, urbanisation, aging 
and increasing levels of obesity and physical inactivity (Wild, 2004). 
 
In the UK it is estimated that 1 in 20 people have diabetes, many of whom are 
undiagnosed. All age groups are at risk, but prevalence is more than two times 
higher in deprived areas. People with diabetes are twice as likely to be admitted to 
hospital, experience prolonged hospital stays, and many incur social services costs 
for nursing care and home help.  As a consequence, the annual cost of diabetes 
related health care is approximately 10% of the NHS yearly budget (~£9 billion), 
which is close to £1 million an hour (Diabetes UK, 2010).  
 
1.1.0  Aetiology of diabetes mellitus 
 
The aetiology of diabetes mellitus is not fully understood, but attributed to a 
combination of genetic and environmental factors. Since several pathogenic 
processes are involved in the development of impaired glucose regulation and 
diabetes mellitus, a system of etiological classification exists (fig. 1.0), which has 
been recently revised by the American Diabetes Association (ADA, 2010). 
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Figure 1.0. Etiological classification of diabetes.  
 
Adapted from American Diabetes Association (2010). 
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1.1.1  Type 1 diabetes mellitus 
 
Up to 10% of people affected by diabetes have type 1 diabetes mellitus (ADA, 2010), 
which results from autoimmune destruction of insulin secreting pancreatic -cells. 
This occurs at variable rates, eventually leading to absolute insulin deficiency. Onset 
is generally in childhood, although latent autoimmune diabetes is known to present 
in approximately 10% of adults first diagnosed with type 2 diabetes mellitus (Palmer, 
2005). Patients rely on insulin replacement therapy for survival, but some individuals 
(usually late-onset) retain limited β-cell function, sufficient to prevent ketoacidosis 
for a variable duration (Hosszufalusi, 2003). 
 
The pathophysiology of type 1 diabetes is related to a permissive genetic background 
and environmental factors that are still poorly defined. It is thought that genetic 
factors contribute 30-70% of disease-factors (Pocoit, 2010). Half of the genetic risk of 
type 1 diabetes is conferred by Human Leukocyte Antigen (HLA) genes found on 
chromosome 6p (Steck, 2011) and the remainder of susceptibility genes are found in 
over 50 regions spread throughout the genome with smaller combined effects 
(Espino-Paisan, 2011).  
 
1.1.2  Type 2 diabetes mellitus 
 
Type 2 diabetes mellitus accounts for the vast majority of diabetes patients (~85%), 
and involves the combined effects of peripheral insulin resistance and impaired 
insulin secretion. Onset, usually in adulthood, tends to be a gradual development of 
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hyperglycaemia that may be asymptomatic in the early stages. At least initially, 
patients survive without pharmacologic treatment and can manage their blood 
glucose levels with diet and exercise modifications. The insulin resistance can also be 
improved with weight loss and/or pharmacological treatment, but insulin levels are 
rarely restored to normal values (ADA, 2010). Data collected by The Department of 
Health and Human Services suggest that ~80% of adult diabetics in the United States 
require some form of medication for diabetes management (CDC, 2010). 
 
Causes of type 2 diabetes are complex and multifactorial. The majority of type 2 
diabetics are obese, or carry a disproportionately large percentage of abdominal 
body fat, which contributes to insulin resistance in liver and muscle tissue. Studies 
have shown that visceral (abdominal) fat cells secrete excess amounts of free fatty 
acids and other biochemicals that interfere with normal glucose metabolism 
(Gastaldelli, 2008). Risk of developing this type of diabetes is also increased with age, 
lack of exercise, and also in people with hypertension or dyslipidemia. Individuals 
from particular ethnic subgroups are affected with higher frequencies than others 
(Zimmet, 2001), and there is also evidence confirming genetic predisposition (Voight, 
2010).  
 
1.1.3  Other types of diabetes 
 
There are many categories of diabetes that make up the remaining 5% or so of cases. 
These include; drug and chemical induced diabetes, endocrinopathies, pancreatic 
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diseases such as pancreatitis and pancreatic carcinoma, infections associated with -
cell destruction, and gestational diabetes mellitus (GDM).  
 
Rare cases of immunological disease can cause diabetes when antibodies against the 
insulin receptor either: competitively inhibit the action of insulin at target tissue, 
resulting in hyperglycaemia, or act as an insulin agonist leading to hypoglycaemia. 
Several conditions, of varying severity, are also derived from mutations in the insulin 
receptor protein, such as Rabson-Mendenhall syndrome and Leprechaunism (ADA, 
2004). 
 
A large number of other genetic defects may contribute to diabetogenesis including 
chromosomal abnormalities, and single and multiple gene mutations. For example, 
maturity-onset diabetes of the young (MODY), characterised by non auto-immune 
juvenile onset hyperglycaemia, is related to autosomal dominant mutations in one of 
at least six different genetic loci, which cause various defects of the insulin secretion 
pathway (Fajans, 2010). There are also genetic syndromes associated with diabetes. 
These include Wolfram syndrome, Prader-Willi syndrome, diabetes and deafness, 
and thiamine-responsive megaloblastic anemia, all differing in pathophysiology and 
etiological background (ADA, 2004).  
 
1.2.0  Diabetes prevention and treatment  
 
There is currently no cure for common diabetes although a range of drug and insulin 
replacement therapies are offered as a management strategy for many patients, 
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each with associated side-effects and individual limitations. An understanding of β-
cell pathways is crucial for the development of better treatments.  
 
Transplanting isolated islet cells, a procedure still in its infancy, is a current focal area 
of diabetes research efforts, and advances in genetic engineering could address the 
anticipated problem of ‘donor’ islet cell shortage in the future. Recent in vivo studies 
have also provided promising evidence that insulin secreting islet β-cells have the 
potential to regenerate in adults after near-total loss, by spontaneous 
reprogramming of endocrine α-cells (Thorel, 2010), or indeed may be induced by a 
combination of specific transcription factors to reprogramme from exocrine cells to 
β-cells (Zhou, 2008). These findings highlight the scope for regenerative treatments 
in patients with β-cell depletion. 
 
A greater understanding of the genetic basis and molecular pathogenesis of diabetes 
would enable development of superior therapeutics and ultimately future 
preventative treatments. Modern technologies advanced since the completion of the 
Human Genome Project, not only enable us to examine disease from a single gene 
perspective, but to perform comparative assays on large-scale data sets relatively 
efficiently. In the field of diabetes research, these types of studies are particularly 
useful for identifying common genetic variants that may contribute to disease 
susceptibility. To date, collaborative genome wide association studies (GWAS) have 
enabled the identification of more than 35 genetic loci associated with type 2 
diabetes in European populations (Voight, 2010). Single nucleotide polymorphism 
(SNP) chips allow analysis of over two thirds of common variation in the human 
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genome. The genes/regions so far identified (fig. 1.1) represent only a modest 
portion (~10%) of the familial risk underlying type 2 diabetes, and many more SNPs 
and copy number variants affecting susceptibility have yet to be discovered. After 
fine-mapping regions of interest, the next step is to explore the relationships 
between genetic variants and disease pathogenesis. It is anticipated that this kind of 
research could, in the future, be applied in a clinical setting to allow more accurate 
prognoses based on individual patient genotypes, where risk alleles can be 
considered for ‘tailor-made’ therapies (Aneesh, 2009; Xie, 2005).  
 
Study of rare monogenic disorders and exceptional familial forms of disease traits 
has provided much of our current knowledge about complex diseases. The 
underlying molecular basis of over 1700 Mendelian disorders have been 
characterised (Peltonen, 2006) and these findings have helped to define critical 
pathways involved in many common ‘multifactorial’ diseases. In the case of diabetes 
research, examining monogenic disorders like MODY and Wolfram syndrome, not 
only directly benefits affected patients by way of specific therapeutic targeting, but 
also provides invaluable insights to the physiology of the β-cell, and this knowledge 
can be applied to understanding disease pathways in more prevalent types of 
diabetes. Since common variants of the Wolfram syndrome-causative gene (WFS1) 
correlate with type 2 diabetes risk (fig. 1.1), studying this rare disease may also have 
relevance to the pathogenesis of type 2 diabetes.  
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Figure 1.1. Genetic loci associated with type 2 diabetes predisposition. Manhattan plots summarizing meta-analysis results from a number of 
genome-wide association studies.  Gene names are denoted on the basis of their proximity to the index SNP and are not presumed to 
indicate causality. 
 
Adapted from Voight, B.F., et al (2010), Nature Genetics, 42(7): 579-590. 
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1.3.0  Wolfram syndrome 
 
Wolfram syndrome (WS), first described in 1938 (Wolfram, 1938), is a rare, 
autosomal recessive, neurodegenerative disease characterised primarily by juvenile 
onset diabetes mellitus and optic atrophy. A typical age of diabetes mellitus onset is 
5.4±3.8 years (Rohayem, 2011), and the pathophysiology is attributed to impaired β-
cell function and selective non-autoimmune β-cell death. A spectrum of associated 
complications also commonly present in patients throughout progression of disease, 
including diabetes insipidus, sensorineural deafness, renal and urinary tract 
abnormalities and neurological manifestations in the later stages (fig. 1.2) (Smith, 
2004). In relation to these features, the syndrome has also been described as 
DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). 
 
 
 
 
 
 
 
Figure 1.2. Natural history of Wolfram syndrome (WS). WS is characterised by juvenile onset 
diabetes mellitus and optic atrophy. All or some of a range of other clinical features may present as 
disease progresses with typical ages of onset indicated. The average life expectancy for a WS patient 
is less than 40 years with death commonly resulting from central respiratory failure due to brain 
stem atrophy.  
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The prevalence of WS in the UK was estimated at one in 770,000 with a carrier 
frequency of 1 in 354, by a nationwide study conducted in 1995 (Barrett, 1995), 
although this figure is likely to have risen over the last fifteen years as more cases of 
WS have been reported. Regions such as North Africa and the Middle East, where 
consanguineous marriages are more common, are likely to have a higher prevalence 
of WS, and possibly a larger number of unreported cases. The average life 
expectancy for a WS patient is less than 40 years, with death often resulting from 
central respiratory failure due to brain stem atrophy. For those patients in 
‘developing’ countries, the life expectancy is probably shorter still, as a consequence 
of poorer health care. 
 
1.3.1  Genetics of Wolfram syndrome 
 
Since WS shares common phenotypic characteristics with diseases of oxidative 
phosphorylation such as Leber’s hereditary optic neuropathy, and maternally 
inherited diabetes and deafness, it was thought that disease pathogenesis could be 
related to defective mitochondrial function. In support of this theory, there have 
been deletions in mitochondrial DNA found in some WS patients (Rötig, 1993; 
Barrientos, 1996a; Barrientos 1996b, Gómez-Zaera, 2001, Mezghani, 2011), although 
there is no evidence to suggest that WS is related to systemic abnormality of 
respiratory chain function (Jackson, 1994). 
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The majority of WS cases are attributed to mutations in the WFS1 gene, located at 
chromosome 4p16, which was mapped to the region firstly by linkage analysis 
(Polymeropoulos, 1994; Collier, 1996), then later identified by positional cloning in 
1998 (Inoue, 1998; Strom, 1998). More recently, a second locus (4q24) containing a 
gene designated WFS2, was found to be associated with a small number of affected 
Jordanian families (Amr, 2007). These patients presented with defective platelet 
aggregation with collagen, and bleeding tendency in addition to typical WS clinical 
features. Some individuals also had peptic ulcer disease and gastrointestinal bleeding 
but none presented with diabetes insipidus.  
 
1.3.2  WFS1  
 
The WSF1 gene contains 8 exons, the first of which is non-coding, and a wide 
spectrum of mutations have been identified throughout the gene sequence 
(Ensembl, 2011). No significant mutational hotspots have been determined although 
the majority have been found in exon 8, which is the largest, representing >70% of 
the total transcript (Ensembl, 2011). Previous mutation analysis studies have been 
unable to identify clear genotype-phenotype correlations in WS cohorts, although 
genetic heterogeneity and small numbers of patients have made analyses difficult. It 
has been postulated that nonsense or insertion/deletion mutations resulting in 
protein truncation may induce a more severe phenotype due to complete loss of 
function (Smith, 2004; Cano, 2007). Possible correlations between location of 
mutations and neurological manifestations have also recently been made 
(Chaussenot, 2011).  
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Some heterozygous WFS1 variants are associated with disease states distinct from 
WS. In addition to the above-mentioned links to type 2 diabetes, some WFS1-
variants may be associated with psychiatric illness (Furlong, 1999; Torres, 2001; 
Swift, 2005; Zalsman, 2009) and others with non-syndromic hearing loss (Young, 
2001; Bespalova, 2001). To date, more than 30 WFS1 mutations are associated with 
cases of autosomal dominant, low frequency deafness, also known as DFNA6 
(Hildebrand, 2008). 
 
1.3.3  Wolframin 
 
The WFS1 gene codes for an 890 amino acid protein named wolframin (WF). Analysis 
of WFS1 mRNA demonstrates ubiquitous expression, including brain, lungs, heart, 
kidneys and pancreas, correlating with many of the organs affected during disease 
progression (Strom 1998; Inoue 1998).  
 
In the pancreas, immunohistochemical staining of mouse tissue has shown that β-
cells are primary sites of wolframin expression (Ueda 2005), corresponding with WS 
pancreas pathology, where β-cells are selectively lost from patient islets. 
 
Studies in rat brain revealed expression in selected neurons, particularly prominent 
in regions such as; hippocampus, amygdala, olfactory tubercle and allocortex 
(Takeda, 2001), which are components of, or closely related to, the limbic system. 
These findings would suggest a possible role for wolframin in emotional and 
behavioural control. This is consistent with the psychiatric abnormalities seen in 
CHAPTER 1 INTRODUCTION 
 
14 
 
some WS patients. Other brain regions of WFS1 expression include the cerebellum 
and brainstem, and affected patients may have severe symptoms related to these 
areas (cerebellar ataxia, central respiratory sleep apnoeas). In a study of the normal 
mouse visual system, WFS1 expression was shown to be widely distributed; present 
in occipital cortex, retina and optic nerve (Kawano, 2005), although notably only 
moderate expression in the optic nerve, which is most susceptible to atrophy in WS.  
 
Immunofluorescence and cell fractionation studies have demonstrated the 
localisation of wolframin primarily to the endoplasmic reticulum (ER) membrane 
(Takeda, 2001), which it spans with nine putative transmembrane domains. The 
amino (N) terminal portion is positioned on the cytosolic side of the membrane, and 
the carboxy (C) terminus lies within the ER lumen (fig. 1.3). More recent 
immunofluorescent and electron microscopy evidence has also shown localisation of 
wolframin to secretory granules in pancreatic β-cells (Hatanaka, 2011). 
 
The wolframin protein has a molecular mass of ~100kDa, but has been shown 
experimentally to organise into higher molecular weight complexes of ~200 and 
400kDa (Hoffman, 2003) in both transfected and endogenously expressing cell lines. 
These could represent combination with other, as yet unknown proteins, but more 
likely homo-dimeric and tetrameric assemblies.  
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Pulse-chase experiments suggest that mature wolframin protein is relatively stable, 
with a half-life estimated at ~2 days (Hoffman 2003). N-linked glycosylation has been 
the only post-translational modification demonstrated, and following treatment with 
tunicamycin (glycosylation inhibitor) appears to confer stability and/or allows proper 
wolframin protein folding (Hoffman 2003; Yamaguchi 2004). 
 
1.4.0  Wolframin function 
 
The sub-cellular localisation and potential dimerisation of the wolframin protein 
points towards functional roles as a protein chaperone and/or in membrane 
trafficking. Indeed, functional studies have implicated wolframin in calcium 
Figure 1.3. Hypothetical structure of the wolframin protein. Wolframin primarily localises to the 
endoplasmic reticulum (ER), spanning the membrane with nine putative transmembrane domains; 
Amino acids 1-310 comprise the cytosolic amino-terminal (N) domain and 653-890 the ER lumenal 
carboxy-domain (C). 
 
Image adapted from Davidson, 2010.  
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homeostasis, insulin biosynthesis and secretion (fig. 1.4), and endoplasmic reticulum 
stress pathways. 
 
1.4.1  Wolframin, insulin secretion and Ca2+ homeostasis 
 
Mouse models lacking functional wolframin have been generated in order to 
examine the pathophysiology of WS. Over time, mice with disrupted wfs1 (WFS1 
homolog) were reported to develop either glucose intolerance or overt diabetes 
depending on their genetic background (Ishihara, 2004, Riggs, 2005). Following oral 
glucose tolerance tests, the mutant mice demonstrated significantly higher blood 
glucose levels compared to control mice, indicating that disruption of the wfs1 gene 
induces impaired glucose homeostasis and is sufficient to cause a diabetes mellitus 
phenotype on a permissive genetic background. This observation is thought to be 
linked predominantly with insulin secretion defects rather than insulin resistance, as 
hormone responses were markedly blunted in wfs1 deficient animals. 
 
The impaired insulin secretion in wfs1 deficient mice was shown to be correlated 
with both a reduction in stimulus-secretion coupling, and an overall reduction in β-
cell mass and insulin content. Compared with wild-type mouse cells, glucose-
stimulated insulin secretion has been shown to be reduced by ~25% in islets from 
mutant mice together with a 36% reduction in cytosolic Ca2+ flux (Ishihara, 2004). 
Normal insulin secretion could be restored following wfs1 re-expression using a 
recombinant adenoviral vector, and significantly enhanced (~50%) by over-
expression of wfs1. Only half of the total number of islet cells could be extracted 
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from mutant mouse pancreata compared to wild-type, and the loss of β-cells is 
considered a consequence of apoptosis, due to glucose toxicity and endoplasmic 
reticulum stress (section 1.5.0).  
 
The role WFS1 plays in insulin secretion could be related to calcium homeostasis. 
Ectopic expression of WFS1 in Xenopus oocytes, demonstrated that WFS1 has a 
modulatory effect on intracellular Ca2+ levels (Osman, 2003) and combined study of 
WFS1 over-expressing and knock-down HEK293 cells showed that wolframin 
positively regulates the Ca2+ filling state of the ER (Takei, 2006). Experimental 
evidence generated from wfs1-/- islets and depleted β-cells also shows that 
decreased glucose-stimulated insulin secretion is partially due to impaired cytosolic 
calcium rise and a defective ATP rise in response to glucose (Ishihara, 2004; Zatyka, 
2008b).  
 
More recently calmodulin (CaM), an important second messenger of intracellular 
calcium signalling, was described as a molecular partner of wolframin (Yurimoto, 
2009). It has been postulated that the wolframin protein may form an ion channel, 
similar to other ER membrane-associated proteins, commonly found in tetrameric 
complexes, although it remains unclear as to whether wolframin acts directly as a 
channel or functions only in a regulatory capacity.  
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Figure 1.4. Glucose-stimulated insulin secretion. Insulin secretion in β-cells is triggered by rising blood glucose levels. Glucose enters cells via the GLUT2 
transporter and the glycolytic phosphorylation of glucose causes a rise in the ATP:ADP ratio. ATP-dependent potassium channels (K+) are activated by this 
change causing membrane depolarisation and inflow of Ca2+ ions through voltage-gated ion channels. Increases in cellular Ca2+ activate release of more Ca2+ 
from endoplasmic reticulum stores, which further raises the cytoplasmic concentration of Ca2+, sufficient to induce release of insulin from secretory 
vesicles. 
 
Adapted from: Ren,  J., et al (2007). 
CHAPTER 1 INTRODUCTION 
 
19 
 
1.4.2  Wolframin and cell proliferation 
 
Alternative studies of wolframin depleted cells suggest that the loss of β-cells seen in 
WS patients could also be linked to reduced rates of cell proliferation. A study of a 
stably wolframin depleted rat β-cell line (BRIN-BD11), demonstrated dramatic 
reduction in cell proliferation rates and changes in morphology compared to normal 
controls (McBain, 2003). Analysis of cellular DNA profiles revealed no evidence of 
DNA fragmentation suggestive of apoptosis, but instead, elevated levels of diploid 
DNA and a reduction of the G2/M peak associated with DNA replication and cell 
division. These results suggest that reduced wolframin expression in vivo may 
negatively affect β-cell replacement during normal cell turn-over, leading to gradual 
depletion of β-cell mass over time. In concordance with these findings, expression 
profile data generated from patient and control fibroblasts (Philbrook, 2005) 
revealed a 2.1 fold up-regulation of fibulin-3 in patient cells, a gene previously shown 
to be associated with cellular senescence (Lecka-Czernik, 1995). 
 
1.5.0  Endoplasmic reticulum stress 
 
The endoplasmic reticulum (ER) is the subcellular organelle involved in the synthesis 
and folding of secretory, membrane, and some organelle proteins and lipids, termed 
ER ‘clients’. Carefully balanced conditions including ATP, Ca2+ and redox state are 
required for optimal client protein folding and thus the ER is highly sensitive to 
environmental changes. Any perturbation that compromises the folding capacity of 
the ER is termed ER stress, and may result in accumulation and aggregation of 
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unfolded proteins. Several neurodegenerative diseases as well as diabetes and 
ischemia (Lindholm, 2006) have been associated with ER stress. 
 
The triggers for ER stress range from acute cellular insults such as hypoxia or glucose 
deprivation, to chronic stressors like viral infections or genetic mutations that cause 
permanent changes in cell function. Some types of cells, including neuroendocrine 
cells are by nature, subject to persistently elevated levels of ER stress due to their 
specialism in protein synthesis and secretion, and high ER client load.  
 
An increase of ER volume is observed in cells under ER stress together with 
activation of complex signalling cascades, termed the ER stress response or unfolded 
protein response (UPR). The outcome of the stress response can be two-fold, 
inducing both adaptive measures to maintain ER homeostasis, such as expansion of 
the ER size and upregulation of protective genes, and apoptosis in cases of 
prolonged stress or irreversible damage.  
 
1.5.1  ER stress sensors 
Three transmembrane receptors known to mediate the ER stress response are; PERK 
(PKR-like ER kinase), IRE1α (inositol requiring enzyme 1α), and ATF6α (activating 
transcription factor 6α). It is understood that the ER luminal domains of all three 
receptors are bound by an ER chaperone BiP (immunoglobulin binding 
protein/GRP78), which maintains them in an inactive state. This coupling is 
recognised as one of potentially several mechanisms controlling the activity of ER 
stress sensors (Oikawa, 2007). Following accumulation of unfolded proteins in the ER 
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lumen, BiP dissociates from the receptors, allowing activation of downstream targets 
(fig 1.5) that collectively constitute an initial pro-survival response. This response 
may ‘switch’ to pro-apoptosis in situations where stress cannot be resolved, 
although the precise mechanisms facilitating this ‘switch’ remain to be elucidated 
(Rutkowski, 2007). 
 
The proposed pro-survival responses include reversible measures to immediately 
relieve the protein folding load, by inhibiting the translocation of many ER substrates 
(Kang, 2006), degradation of some ER-associated mRNAs to assist in membrane 
clearance, and general inhibition of ER processing pathways. More long-term coping 
strategies involve the upregulation of genes relating to protein folding and 
processing, thus increasing ER capacity for handling client proteins (Schröder, 2005). 
Adaptive responses to ER stress are also coupled with transcriptional activation of 
processes not specifically ER-dependent, such as regulation of energy production, 
amino acid metabolism, and cellular redox state (Rutkowski, 2007).  
 
Following dissociation of BiP, PERK homodimerises and autophosphorylates. This 
‘active’ PERK has been shown to attenuate general protein translation, via 
phosphorylation of eIF2 (eukaryotic initiation factor 2), whilst concomitantly 
increasing transcription of selected target genes such as ATF4 (activating 
transcription factor 4). These genes link to downstream pathways involving growth 
arrest and DNA damage, apoptosis, redox balance, and amino acid synthesis 
(Harding, 2000).  
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Figure 1.5. Endoplasmic Reticulum (ER) stress pathways. ER transmembrane stress sensors PKR-like ER kinase 
(PERK), activating transcription factor 6α (ATF6α) and inositol requiring enzyme 1α (IRE1α) activate various arms 
of the unfolded protein response (UPR). The outcome of this response may be adaptive enabling the cell to more 
efficiently cope with a high client protein load, or apoptosis, when stress cannot be resolved. The mechanisms 
causing a switch between survival and death decisions are not yet fully understood (Rutkowski, 2007).   
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IRE1α has downstream endonuclease activity, which results in cleavage of a 26-
nucleotide intron from XBP1 (X-box-binding protein 1) mRNA. The XBP1 splice 
variant (sXBP1) translates to a stable, active transcription factor, which targets 
several genes encoding folding chaperones such as PDI (protein disulphide 
isomerise) and BiP/Grp78 (also a Ca2+ binding chaperone), and others involved in ER-
associated protein degradation (ERAD). Another protein activated by sXBP1 is P58IPK 
(P58 inhibitory protein kinase), which binds and inhibits PERK. This has been 
proposed as a negative feedback loop that may signify the termination of the ER 
stress response, since upregulation of P58IPK occurs several hours after PERK 
activation and translation-block (Yan, 2002). Recent reports show that other mRNA 
substrates are targeted for degradation by IRE1α (Hollien, 2009) through the 
regulated IRE-1 dependent decay (RIDD) signalling pathway, an additional measure 
to alleviate the ER burden. 
 
The third sensor ATF6, is reduced following initiation of ER stress and subsequently 
translocated to the golgi apparatus, where it is cleaved and activated by site-1 and 
site-2 proteases (Chen, 2002). Active ATF6 is a basic leucine zipper (bZIP) 
transcription factor. Like XBP1, ATF6 stimulates expression of protein folding and 
ERAD-associated genes, thus promoting clearance of proteins from the ER lumen 
(Kokame, 2001). ATF6 also has the ability to regulate XBP1 mRNA expression and 
interact directly with the XBP1 protein. This cross-talk may have evolved due to 
redundancies in the stress response pathways, or may in fact represent adaptive 
features that enhance the efficiency and feedback of the system (Wu, 2007).  
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1.5.2  ER stress and apoptosis 
 
ER stress mediated apoptosis is thought to occur via a number of pathways; some 
linking to general apoptotic signalling, others seemingly more specific to ER stress. 
All three arms of the ER stress response have been linked with proapoptotic 
signalling, so in addition to adaptive gene upregulation, the ER stress sensors are 
able to initiate the cell death machinery.  
 
A well characterised end-point of programmed cell death is the activation of effector 
caspases. These proteins are cysteine proteases, present within cells as inactive 
zymogens, which are cleaved to active enzymes following the induction of apoptosis. 
During programmed cell death caspases are responsible for cleaving critical cellular 
substrates such as chromosomal DNA, and the sequential dismantling of structural 
nucleic proteins, typical of apoptosis.  
 
Many pathways may converge upstream of this stage, involving sub-sets of initiator 
caspases, which have yet to be wholly ascertained in terms of ER stress signalling. 
Some studies of caspase-12 -/- mouse embryonic fibroblasts have demonstrated a 
partial resistance to ER stress induced apoptosis (Szegezdi, 2003), suggesting this 
may play a principal role in death decisions. When translating these findings to 
human systems, it has been proposed by some that caspase-4 could perform a 
similar function, although recent work on knock-out models (Saleh, 2006), produced 
contradictory results, leaving the role of caspase-12 in ER stress mediated apoptosis 
a topic of current debate. 
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Other works using over-expression and knockout mouse models have identified 
potent upstream components of the pro-apoptotic response such as CHOP (C/EBP 
homologous protein), ASK1 (apoptosis signal-regulating kinase), and members of the 
Bcl2 (B-cell lymphoma 2) protein family, indicating signal relay between the ER and 
mitochondria (Rutkowski, 2007). 
 
CHOP activation under conditions of ER stress is linked to all three of the stress 
sensors, although upregulation of CHOP protein expression is essentially carried out 
via PERK induced ATF4. The importance of CHOP signalling has been confirmed in 
knock-out mouse models (CHOP-/-), which show a partial resistance to ER stress 
induced apoptosis (Oyadomari, 2002). Genes involved in cell death pathways are 
promoted by CHOP expression and numerous downstream targets have been 
identified including; BCL2, GADD (growth arrest and DNA-damage-inducible) 134 and 
38, and ERO1α (endoplasmic reticulum oxidoreductin 1).  
 
Notably, active IRE-1 can bind to TRAF2 (TNF-receptor-associated 2), which in turn is 
thought to recruit ASK1 (apoptosis-signal-regulating 1). This complex is able to 
communicate with downstream kinases such as p38 MAPK (mitogen-activated 
protein kinase) and JNK (c-Jun N-terminal kinase), which are known to initiate 
apoptosis (Urano, 2000). Further evidence of pathway convergence comes from the 
post-translational regulation of CHOP by p38 MAPK, linking the predominantly PERK 
activated CHOP upregulation with IRE1 induced p38. It is thought that this 
mechanism may serve to perpetuate CHOP-mediated apoptotic cascades in the late 
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stages of severe or prolonged ER stress, since the IRE1 arm of the UPR is considered 
the last to be activated.  
 
Despite evidence linking the various UPR pathways, a fundamental question that still 
remains unanswered is whether these multiple stress response pathways are all 
equally necessary and sufficient for making the transition from prosurvival to 
proapoptosis, or is there a key event that is paramount in executing cell death 
decisions? Also unclear, is to what extent the switch from adaptation to 
programmed cell death involves down-regulation of protective genes, and 
upregulation of suicide genes, and when does a cell under ER stress reach a point of 
no return? 
 
1.5.3  ER stress and diabetes  
 
Links between ER stress and diabetes pathology have been directly demonstrated in 
studies of human monogenic and type 2 diabetes with supporting evidence from a 
number of rodent diabetes models. Some tentative connections have also been 
made between immune-mediated type 1 diabetes and the UPR in sealing the fate of 
apoptotic β-cells. 
 
Autopsy data from type 2 diabetic patients reveals the decline in insulin secretion 
can be attributed to a decrease in β-cell mass following apoptosis (Butler, 2003). 
Histological staining of human pancreas sections taken from type 2 diabetics, 
illustrated markedly higher levels of ER stress markers, such as CHOP and P58IPK in 
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islet cells (Laybutt, 2007), as well as a two-fold increase in ER size when compared to 
normal controls (Marchetti, 2007), indicating UPR pathways are likely to be engaged 
in the execution of apoptosis. The ER stress response may also explain the 
association between obesity and type 2 diabetes; Free fatty acids trigger ER stress 
signalling, cell dysfunction and death in rodent β-cells (Kharroubi, 2004; Karaskov, 
2006; Cnop, 2007), suggesting lipotoxicity is an important factor in the health and 
survival of β-cells in vivo.  
 
Involvement of ER stress in human type 1 diabetes has yet to be proven, although 
studies in animal models have shown that cytokine induced β-cell apoptosis does in 
fact link in with UPR signalling pathways. In rodent models of type 1 diabetes, islet β-
cell destruction is known to be coupled with the infiltration of T cells (O’Brien 1997, 
Jörns 2005), and also with the expression of cytokines (IL-1β, interferon-γ, TNF-α) 
and inducible nitric oxide synthase (iNOS) (Jörns 2005, Uno, 2007), which may be 
early mediators of cell death. In vitro, IL-1 β or TNF-α combined with IFN-γ can 
induce nitric oxide (NO) production, severe functional repression and death of β-cells 
(Southern 1990, Eizirik 1992), and several well established UPR signalling molecules 
such as XBP1 and CHOP are upregulated by these cytokines (Pirot 2007, Cardozo 
2001,  Kutlu 2003, Cardozo 2005). NO action may also serve to deplete ER Ca2+ stores 
through inhibition of SERCA (sarco-endoplasmic reticulum Ca2+-ATPase) expression 
(Cardozo 2005) and interaction with SNAP (synaptosomal-associated protein), a 
chemical donor of NO (Oyadomari 2001). This Ca2+ depletion likely compromises the 
protein folding capacity of ER resident chaperones, triggering the UPR.  
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1.5.4  Wolfram syndrome and ER stress  
 
A lack of wfs1 in mice is sufficient to cause the diabetes mellitus phenotype (Riggs, 
2005) and accumulating evidence indicates that the pathogenesis of Wolfram 
syndrome involves chronic ER stress, which triggers apoptosis due to loss of 
wolframin function. Compared to wild-type cells, elevated levels of ER stress markers 
such as BiP and CHOP have been detected in cells derived from rodent wfs1 knock-
out (wfs1-/-) models (Riggs, 2005), and transcriptional up-regulation of WFS1/wfs1 in 
both human and mouse cells is triggered by stress inducing agents such as 
thapsigargin, dithiothreitol and tunicamycin (Yamaguchi, 2004; Ueda, 2005; Fonseca, 
2005). Under the electron microscope, further signs of ER stress in wfs1-/- cells are 
indicated by dramatic abnormalities in morphology, including reduced secretory 
granules and dilated ER (Riggs, 2005).  
 
It seems that WFS1 may be necessary for cell survival, particularly under conditions 
of ER stress. Wfs1 deficient mouse insulinoma (MIN6) cells grown in vitro under 
standard conditions exhibit ~10% increase in apoptosis and display a 2.5-fold 
increase in cleaved caspase-3, a marker of apoptosis (Riggs, 2005). Furthermore, a 6-
fold increase in wfs1 protein expression can be detected in cells derived from Akita 
mice (Ueda, 2005), which are a model of MODY. These mice carry a C96Y mutation in 
the Ins2 gene, and have progressive loss of β-cells, shown to be a result, at least in 
part, of ER stress-induced apoptosis.  
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Links have been uncovered between wolframin and all three of the known ER stress-
sensing proteins. Firstly, in both IRE1α-/- and PERK-/- cells, the induction of 
wolframin protein expression normally triggered by ER stress is attenuated (Fonseca, 
2005). These findings suggest that wolframin expression under stress conditions is 
regulated by IRE1α and PERK.  
 
Furthermore, transcriptional activity of ATF6α is abated by WFS1 expression, 
suggesting wolframin has a role in the negative regulation of a feedback loop during 
ER stress signalling (Fonseca, 2010). Previously shown to be anchored to the ER 
membrane by BiP, ATF6α is cleaved and released from the ER to upregulate target 
genes in the nucleus under ER stress conditions. An even stronger suppression of this 
activity by wolframin was recently demonstrated with a promoter reporter assay 
(Fonseca, 2010). Further to these findings, a direct protein-protein interaction was 
observed under non-stress conditions between ATF6α and wolframin in pancreatic 
and neuronal cell lines, which dissociated in a time-dependent manner following 
treatment with stress inducing agents (thapsigargin, dithiothreitol).  
 
Experiments carried out in pancreatic MIN6 cells stably expressing shRNA against 
WFS1, lead to the conclusion that ATF6α is regulated by wolframin at the post-
translational level (Fonseca, 2010). ATF6α mRNA levels remained unchanged in 
wolframin depleted MIN6 cells, whereas a dose-dependent increase in ATF6α 
protein and downstream target genes (p58IPK, BiP) were observed, which could be 
reversed upon reintroduction of WFS1 with a lentiviral vector. The two other known 
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UPR master regulators, IRE1 and PERK, appeared unaffected by the reduction of 
WFS1.  
 
WFS1 enhances ubiquitination of ATF6α and seems to have a role in proteasomal 
degradation of ATF6α, which can be rescued following proteosome inhibition with 
MG132 (Fonseca, 2010). Glycerol gradient fractionation of ER-isolated lysates 
resulted in comigration of the proteosome, ATF6α and wolframin, suggesting the 
possibility of complex formation between these three proteins. Furthermore, HRD1 
(ER-resident E3 ligase) was also found to form a complex with these proteins and in 
wfs1-/- islets and patient cells has been shown to be upregulated by WFS1 
expression. The interaction between HRD1 and ATF6α was disrupted by ER stress 
conditions. Collectively, these results suggest that wolframin stabilises and enhances 
HRD1, which functions as an E3 ligase for ATF6α. ATF6α hyperactivation, likely to 
occur in Wolfram syndrome patients is probably involved in β-cell apoptosis, due to 
dysregulated ER stress signalling.  
 
Contrary reports have attributed beneficial effects of ATF6α upregulation in the 
protection of neurones and cardiomyocytes from ER stress/ischemia-mediated 
apoptosis (Martindale, 2006; Kudo, 2008), and also to attenuate diet-induced obesity 
and insulin resistance (Ye, 2010). Additional evidence comes from ATF6α -/- mice, 
and knock-out hepatocytes, both of which are more susceptible to the effects of ER 
stress compared to their wild-type counterparts (Wu, 2007). It seems likely that the 
opposing roles for ATF6α in both cell survival and death under conditions of stress 
are related to the extent of the ER stress and play a key part in the switch from 
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adaptive to apoptotic decisions. Polymorphisms and haplotypes of ATF6α are 
associated with type-2 diabetes and impaired glucose regulation (Meex, 2007), 
further highlighting the importance and likely involvement of this gene in WS 
pathology, and overall development of diabetes.  
 
 
1.6.0  WFS2 
Genetic heterogeneity was first demonstrated in Wolfram syndrome by El-shanti and 
colleagues in 2000 (El-shanti, 2000) who showed linkage to chromosome 4q22-24 in 
four consanguineous Jordanian Bedouin families (16 patients). Further microsatellite 
marker analysis within the defined critical region, direct sequencing and SSCP 
analysis revealed a novel gene, designated WFS2 (ZCD2), which carried a single 
homozygous nucleotide change (E37Q) in all affected individuals (Amr, 2007).  
 
WFS2 is a 3 exon gene, coding for a small, 135 amino acid, transmembrane protein 
known as ERIS (endoplasmic reticulum intermembrane small protein), which is 
expressed in a variety of tissue-types. Immunocytochemical analyses demonstrated 
co-localisation of ERIS and calnexin, an ER marker, but no direct interaction could be 
detected when co-immunoprecipitated with wolframin (Amr, 2007). 
 
WFS2, otherwise known as CISD2 or Miner1 belongs to an iron-sulphur domain gene 
family, which includes CISD1 (ZCD1, mitoNEET) and CISD3 (Miner 2) (Wiley, 2007). 
WFS2 shares a unique highly conserved CDGSH consensus sequence with both 
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Miner2 and mitoNEET, which is thought to be important for iron-binding. The 
mitoNEET protein (CISD1) resides on the outer mitochondrial membrane and is a 
target protein for pioglitazone, an insulin sensitiser drug used to treat type 2 
diabetes (Colca, 2004). It is thought that mitoNEET functions in some capacity in 
redox reactions and electron transport due to the reduction of oxidative capacity 
observed in mouse mitoNEET-null heart tissue (Wiley, 2007). Although the function 
of WFS2 is not clearly defined, iron-containing proteins are known to frequently 
function as redox-sensitive molecules and dysregulation of iron metabolism is 
associated with diabetes (Fernandez-Real, 2004). 
 
WFS2 deficiency appears to confer susceptibility to apoptosis, as demonstrated by 
the presence of pro-apoptotic markers CHOP and BAX (Bcl2-associated X protein) in 
knock-down rat pancreatic β-cells (Amr, 2010). Unlike findings from WFS1 knock-
down models, no activation of the UPR was detectable in WFS2 depleted (INS-1) 
cells. Translational upregulation of antioxidant enzymes SOD1 and SOD2 (superoxide 
dismutase 1 and 2) together with a significant increase in global tyrosine nitration 
were detected however, suggesting the presence of oxidative stress. It is unclear 
whether this is a cause or consequence of WFS2-mediated pathogenesis. 
 
Earlier murine knockout (WFS2-/-) studies indicated that WFS2 is necessary for 
mitochondrial integrity, and reported co-localisation with mitochondrial markers 
(Chen, 2009). Deficiency of WFS2 in mice caused autophagic cell death accompanied 
by mitochondrial breakdown and dysfunction, which are precedents to nerve and 
muscle degenerative pathways, classic phenotypic features of premature aging. 
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Notably, the same region of chromosome 4q in which WFS2 is located was linked to 
longevity in humans (Puca, 2001). These observations support the previously 
disputed notion that WS is at least in part associated with mitochondrial defects, 
although the phenotypic effects of WFS2-/- in these model mice are somewhat 
distinct from that of WS in humans, so proposed links remain debatable. 
 
1.7.0  Understanding Wolfram syndrome pathogenesis and the role of 
WFS1 in type 2 diabetes 
 
It is known that the majority of Wolfram syndrome patients carry mutations in 
WFS1, although how genetic alterations disrupt the function of the wolframin 
protein is unclear. Previous study of WFS1 mutants and WFS1-null models has led to 
the belief that WS is caused by loss of WFS1 function, which leads to ER-stress 
mediated apoptosis of pancreatic β-cells and other susceptible cell-types.  
 
An interesting feature of WS is the variability of phenotype, which is as yet 
unexplained. Some individuals present with the full spectrum of associated clinical 
features, whereas others appear only to develop a select few. A number of 
individuals also appear to have a milder form of WS, with relatively late-onset of 
disease characteristics (Van de Ouweland, 2003; Cano, 2007; Gasparin, 2009).  
 
Accepting unresolvable ER stress as the primary cause of disease pathogenesis, the 
question arises as to why clinical manifestations of disease present with delayed 
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onset in some individuals? Perhaps it requires a number of years for levels of chronic 
cellular stress to reach a critical threshold where the ‘switch’ to apoptosis is 
activated, beginning the process of irreversible tissue degeneration. Conversely, 
apoptotic pathways may indeed be activated from earlier stages of life, but go 
undetected until sufficient tissue damage prompts clinical detection.  It is certainly 
possible that background genetics of WS patients may play a fundamental role in the 
severity of disease progression. Combined actions of other undefined proteins 
involved in wolframin functional pathways including the UPR, could play a significant 
role in the efficiency of the system as a whole. A poorer prognosis or more severe 
phenotype may then depend on the presence of WFS1 mutation together with one, 
or a number of other risk alleles. 
 
The mutation-type carried by an affected individual could also determine the relative 
severity of disease. Other studies postulate that mutation causes loss of wolframin 
function as a result of protein aggregation or instability leading to degradation of 
wolframin (Hofmann, 2003; 2006).  
 
HYPOTHESIS 
 
In light of the phenotypic variability in WS and the additional non-syndromic 
disorders linked to WFS1-variants, we hypothesise that a number of alternative 
wolframin-dependent pathways could be affected distinctly by different types of 
mutation, and this may reflect the spectrum of phenotypic features observed in WS 
patients and WFS1-related disorders.  
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The work presented in this thesis is aimed at exploring the hypothesis that some 
wolframin variants retain partial function. The basis for this proposal is drawn from a 
number of WS attributes, namely the heterogeneous complement of clinical features 
associated with WFS1 mutations. The report of ‘milder’ phenotypes suggests that 
some wolframin variants have partial function. We would like to ascertain whether 
this may be the case, perhaps opening the door for new therapeutic intervention in 
these instances. Furthermore we hope to understand more about how the diabetes 
risk allele (WFS1-H611) contributes to disease pathogenesis, by establishing the 
foundations for functional experiments. 
 
By characterising representative wolframin variants we intend to test aspects of 
wolframin function such as protein-interaction, ER stress response, insulin secretion 
and Ca2+ homeostasis and uncover any contrast in function, which might explain the 
phenotypic variation. It is anticipated that those wolframin variants relating to mildly 
affected individuals may display at least some residual function. Our aim is to expand 
current functional data about missense variants from the perspective of genotype-
phenotype relations. To achieve this we are primarily asking: 
 
Do some WFS1 mutations allow partial function of wolframin? 
 
We will begin to address this question by firstly expanding the current WFS1 
mutational spectrum, to provide the largest single UK Wolfram syndrome patient 
cohort to date. The groundwork for functional study of WFS1 genotype and 
phenotype relationships is then laid by characterisation of selected WFS1-variants 
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corresponding to phenotypes of variable severity. Finally, a number of potential 
novel wolframin molecular partners from the pancreas are described, together with 
the first evidence of WFS1 expression in exocrine tissue, providing further insights 
about wolframin function.  
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CHAPTER 2 
MATERIALS AND METHODS  
 
2.0.0  Suppliers of laboratory materials 
 
Appendix 1A-B lists supplier details of laboratory equipment and reagents. Unless 
otherwise stated, general tissue culture plastics were obtained from Corning Life 
Sciences (Appleton Woods).  
 
2.0.1  Patient DNA samples and clinical data 
 
The Wolfram patient DNA was obtained from Birmingham Womens Hospital diagnostics 
department, courtesy of Prof. T.G. Barrett. Stored samples were collected from patients 
referred to the West Midlands Regional Genetics Laboratory over a period from the 
early 1990s to 2010. Healthy control DNA was available from the Birmingham 
University, Medical and Molecular Genetics laboratory.  
 
Patient clinical data was provided by Prof. T.G Barrett, Diabetes Unit, Birmingham 
Children’s Hospital, UK. 
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2.0.2  Cell lines 
 
The mammalian cell lines used for this work, unless stated, were available from the 
Birmingham University, Medical and Molecular Genetics laboratory.  
 
2.1.0  DNA amplification 
 
The polymerase chain reaction (PCR) is used to amplify specific target regions of DNA 
from starting material by several orders of magnitude. This technique enables 
generation of quantities necessary for applications such as sequencing, cloning and gene 
expression assays.  
 
Starting DNA is mixed with an excess of deoxynucleoside triphosphates (dNTPs), which 
provide the building blocks for synthesis of new DNA strands. A heat-stable DNA 
polymerase in a suitable buffering solution provides the enzymatic activity for assembly 
of new complementary ‘daughter’ DNA strands from primers specific to both sense and 
anti-sense strands of the parent DNA. 
 
Reactions, typically carried out on a thermal cycling machine, involve 20-40 repeat 
cycles of 3 discrete temperature intervals. The first denaturing step is achieved at 
temperatures between 94˚C-98˚C and serves to separate the DNA template into single 
CHAPTER 2 MATERIALS AND METHODS 
 
 
39 
 
strands by disruption of the hydrogen bonds between complementary bases. The 
second annealing step allows primers to bind to the DNA templates and is achieved at 
temperatures specifically just below the melting point of the primers, usually in the 
region of 50˚C-68˚C. At this stage the polymerase is able to bind to the primer-template 
complex and initiate synthesis of new DNA strands.  A final elongation step at a 
temperature optimal for polymerase activity (72˚C-80˚C) allows dNTPs to be 
sequentially added to the template by condensing the 5’ phosphate group of the free 
dNTPs with the 3’ hydroxyl group at the end of the new DNA strand. In optimal 
conditions exponential amplification of the DNA fragment occurs. Once the repeat 
cycles have completed, an additional elongation step of several minutes usually 
concludes the reaction to ensure any remaining single-stranded DNA is fully extended.  
 
2.1.1  Genomic DNA PCR 
 
Components 
Standard 30µl reactions consisting of 50ng DNA and 20pmol of appropriate forward and 
reverse primers (see appendix 2), were mixed with reagents obtained from Invitrogen 
including: 0.25mM dNTP mixture, 2.0mM magnesium chloride, 0.5 units Taq DNA 
polymerase and x1 PCR reaction buffer. Q-solution (x1), a novel additive developed by 
Qiagen, was added to reactions where appropriate. This reagent helps to increase the 
efficiency of reactions containing G-C rich templates, which are often particularly 
difficult to amplify. 
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The remaining reaction volume (up to 30 µl) was made up with ddH2O and mixed 
thoroughly by pipetting.  
 
Conditions 
Initial reaction conditions were set at 95˚C for 5 minutes for preliminary denaturation, 
followed by 35 cycles of 95˚C for 30 seconds, a specified annealing temperature (see 
optimisation below) for 30 seconds, and 72˚C for 1 minute to allow for elongation. The 
programme was completed with a final extension time of 10 minutes at 72˚C. 
 
Optimisation 
Primer annealing temperatures were initially set according to GC content using the 
formula (64.9+0.41 {GC%}-600/n), where n is equal to the number of bases in the 
primer. Extension time allowed 1 minute for every 1kb of DNA to be amplified, with a 
minimum of 30 seconds. Optimisation of PCR was achieved with variation of annealing 
temperature, and magnesium chloride concentration. Touchdown PCR programmes 
were also used to successfully amplify DNA fragments from particularly difficult primer 
sets. These programmes include additional cycles of annealing and elongation at 
decreasingly higher than optimal temperatures to minimize non-specific primer 
annealing. 
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Controls 
To test for the presence of possible contaminating amplicons, negative controls 
containing all reaction components except template DNA (substituted with ddH20) were 
included.  
Positive external control samples, known to amplify in given conditions, were also used 
to verify negative amplification results where appropriate. These controls test the 
efficiency of primer sets, reaction components and cycling conditions. 
 
Primers 
Primers were designed manually or using the Primer 3 design software (Rozen, 2000) 
and obtained, unless stated otherwise, from AltaBioscience. Primer sets ideally spanned 
a maximum of 400-600 base pairs (bp) of DNA with the 5’ end at least 50 bp upstream of 
the region of interest. Oligonucleotides ranged between 20-30 bases in length, with 
~50-60% G+C base composition, to provide for practical annealing temperatures. 
Inverted repeat sequences and self-complementary sequences were avoided to 
minimize the synthesis of primer dimers and 2o structures such as hairpins. Runs of any 
single base or dinucleotide repeats were also avoided to reduce mispriming. Where 
possible G and C rich 3’ ends were selected, to enhance the annealing end for extension. 
 
A comprehensive list of primer sequences can be found in appendix 2. 
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2.1.2  Reverse-transcription PCR 
 
Reverse transcription PCR enables synthesis of single-stranded complementary DNA 
(cDNA) from total or poly (A)+ isolated RNA, and these types of assay are a useful 
method for characterizing and confirming gene expression patterns. The reverse 
transcription reaction is carried out using a retroviral enzyme with the capability of 
producing cDNA copies from RNA templates. The resulting cDNA may then be stored at -
20°C or used as a template in a subsequent traditional PCR amplification (section 2.1.1) 
with specific primers as desired. 
Conditions 
According to protocol, two methods of cDNA synthesis were used: 
 
Promega Reverse Transcription system 
Isolated RNA, extracted from cells using TRIzol (section 2.10.2), was prepared by initial 
incubation at 70°C for 10 minutes, followed by a brief spin in a micro-centrifuge and 
incubation on ice. Reactions were mixed using Reverse Transcription System reagents 
from Promega consisting of:  5mM MgCl2, reverse transcription buffer (x1), 1mM dNTP 
mixture, 0.5 units recombinant RNasin ribonuclease inhibitor, 15 units AMV reverse 
transcriptase (high conc.), 0.5µg (1µl) random primers, 1µg total RNA and nuclease free 
H20 to a final volume of 20µl. 
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Reactions were incubated at room temperature for 10 minutes, then 42°C for 15 
minutes to allow primer annealing and enzymatic extension of new cDNA strands by 
reverse transcriptase. Samples were then heated at 95°C for 5 minutes to inactivate the 
AMV reverse transcriptase, and incubated at 4°C to prevent binding of enzymes to the 
cDNA.  
 
Applied Biosystems High Capacity cDNA Reverse Transcription kit 
A reverse transcription master mix was prepared on ice with: 2µl RT buffer (x2), 0.8µl 
100mM dNTP mix, 2µl random primers, 1µl MultiScribe reverse transcriptase, 1µl RNase 
inhibitor and 3.2µl nuclease-free H20. In a 96-well plate, 10µl of master mix was 
pipetted into each well and mixed with 10µl (350ng) of sample RNA. Reverse 
transcription was carried out on a thermal cycler, following the same principles as that 
described above, with slightly different optimal temperature intervals: 25°C for 10 
minutes, 37°C for 120 minutes, 85°C for 5 minutes, then cooling at 4°C. 
 
2.1.3  Real-time PCR/Quantitative PCR (Q-PCR) 
 
Q-PCR is a method which allows simultaneous amplification, detection and 
quantification of targeted DNA molecules. It is often preceded by reverse transcription 
of RNA samples to enable measurement of mRNA levels in cells and tissues. The general 
principles of the reaction are similar to standard PCR (section 2.1.1) but include probes 
and fluorescent reporter dyes for specific or non-specific target sequences, which 
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permit quantification of copy numbers, either absolutely or relative to normalising 
genes.  
 
Conditions and analysis 
Real-time PCR was employed for the measurement of WFS1 expression in different 
sample sets, normalized to the β-actin gene. Total RNA was harvested from cells with 
Trizol (section 2.10.2) and reverse transcribed to cDNA using the Applied Biosystems 
High Capacity cDNA Reverse Transcription kit (section 2.1.2).  
 
The Taqman Gene Expression Assay from Applied Biosystems, which runs under 
universal cycling conditions, was the assay of choice as the system is target specific and 
pre-optimized for measurement of a wide range of genes, including WFS1. FAM dye-
labelled probes for a specific region of the human WFS1 and ACTB (β-actin) genes were 
selected (Applied Biosystems) and used in conjunction with Taqman universal 
mastermix. 
 
Samples were prepared in a 7500 System compatible 96-well plate (Applied Biosystems) 
including: 5µl cDNA (8.75ng), 10µl Taqman universal mastermix, 1µl (250nM) combined 
forward and reverse primers (labelled), and ddH20 to a final volume of 20µl. Q-PCR runs 
were then performed on an Applied Biosystems 7500 Real-time PCR machine with 7500 
v.2.0 software using the comparative Ct (threshold cycle) method for relative 
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quantification of WFS1 expression. This programme features an initial 10 minute hold 
step at 95°C, followed by x40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
 
The Ct value for a given sample following Q-PCR is defined as the number of cycles 
required for the signal to exceed background levels (threshold). These values are 
inversely proportional to the amount of target nucleic acid in the sample. Ct values for 
all samples were normalised to an appropriate endogenous house-keeping gene (e.g. 
ACTB), then experimental samples compared to ‘non-treated’ controls. The change in 
gene expression between samples and controls is expressed as [delta][delta]Ct and was 
calculated according to the formula below: 
 
[delta][delta]Ct    =  [delta]Ct experiment   -   [delta]Ct control 
 
 
Where [delta]Ct experiment is the Ct value for any sample normalised to the endogenous 
housekeeping gene and [delta]Ct control is the Ct value for the control also normalised to 
the house-keeping gene. In this case the experimental samples refer to WFS1-variants 
and reference controls represent wild-type WFS1.  
 
Assuming efficiency is 100%, we also calculated fold change between control and 
experimental samples (2^ [delta][delta]Ct = fold change): 
 
Ratio experimental/control =            fold change in target gene (WFS1-mutant) 
              (fold change)                           fold change in control gene (WFS1-wild-type) 
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2.2.0  Restriction Digestion  
 
A range of restriction endonucleases were used to cut specific fragments of DNA for the 
purposes of isolation and identification. DNA was incubated with an appropriate 
amount of restriction enzyme, in its respective buffer as recommended by the supplier. 
Reactions typically incubated for 1-3 hours at the enzyme specific optimal temperature 
(~37C). Double digests were performed with enzymes activated in the same buffer and 
incubation temperature. 
 
Typical digestions included a unit of enzyme per microgram of starting DNA, where one 
enzyme unit (depending on the supplier) is defined as the amount of enzyme needed to 
completely digest one microgram of double-stranded DNA in one hour at the 
appropriate temperature. Completed restriction digests were separated into constituent 
fragments and visualized by agarose gel electrophoresis (section 2.3.0). 
 
2.3.0  Agarose Gel Electrophoresis 
 
Electrophoresis on agarose gel was used to detect successful PCR amplification and 
restriction digestion of correctly sized DNA fragments. When DNA (negatively charged) 
is moved by an electric current through an agarose matrix, products can be 
distinguished by position (band) as differing sized fragments move through the gel at 
variable rates towards the cathode. Gels were made with agarose heated to dissolve in 
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x1 TBE buffer solution (890mM Tris Borate pH8.3 and 2mM Na2EDTA). Typical gel 
concentrations were 1-2%, depending on product size to be resolved. Approximately 
20ng ethidium bromide (EtBr) was added on cooling of solution. EtBr fluoresces under 
ultraviolet light when intercalated with DNA, thus allowing visualization of products.  
 
Once cooled (below 60°C), molten agarose was poured carefully into an electrophoresis 
tray and left to polymerize with one or several well-combs inserted (size dependent on 
samples). The combs were removed from solidified gel and trays placed into 
electrophoresis tanks, immersed in x1 TBE buffer solution. Samples (≥20ng) mixed in 
loading buffer (30% glycerol, ddH20 and Orange G dye) were pipetted into empty wells 
and an appropriately sized DNA ladder (Invitrogen) was loaded alongside as a size 
marker. Gels were routinely run at 180 volts as required. 
 
The results were visualized and imaged in a UV light box connected with a high-
resolution camera and GelDoc software (Syngene). 
 
2.3.1  Agarose Gel Extraction  
 
The QIAquick gel extraction kit (Qiagen) was used to extract DNA from agarose gel 
following manufacturers’ guidelines. DNA samples run through agarose gel were 
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visualized under a UV light source and bands of interest were excised using a sterile 
scalpel.  
 
Three volumes of buffer QG were added to 1 volume of gel and incubated at 50C for 10 
minutes to dissolve. One gel volume of isopropanol was added to the mixture, which 
was then loaded onto a Qiagen spin column. The column was centrifuged for 1 minute 
at 13,000rpm and the flow-through discarded. The DNA (bound to column matrix) was 
then washed and centrifuged at 13,000rpm; firstly with 0.5ml of buffer QG to remove all 
traces of agarose, then 0.75ml of wash buffer PE. A further 1 minute spin ensured the 
removal of any remaining flow-through from the column. The DNA was eluted in 30µl of 
sterile H2O following a final centrifugation step of 1-2minutes at 13,000rpm. 
 
2.4.0  Sequencing 
 
DNA Cleanup 
PCR products were cleaned up in preparation for sequencing using a combination of 
hydrolytic enzymes in suitable buffer. Antarctic Phosphatase, used to remove excess 
dNTPs and primers, was combined with Exonuclease I, which degrades residual single-
stranded primers and any extraneous single-stranded DNA from the PCR reaction. 
 
Reactions were carried out on a thermal cycler in 10l total volumes, comprising 5l 
PCR product, 1l Antarctic Phosphatase (20 units), 1l Antarctic Phosphatase buffer, 
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0.25l Exonuclease I (0.25 units), and 0.75l sterile H2O. Enzymes were activated at 
37C for 30 minutes then subsequently inactivated at 85C for another 30 minutes. 
 
Sequencing Reaction 
Sequencing reactions were carried out on 96-well plates (Fisher) in a thermal cycler. 
Each sample was prepared in a 10l total volume, comprising; 5l DNA (≥5ng), 1l Big 
Dye Terminator mix (Applied Biosystems), 2l sequencing buffer (200mM Tris-HCl pH 
9.0, 5mM MgCl2), 1l sterile H2O, and 1l primer (20pmol).  
 
The samples were heated to 95C for 25 seconds, cooled to 50C for 25 seconds, and 
ramped up to 60C over 28 cycles. Following the reaction, samples were kept covered at 
4C.  
 
Ethanol precipitation 
Ethanol precipitation was used to concentrate and de-salt DNA prior to sequencing. 
100l of absolute ethanol, plus 3.5l sodium acetate (3M pH 5.2) EDTA (125mM pH 8.0) 
was added to samples taken directly from a sequencing reaction (see above). DNA was 
then pelleted in a centrifuge (4C) at 4,000rpm for 30 minutes. Supernatant was poured 
from wells by inversion of the plate.  
 
Two subsequent washes in 70% ethanol (200l) were carried out as per the above 
conditions. Following the final spin, and supernatant removal, the plate was inverted 
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and centrifuged in a swinging bucket rotor at 400rpm for 30 seconds to remove excess 
ethanol. The plate was then left to air dry for up to 30 minutes. 
 
Sequencing analysis 
Samples were resuspended after air-drying in 10l of Hi-Di Formamide, a ready to use 
stable injection solvent from Applied Biosystems that is suitable for use on ABI PRISM 
DNA analysis machines. The plate was denatured on a heat block at 95C for 5 minutes 
then placed directly onto ice for at least 5 minutes to cool prior to sequencing.   
 
DNA was sequenced on an automated ABI3730 sequencer and analysed using the ABI 
sequencing analysis software (Applied Biosystems). 
 
2.5.0  Microsatellite marker analysis  
 
Microsatellites, or simple sequence repeats (SSRs) are tandemly repeated genetic 
elements of 1-4 nucleotides, usually found in non-coding regions of DNA. The number of 
repeats in a given microsatellite is highly variable, which makes them very useful as 
genetic markers for application in mapping, linkage analysis and tracing inheritance 
patterns.  
 
PCR amplification of SSRs of interest generates DNA fragments of differing lengths 
according to the haplotype of the individual. A fluorescent probe can then be mixed 
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with the products and loaded onto a sequencing machine with appropriate software 
(e.g. GENESCAN, ABI) that will analyze the fragment lengths for comparison. 
 
In this study (section 3.3.2) microsatellite analysis was used to compare specific markers 
between families with WFS2-associated Wolfram syndrome to investigate the likelihood 
of common ancestry. A common haplotype previously described in WFS2 families (Amr, 
2000), was investigated in our affected individual with WFS2 mutations.  
 
PCR with selected markers 
PCR reactions were carried out on a thermal cycling machine (section 2.1.1) using 
labeled primers (appendix 2) corresponding to the critical region (D4S3256, D4S1531, 
D4S1564; Amr, 2000) and DNA from: our affected individual, a normal control, and an 
affected individual from the earlier WFS2 cohort (Amr, 2000) kindly provided by Dr Rita 
Shiang, Virginia Commonwealth University.  
 
Total reaction volumes of 10µl comprised: 20ng of genomic DNA, fluorescently labeled 
forward primer (0.2mM), unlabelled reverse primer (0.2mM), dNTPs (0.2mM), Taq 
polymerase (0.5 units) in x1 Taq buffer (containing 1.5mM MgCl2). After initial 
denaturation (3 min at 95°C), amplification was performed over 26 cycles (95°C for 
30sec, 55°C for 30sec, 72°C for 30sec) followed by a final extension at 72°C for 10 
minutes.  
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Concentrated PCR products (1l), and 1:10, 1:20 and 1:50 dilutions in ddH2O, were 
mixed with 0.5l GeneScan Internal Lane Size Standard (Applied Biosystems) and 12l 
deionized formamide and loaded onto 96 well plates. Empty wells were filled with equal 
volumes of ddH2O (12.5l). The samples were denatured for 5 minutes at 95°C on a heat 
block and then placed on ice to cool.  
 
Products were analyzed on an automated ABI3730 sequencer, using the Genotyper 
v3.5/4 software (ABI). 
 
2.6.0  Site-directed mutagenesis 
 
The QuickChange Site-Directed Mutagenesis kit (Stratagene) was used to introduce site-
specific point mutations into double-stranded plasmid DNA. Complementary primers 
containing a desired single base change were extended by PfuTurbo DNA polymerase 
during a thermal cycling reaction. The products were treated with Dpn I endonuclease, 
which specifically targets methylated and hemimethylated DNA. This allows targeted 
degradation of ‘non-mutated’ parental DNA templates since the majority of E.coli 
strains, including vectors used in this protocol, contain dam methylated DNA. The newly 
synthesized vector DNA incorporating the desired mutation could therefore be selected 
and transformed into XL-1 Blue supercompetent cells, which serve to repair the nicks in 
the plasmid and produce large numbers of copies. 
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Mutagenic primer design 
The web-based QuikChange Primer Design Programme from Stratagene (table 2.3) was 
used to design primers for mutagenesis.  
 
The oligonucleotide design parameters specify primer lengths ranging from 25-45 bases 
with the desired mutation in the middle. Both forward and reverse primers should 
contain the mutation with matched complementary sequences to opposite strands of 
the plasmid. The primer sequence should ideally terminate with one or more guanine or 
cytosine residues and have over 40% GC content. An optimum melting temperature 
(Tm) is ≥78C, which was checked with the following formula; 
 
Tm = 81.5 + 0.41 (%GC) - 675/N - % mismatch 
 
Where N is the length of oligonucleotide, and values for %GC and % mismatch are whole 
numbers. 
 
Mutagenesis reaction 
Sample reactions were set up with 10ng of dsDNA template, 5l of 10x reaction buffer, 
125ng of both forward and reverse primers (FPLC purified), 1l dNTP mix (of a 
proprietary composition optimised by Stratagene), 3l Quiksolution (Stratagene), 1l 
(2.5 units) PfuTurbo DNA polymerase and ddH2O to a final volume of 50l. 
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A control reaction was included to test the efficiency of the polymerase and 
demonstrate the effectiveness of the QuikChange Mutagenesis kit. This comprised 10ng 
of pWhitescript 4.5kb control plasmid, 5l of 10x reaction buffer, 125ng of both forward 
and reverse control primers, 1l dNTP mix, 3l Quiksolution, 1l (2.5 units) PfuTurbo 
DNA polymerase and ddH2O to a final volume of 50l.  
 
The pWhitescript plasmid contains a stop codon (TAA) in the position where a glutamine 
codon (CAA) would normally appear in the β–galactosidase gene of the pBluescript II 
SK(-) phagemid. The control primers create a point mutation to revert the T residue of 
the stop codon back to the C of glutamine. This enables successfully mutated and 
transformed clones to appear ‘blue’ when grown on selective media containing IPTG 
and X-Gal. 
 
On a thermal cycler, reactions were run at 95C for 1 minute, followed by 12 cycles of; 
95C for 50 seconds, 60C for 50 seconds, and 68C for 9 minutes.  
 
Dpn I digestion 
Following the temperature cycling, the products were cooled on ice for at least 2 
minutes, before addition of 1l (10U) Dpn I restriction enzyme. The solutions were 
mixed with a pipette and incubated at 37C for 1 hour. 
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Transformation of XL1-Blue Supercompetent cells 
XL1-Blue Supercompetent cells were thawed on ice and aliquoted to pre-chilled 1.5ml 
polypropylene tubes in 50l volumes. The Dpn I treated DNA samples (1l) were added 
to the cells, mixed gently with a pipette tip, and incubated on ice for 30 minutes. To test 
the transformation efficiency of the Supercompetent Cells, 1l of pUC18 control plasmid 
(0.1ng) was added to a separate aliquot of cells as a positive control.   
 
Following the incubation period, the tubes were heat-shocked in a 42C water bath for 
45 seconds, and placed immediately on ice for 2 minutes. Recovery medium was added 
to the cells (0.5ml SOC) and the transformed cells were placed into an orbital shaker for 
1 hour at 37C. 
 
The cells were subsequently spread in 250l volumes onto LB-ampicillin agar plates 
containing 80g/ml X-Gal and 20mM IPTG (section 2.7), and incubated at 37C for >16 
hours. 
  
2.7.0  Microbial cell culture and manipulation 
 
Microbes were exploited for their ability to replicate quickly and reliably in the 
laboratory for the purposes of cloning and manipulation of plasmid DNA. Typical steps 
for handling E. coli strains are outlined in figure 2.0.  
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2.7.1  Long-term storage and revival of bacteria  
 
Although agar plates can be used for short-term storage of bacteria (4C), glycerol 
stocks of various strains were prepared for long-term storage in liquid nitrogen 
(approximately -196C).  Screw cap cryovials (2ml) were filled with 0.85ml logarithmic-
phase cell culture and 0.15ml sterile glycerol and vortexed to thoroughly mix. Cells were 
frozen to -80C before transfer to liquid nitrogen. Stocks cells were revived by warming 
ampoules and inoculating selective growth plates (section 2.7.3). 
 
Figure 2.0. Essential steps for storage and handling of E. coli strains 
(adapted from QIAGEN Bench Guides)  
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2.7.2 Preparation of Luria-Bertani (LB) broth and agar plates 
 
LB broth was prepared using 20g of LB broth powder (Sigma) per 100ml water required. 
The suspension was autoclaved and allowed to cool prior to use or storage (4C). 
 
LB agar plates were prepared using 35g of LB agar powder (Sigma) per 100ml water 
required. The suspension was autoclaved and allowed to cool below 50C. In a laminar 
flow cabinet any necessary antibiotics or selection reagents were added and swirled 
gently to mix. Molten agar was then poured into sterile Petri dishes (10cm diameter) 
filling to approximately 1/8”, taking care to avoid formation of air bubbles. Once air 
dried, the plates were ready for use or storage at 4C. The plates were stacked and 
inverted for refrigeration to prevent condensation dripping onto the agar surface.   
 
Selection additives 
During cell culture, selection additives such as antibiotics are combined with the growth 
media as a method of isolating clones of interest. Depending on the genetic 
complement of the cells, the ability of microbes to grow on a given substrate varies and 
this can be manipulated in the laboratory by introducing plasmids containing specified 
genes, such as antibiotic resistance or other markers, which can be used to distinguish 
transformed cells.  
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Antibiotics 
Antibiotics were added to broth or molten agar after cooling below 50C at a typical 
concentration range of 50-100µg/ml.  
 
X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) 
X-Gal was used as a substrate for the purposes of blue/white screening, a technique 
used to indicate the presence of β-galactosidase expression, encoded by the lacZ gene. 
β-galactosidase cleaves X-Gal to produce an insoluble blue product, so incorporating 
lacZ onto cloning plasmids can be a useful tool for distinguishing clones of interest. For 
the purposes of cloning, successful ligations can be isolated by inserting fragments 
within a functional LacZ sequence so that all ‘ligated’ colonies grown on X-Gal media will 
be white in colour.  
 
X- Gal was dissolved at 2mg/ml in dimethylformamide (DMF) and stored in the dark at -
20C. For incorporation into agar plates 2µl of X-Gal stock per ml of autoclaved molten 
agar (cooled below 60C) was mixed before pouring to give a final concentration of 
40µg/ml. Concentrations vary according to protocol. 
 
IPTG (isopropyl beta-D-thiogalactopyranoside) 
IPTG is a compound that triggers transcription of the lac operon and production of the 
β-galactosidase enzyme. For application in blue/white colony screening protocols IPTG 
was used as an additive to agar plates in combination with X-gal. 
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A 0.1M stock solution of IPTG in sterile H2O was prepared, filtered and stored at -20C. 
For incorporation into agar plates, 1µl IPTG stock per ml of autoclaved molten agar 
(cooled below 60C) was mixed before pouring to give a final concentration of 0.1mM 
IPTG. Concentrations vary according to protocol. 
 
2.7.3  General culture and selection of bacterial cells 
 
Growth on agar plates and selection of clones 
To obtain isolated clonal colonies: in a sterile environment, an inoculum of bacteria was 
taken from a glycerol stock, another plate, or from a stab culture and streaked with a 
loop onto the corner of an agar plate containing appropriate selection additives. A fresh 
loop was then passed through the first streak and streaked again across a fresh corner 
of the plate. The plate was incubated upside down at 37C for 12-24 hours until colonies 
developed. 
 
To select a single clone, a well isolated colony was picked gently from the surface of the 
plate with a sterile loop and seeded into 2-5mls of LB broth (with selection additives). 
Following an incubation period of ~16 hours (37C), the cells were either harvested or 
added as a pre-culture to a larger volume of LB broth (100ml), which was grown for a 
further 16 hours (37C) to propagate much larger quantities of cells. 
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Growth in liquid culture 
Bacterial cell cultures were grown in Luria-Bertani (LB) broth at 37C in an orbital 
shaker. Flasks that enabled liquid culture with a large surface to volume ratio were used 
to facilitate aeration and respiration; typically no more than 10-20% of the total volume 
of the vessel was filled with broth.  
 
Following propagation of liquid culture cells were harvested. Centrifugation (≤6,000xg 
for 5-15 minutes) in suitable polypropylene tubes removed cells from suspension to 
form a dense pellet at the bottom of the tube. The supernatant was decanted and tubes 
were inverted for a few minutes to allow any excess media to run out. The remaining 
bacterial pellets were then ready for DNA extraction (section 2.7.5) or stored (-20C).  
 
2.7.4  Transformation of bacterial cells (cellular cloning) 
 
Bacterial cells were transformed with plasmids of interest and subsequently grown into 
culture derived from a single clone. This allowed rapid multiplication of plasmid copies 
for later extraction and purification. Foreign DNA was introduced into competent cells 
using chemical or electrical transformation.  
 
CHAPTER 2 MATERIALS AND METHODS 
 
 
61 
 
Electroporation has the advantage of yielding more efficient transformation although is 
limited by either small volumes or pre-treatment of DNA as the procedure is sensitive to 
high concentrations of salt. 
 
Chemical transformation 
Suspension of cells in CaCl2 solution confers chemical competence. Ca
2+ ions are thought 
to create pores in cell membranes and mask the negative charges on DNA to allow 
easier passage across the hydrophobic cell membrane. A short heat shock applied to a 
cell/DNA mixture creates a thermal current that sweeps DNA into the cells. 
 
Transformation of purified plasmid preps was carried out using subcloning efficiency (1 x 
106 cfu/µg pUC19) DH5 competent cells (Invitrogen). Cells of increased efficiency, 
according to requirements were favoured for use in molecular cloning protocols (section 
2.19).  
 
Chemically competent cells (stored at -80C) were thawed on ice and pipetted gently 
(50-100µl) into pre-chilled 1.5ml micro-centrifuge tubes. DNA preps (1-5µl) were added 
to individual aliquots of cells, stirred carefully with the pipette tip, and incubated on ice 
for 30 minutes. A separate transformation control containing 2.5µl of pUC19 plasmid 
(250pg) was also prepared. The mixture was then heat shocked for up to 1 minute in a 
water-filled heat block at 42C, and transferred to ice for 2 minutes. Shocked cells were 
then suspended in 0.5ml SOC medium (Super Optimal Broth with Catabolite repression) 
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from Invitrogen (2% w/v bacto-tryptone, 0.5% w/v yeast extract, 10mM NaCl, 2.5mM 
KCl, 10mM MgCl2, 10mM MgSO4, 20mM glucose, ddH2O) and recovered for 1 hour at 
37C, in an orbital shaker.  
 
Recovered cells were plated onto LB agar (section 2.7.2) containing appropriate 
selection additives and incubated at 37C for up to 16 hours. 
 
Electroporation 
The principle of electroporation is based on applying a quick voltage shock across a cell 
membrane, which causes temporary disruption to the phospholipid bilayer allowing 
polar molecules (e.g. DNA) to pass into the cell. Cells (available commercially) are made 
electrically competent by removal of all medium salts, which ensures a charge is not 
conducted through the medium.  
 
ElectroMAX DH5α-E electrocompetent cells (Invitrogen) were thawed on wet ice. In pre-
chilled micro-centrifuge tubes 20µl of cells were gently mixed with 1µl (≤100ng) of 
purified DNA. A control sample with 1µl (100pg) pUC19 plasmid DNA was included to 
assess the transformation efficiency.  
 
The cell/DNA mixture was carefully pipetted into a 0.1cm cuvette, loaded into an 
electroporator (BioRad GenePulser) where a 2.0kV pulse was applied. SOC medium 
(1ml) was immediately added to cells in the cuvette and the suspension was transferred 
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to a 15ml polypropylene tube and recovered for 1 hour at 37°C in an orbital shaker 
(225rpm). 
 
A range of dilutions in SOC media were made with cell suspensions following recovery. 
Typically 50-100µl of cell suspension was spread onto selective LB plates (section 2.7.2) 
and incubated overnight at 37°C. 
 
2.7.5  Extraction of plasmid DNA from bacterial cells 
 
Plasmid DNA can be separated from bacterial genomic DNA following the basic 
principles of alkaline lysis, first described in 1979 (Birnboim, 1979). Cells containing the 
desired plasmids are cultured then separated from growth medium by centrifugation, 
before resuspension in a specialised solution containing glucose, RNase A, EDTA and 
Tris. These components serve to maintain the osmotic pressure of the cells, disrupt the 
cell wall, protect plasmids from damage by DNases, and degrade cellular RNA (after 
lysis). 
 
Cells are then lysed in NaOH (sodium hydroxide) and SDS (sodium dodecyl sulfate), 
which solubilise cell membranes, break down cell walls and also convert double-
stranded DNA (dsDNA) to single-stranded DNA (ssDNA) and denature most of the 
proteins. Isolation of plasmid DNA from genomic DNA occurs during neutralisation of 
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lysis buffer with potassium acetate, which decreases the alkalinity of the mixture 
allowing hydrogen bonding between bases of ssDNA to reform into double strands. Due 
to small size, circular plasmid DNA re-natures much more readily than longer strands of 
genomic DNA that cannot properly re-anneal. The ssDNA and denatured proteins form 
insoluble precipitates in this solution, which can be removed by centrifugation.    
 
The final clean-up step enables purification and concentration of plasmid DNA from the 
extraneous cell debris and solution additives. This can be achieved in a number of ways 
including chloroform extraction, ethanol precipitation, and variations of affinity 
chromatography. 
 
Plasmid DNA from bacterial culture (section 2.7.3) was isolated with Qiagen plasmid kits 
(Qiagen) following manufacturers guidelines, for use in subsequent sequencing, 
transfection and cloning. The kits comprise; bacterial cell lysis buffer, anion-exchange or 
silica columns that are designed to selectively bind DNA under appropriate salt and pH 
conditions, and appropriate washing and elution buffers to purify the immobilized DNA. 
 
Miniprep kits were used to extract DNA from small volumes of cells (~5ml) to be 
subsequently used for analysis or transformation. Maxipreps, which include endotoxin 
removal, were used to extract larger quantities of transfection grade plasmid DNA 
(typically from 100ml culture). 
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QIAprep Spin Miniprep Kit 
Cells were harvested from 5ml cultures by centrifugation at 4,000rpm (5 minutes), 
resuspended in 250l buffer P1 containing RNase and transferred to a 1.5ml micro-
centrifuge tube. Lysis buffer P2 (250l) was then added to the cell mixture and 
incubated at room temperature for up to 5 minutes. The lysis reaction was neutralized 
with addition of buffer P3 (350l) and the mixture was centrifuged for 10 minutes at 
13,000rpm to pellet the cell debris. Supernatant was loaded onto a QIAprep spin column 
and passed through the column matrix by centrifugation (1 minute) at 13,000rpm. Two 
wash buffers, PB (0.5ml) and PE (0.75ml) were both sequentially loaded and centrifuged 
through the column at 13,000rpm for 1 minute each, followed by an additional 1 minute 
spin (13,000rpm) to remove any residual buffers from the column. DNA was eluted into 
a clean micro-centrifuge tube by adding 30l sterile H2O to the centre of the column, 
standing for 1 minute, and centrifuging for 1 minute (13,000rpm). Plasmid DNA was 
stored at -20C. 
 
QIAGEN Plasmid Maxi Kit 
Cells were harvested from 100ml cultures by centrifugation at 6,000xg for 15 minutes 
and resuspended by vortexing in 5ml buffer P1 containing RNase.  Lysis buffer P2 (5ml) 
was then added to the cell mixture and incubated at room temperature for up to 5 
minutes. The lysis reaction was neutralized with buffer P3 (10ml) and incubated on ice 
for 20 minutes to allow precipitation of DNA, proteins and cell debris. The mixture was 
then centrifuged (14,000rpm) for 30 minutes at 4C, and the supernatant filtered 
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through 3mm Whatman filter paper. A QIAtip spin column was equilibrated by applying 
10ml of buffer QBT and allowing the column to empty by gravity flow. The filtrate 
(containing DNA) was passed through the prepared column by gravity flow allowing DNA 
to bind selectively to the column matrix. The column was washed twice with 30ml of 
buffer QC to remove impurities such as RNA, metabolites and proteins, and finally 
eluted to a clean 50ml centrifuge tube in 15ml sterile H2O. Isopropanol (10.5ml) was 
added to the eluate and centrifuged (4C) at 14,000rpm for 30 minutes to precipitate 
DNA. The resulting DNA pellet was washed in 5ml of 70% ethanol and spun (4C) for a 
further 10 minutes at 14,000rpm. The ethanol was carefully decanted from the tube 
leaving the DNA pellet to air-dry at room temperature for ~10 minutes. The dried DNA 
was resuspended in 200l sterile H2O and stored at -20C. 
 
2.8.0  Yeast cell culture and manipulation 
 
2.8.1  General culture and selection of yeast cells 
Yeast cells were cultured at 30C in a blend of yeast-extract, peptone and dextrose 
(YPD), and single colonies (clones) were obtained from YPD agar plates streaked with 
small volumes of cells.  
 
Plasmid selection was achieved with the use of ‘auxotrophic’ mutated strains of yeast 
that cannot synthesize particular amino acids necessary for growth/metabolism on 
specific media. Transforming yeast with plasmids containing genes coding for the 
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required factor enables only the transformants to grow on the selective media. A 
minimal base medium can be prepared for this purpose with one, or a combination of 
missing essential nutrients: leucine, tryptophan, adenine and histidine. 
 
A further method of identifying potential protein interactions was blue/white screening 
with X-α-Gal and IPTG (see chapter 5). 
 
2.8.2  Preparation of YPD broth and agar plates 
YPD broth was prepared using 50g YPD (Clontech) per 100ml water required. The 
suspension was autoclaved and allowed to cool before use or storage at 4C. 
 
YPD agar plates were prepared using 67g of YPD agar powder (Clontech) per 100ml 
water required. The suspension was autoclaved and allowed to cool to ~50C. Any 
necessary selection reagents were added in a laminar flow cabinet, and approximately 
20-25ml of molten agar poured into each plate. Plates were left to air dry before use or 
storage at 4C. 
 
Selective drop-out media (SDM) 
SDM was prepared using 27g of minimal SDM base (Clontech) per 100ml water 
required. The appropriate drop-out supplement (Clontech) was added and the mixture 
autoclaved and allowed to cool before use or storage at 4C. 
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Drop-out supplements resulted in media; 
i) minus leucine 
ii) minus tryptophan 
iii) minus leucine/tryptophan 
iv) minus leucine/tryptophan/adenine/histidine (Quadruple drop-out) 
 
X-α-Gal/IPTG indicator plates 
Molten YPD agar was allowed to cool to ~50C before the addition of IPTG and X-Gal to 
final concentrations of 0.1mM and 40µg/ml respectively (section 2.7.2). The mixture 
was gently swirled, poured (~25ml) into 10cm petri dishes and left in a laminar flow 
cabinet to set before use or storage at 4C. 
 
2.8.3  Long-term storage and recovery of yeast  
Yeast strains/clones were stored long-term at -80°C in 1.5ml micro-centrifuge tubes. 
One large colony was suspended and mixed evenly in YPD medium with 25% glycerol. 
Dependent on clone, minimal media as appropriate was used to maintain selective 
pressure. 
 
On recovery, a small amount of thawed yeast was streaked onto appropriate agar plates 
and incubated at 30C for ~4 days, or until individual colonies reached a size of ~2mm in 
diameter. Yeast strains were grown on YPD agar, and yeast clones grown on SDM agar. 
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2.8.4  Transformation of yeast 
Yeast cells were transformed with combinations of plasmids to confirm the initial yeast 
two-hybrid findings.  
SD medium (5ml) was inoculated with yeast-colonies 2-3mm in size and mixed 
vigorously by vortexing. This suspension was transferred into a 50ml volume of SD 
medium, incubated at 30°C for 16-18 hours with shaking (250rpm) to stationary phase 
OD600>1.5. Overnight culture was added to 300ml of YPDA (yeast peptone dextrose 
adenine) and placed into an orbital shaker at 230-270rpm for 3 hours (30°C). Cells were 
then pelleted by centrifugation at 1,000xg (5 minutes) in 50ml polypropylene tubes and 
thoroughly resuspended in 50ml volumes of sterile H20. Each tube was pooled, 
centrifuged at room temperature for 5 minutes (1,000xg) and supernatant discarded. 
Yeast pellets were resuspended in 1.5ml of freshly prepared sterile 1.1x TE/LiAc solution 
(1.1x TE buffer (Clontech), 0.11M lithium acetate). 
Plasmid combinations as desired were mixed in 1.5ml polypropylene tubes: 0.1µg DNA-
BD/bait (WFS1-N), 0.1µg AD/library and 0.1mg herring testes carrier DNA. Competent 
yeast cells (0.1ml) and sterile PEG/LiAc solution (0.6ml) (40% polyethylene glycol 3350, 
1x TE buffer, 0.1M lithium acetate) were added to the plasmids and mixed with a vortex 
at high speed. Tubes were incubated for 30 minutes (30°C) with shaking (200rpm) 
before adding 70µl DMSO and gently swirling the mixture. 
Plasmids were introduced to yeast cells by heat-shock for 15 minutes in a 42°C water 
bath, swirling occasionally. Tubes were chilled on ice (2 minutes) prior to centrifugation 
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at 14,000rpm for 5 seconds. Supernatant was removed, cells resuspended in 0.5ml of 
YPDA, spread onto appropriate selective plates (section 2.8.1) and grown at 30°C.  
 
2.8.5  Isolation of DNA from yeast 
For preliminary analysis of positive clones identified from a yeast two-hybrid screen, the 
Yeastmaker Yeast Plasmid Isolation kit (Clontech) was used to isolate plasmid DNA from 
yeast cells. Plasmid extracts were then suitable for direct use as a PCR template or for 
transformation into E. coli. 
 
Yeast clones (taken from SD minimal agar medium or frozen stocks) were initially 
resuspended in 50l Potassium Phosphate (67mM KH2PO4; pH7.5) in a 1.5ml micro-
centrifuge tube. The cells were lysed by adding 10l lyticase solution (5 units/l in TE 
buffer), thorough mixing and incubation at 37°C for 60 minutes. 10l of SDS (20%) was 
added to the mix then tubes were vortexed vigorously for 1 minute. To ensure complete 
lysis, the cells were also put through one freeze/thaw cycle at -20°C and vortexed again. 
 
CHROMA SPIN Columns were used for purification of plasmids: Columns were inverted 
and vortexed to thoroughly resuspend the gel matrix, the cap was removed and tip 
broken-off. The column was then placed into a 2ml polypropylene tube and centrifuged 
in a swinging bucket rotor at 700xg for 5 minutes to allow the buffer to run through. The 
column was placed into a clean micro-centrifuge tube where samples were carefully 
applied to the centre of the gel matrix within the column. After centrifugation for 5 
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minutes (700xg) the purified DNA filtered through into the eluate, which was collected 
and stored at -20°C. 
 
2.9.0  Mammalian cell culture and manipulation 
 
2.9.1  General tissue culture 
Mammalian cell lines were grown in 25cm3/75cm3 sterile vented flasks incubated at 
37C, with 5% CO2. All handling and manipulation was carried out in class II tissue 
culture hoods using sterile instruments and consumables. 
 
Cell maintenance and propagation 
Cells were typically cultured in pre-warmed Dulbecco’s modified eagle media (DMEM), 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, 1% non-essential 
amino acids, and 1% penicillin/streptomycin solution (Invitrogen). The volume of 
medium added to each flask was sufficient to provide adequate coverage of cells 
without liquid contact with filter (~8ml per 25cm3/~13ml per 75cm3). Cells were grown 
to approximately 80-90% confluency before passaging in a 1:1-1:10 ratio depending on 
cell growth rate and experimental requirements. Table 2.0 outlines specific 
requirements for various cell lines. 
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For passaging adherent cell lines, growth media was firstly removed from the flask and 
discarded, followed by gentle washing of cells with phosphate buffered saline (PBS). 
Cells were then lifted from the flask by trypsinization in 1x trypsin-EDTA 
(ethylenediaminetetraacetic acid) solution (1ml per 25cm3/ 2ml per 75cm3) and 
incubation at 37C for up to five minutes. The cell suspension was diluted with an 
appropriate volume of completed growth media and split as required.  
 
For passaging semi-adherent or suspended cells, media was decanted from a growing 
flask to a centrifuge tube. Any remaining adherent cells were detached from the flask by 
incubation in 0.2% EDTA (1-2ml) at 37C for up to 5 minutes and added to the centrifuge 
tube. The cell suspension was centrifuged ≤1,000xg for 3 minutes (22C) and 
supernatant was decanted carefully from the pellet. The cells were resuspended in fresh 
completed medium, and diluted/split to desired volumes and placed into fresh flasks. 
 
2.9.2  Freezing cells for long-term storage 
Mammalian cell lines were stored long-term in liquid nitrogen. Approximately 1 x 106 
cells were mixed in 1ml aliquots of 90% growth medium or foetal bovine serum, with 
10% Dimethyl sulfoxide (DMSO) cryoprotectant and transferred to cryovials. The 
cryovials were then placed in a cryo-freezing container, containing 100% isopropanol 
and initially stored at -80C to allow gradual freezing (1C per minute) and minimal ice-
crystal damage, before transferring vials to liquid nitrogen.  
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Table 2.0. Culture conditions for mammalian cell lines.  
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2.9.3  Reviving frozen cells 
Frozen cells recovered from storage were floated in a 37C water bath until just thawed 
(~1 minute) to minimize exposure to the toxic effects of warmed DMSO. The cell 
suspension was transferred to a polypropylene tube, diluted with ~5ml completed 
medium and centrifuged for 3 minutes at ≤1,000xg (22C).  The supernatant was 
decanted-off and the remaining cell pellet was resuspended in ~8ml of completed 
medium, placed into a 25cm3 vented flask and incubated at 37C with 5% CO2. 
 
2.9.4  Cell counting 
A haemocytometer viewed under a light microscope was used to count cells. The slide 
and coverslip were firstly cleaned with 70% ethanol before placing the coverslip over 
the counting grid. Cells were pelleted by centrifugation at ≤1,000xg for 3 minutes and 
resuspended in a known volume of appropriate growth medium. Thorough mixing 
dispersed the cells as evenly as possible then 70µl of the suspension was loaded into the 
haemocytometer through the ‘v’ trough. Using the microscope x10 objective, all cells 
present in a 1mm2 square were counted and recorded. Results were averaged from 
three independent sample counts. A 1mm2 area is equivalent to the number of cells x 
104/ml. 
 
2.9.5  Transfection 
All transfections unless specified were achieved with Fugene 6 or Fugene HD (Promega) 
transfection reagent. Cells for transfection were seeded into 10cm culture dishes (~1.7 x 
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105 cells) with suitable completed growth medium (table 2.0), and allowed to establish 
overnight to reach optimal transfection density (typically 50-80% confluency) according 
to manufacturers recommendations.  
 
Transfection mixes were typically prepared in 1.5ml polypropylene tubes. Fugene was 
pipetted and mixed carefully into serum-free medium without contacting the tube wall 
directly (3µl: µg DNA). Purified plasmid DNA (1µg) at a concentration of 1µg/µl was then 
added and left to incubate at room temperature for up to 30 minutes. More than one 
DNA complex was added to the mixture at this stage for co-transfection protocols. 
Following incubation the transfection mix was added onto cells in culture dishes and 
swirled gently to mix. Transfected cells were cultured at 37C (5% CO2) for a specified 
time dependent on protocol (generally ~24-48 hours).   
 
2.10.0  Harvesting cells for protein and RNA extraction 
 
2.10.1  Protein extraction 
Cells cultured on plates were harvested for protein extraction using a range of lysis 
buffers (table 2.1). Adherent cells were washed and harvested directly from the culture 
dish. The growth media was firstly aspirated and discarded, followed by two careful 
washes in 0.1M phosphate buffered saline (PBS). Following removal of the second wash, 
lysis buffer was pipetted onto the cells and left for up to fifteen minutes at 4°C. A cell 
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scraper was used to collect the lysed cells, which were then transferred to a micro-
centrifuge tube.  
 
Semi-adherent cells were harvested as above, with the additional step of centrifuging 
growth medium to collect any suspended cells. Medium was removed from the culture 
dish and centrifuged at ≤1,000xg for 3 minutes. After the supernatant was poured away, 
the cell pellet was resuspended in lysis buffer and added to adherent cells subsequently 
collected from the plate.   
 
The cell lysate was centrifuged (4C) at 14,000rpm for 30 minutes to pellet large cell 
debris. The supernatant, containing any soluble protein was decanted into a fresh 
micro-centrifuge tube for further use or storage at -20C. A sonication step prior to 
centrifugation was included for release of membrane-bound proteins using a Soniprep 
150 sonicator (Wolflabs). This was typically carried out in 10 second bursts (x2) at 10 
micron amplitude, with inversion of the tube in-between to mix the cell lysate. The 
sample was kept cool throughout to minimise the potential for unwanted protein 
aggregation. 
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2.10.2  RNA extraction 
 
Isolation of total RNA from cell samples was carried out prior to reverse transcription 
and real-time PCR. Dependent on protocol, extraction of RNA was performed with 
TRIzol reagent (Invitrogen) or an RNeasy kit (QIAGEN).  
 
Harvesting with TRIzol  
Cells grown in a monolayer were lysed directly in the culture dish by adding 1ml of 
TRIzol reagent per 10cm2 surface area and pipetting to mix. Homogenized samples were 
incubated for 5 minutes at room temperature to allow complete dissociation of 
nucleoprotein complexes. The lysates were transferred to polypropylene tubes, where 
* Prior to use, 1 protease inhibitor tablet (Complete Mini, Roche) per 10ml was mixed with buffer. 
This 'working' mixture was then stored at -20oC. 
Table 2.1. Cell lysis and IP wash buffer recipes. 
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0.2ml of chloroform per 1ml of TRIzol reagent was added, before vigorous shaking for 
15 seconds and further incubation at room temperature for 3 minutes. 
 
Samples were centrifuged at 12,000xg for 15 minutes (4C), which serves to phase-
separate the mixture into: a lower red phenol-chloroform phase, an interphase, and a 
colourless upper aqueous phase containing the RNA. The aqueous phase was carefully 
transferred into a fresh tube. 
 
Isopropyl alcohol (0.5ml per 1ml TRIzol) was added to precipitate the RNA. After 
incubating for 10 minutes at room temperature and centrifuging (12,000xg) for 10 
minutes at 4C the RNA precipitate formed a visible pellet. Once the supernatant was 
carefully removed the pellet was washed with 75% ethanol (1ml per 1ml of TRIzol 
reagent), vortexed, then centrifuged at 7,500xg for 5 minutes (4C).  
 
Finally, the RNA pellet was air-dried for 5-10 minutes, dissolved in RNase-free water and 
stored at -70C. 
 
RNeasy 
The RNeasy kit from QIAGEN incorporates silica-based membranes with selective 
binding properties to purify RNA. The maximum amount of starting material and 
volumes of reagents used during purification were determined according to 
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manufacturers’ recommendations to ensure spin columns were not overloaded, which 
reduces the binding capacity and overall RNA yield.  
 
Cells were harvested from culture by trypsinisation (if adherent) and centrifugation in a 
micro-centrifuge tube for 5 minutes at 300xg. All supernatant was carefully aspirated 
and discarded. Lysis buffer containing a denaturant to inactivate RNases (RLT) was 
added to the cell pellet and vortexed to thoroughly mix before the lysate was loaded 
onto a QIAshredder spin column and centrifuged for 2 minutes at full speed to 
homogenize. 
 
To provide appropriate binding conditions, 1 volume of 70% ethanol was mixed with the 
homogenized lysate. Up to 700µl of the sample at a time was transferred to an RNeasy 
spin column and centrifuged (15 seconds at 8000xg). At this stage total RNA binds to the 
column matrix and the flow-through is gathered in the collecting tube and discarded.  
 
Several washing steps to remove any unwanted contaminants from the membrane were 
then performed. Buffer RW1 (700µl) was loaded into the spin column and centrifuged 
(15 seconds at 8000xg), followed by two washes in 500µl buffer RPE (15 seconds then 2 
minutes at 8000xg). A further full speed spin for 1 minute in a fresh tube ensured that 
any residual buffer was removed. RNA was eluted into a fresh collection tube with 30-
50µl RNase-free H20 spun through the column for 1 minute at 8000xg.  
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2.11.0  Protein quantification 
 
A Bio-Rad DC Protein Assay (Bio-Rad) was used to determine the concentration of 
solubilised protein. The reaction between alkaline copper tartrate solution and Folin 
reagent when mixed with protein causes a colour change to develop according to the 
concentration of protein, which can be measured on a microplate reader. 
 
A working solution A’ was firstly prepared by mixing 20µl reagent S to every 1ml of 
reagent A. Protein standards, ranging from 0.2mg/ml-1.6mg/ml, were also prepared 
using bovine serum albumin (BSA) diluted in lysis buffer matched to that of protein 
samples.  
 
Samples and protein standards (5µl) were pipetted onto a 96-well microtitre plate (Bio-
Rad) with the well positions carefully recorded. Using a clean pipette tip for each, 25µl 
of reagent A’ was then added to each sample followed by 200µl of reagent B. The 
reagents were mixed gently to avoid air bubbles and left for 15 minutes for colour to 
develop. 
 
The absorbances were read at 750nm on a Bio-Rad Microplate Absorbance Reader with 
Microplate Manager software. A standard curve calculated from the BSA standards was 
used to extrapolate the relative concentration of experimental samples. 
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2.12.0  RNA/DNA quantification  
 
Quantitation of DNA/RNA was performed on a Nanodrop 2000 spectrophotometer with 
accompanying software (Thermo Scientific), which performs efficient automated 
measurement of small volume samples. This instrument exposes samples of nucleic 
acids to ultraviolet light at a wavelength of 260nm and a photo-detector measures the 
light that passes through. The concentration of nucleic acid in the sample is proportional 
to the amount of light that is absorbed. As single and double-stranded DNA and RNA 
have different absorbance characteristics, a conversion factor for each may be equated 
according to the Beer-Lambert Law. Sample purity may also be determined by 
calculating the ratio of the absorbance at 260 and 280nm (A260/280): The absorbance 
ratio for pure DNA is A260/280 = ~1.8 and for pure RNA A260/280 = ~2. 
 
Prior to sample measurement, 2µl of ddH2O (or control fluid) was loaded onto the 
apparatus pedestal for an instrument self-calibration check. With careful blotting of the 
pedestal in-between, samples (2µl) were then individually measured and recorded. 
 
 
2.13.0  Polyacrylamide gel electrophoresis and Western-blotting 
 
Proteins were size separated for identification using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins prepared for electrophoresis 
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were solubilized in SDS detergent, which denatures secondary and tertiary structures, 
and applies a negative charge to protein proportional to its mass.  
 
2.13.1  Preparation of polyacrylamide gel 
Polyacrylamide gel was made with polyacrylamide (10-15%), 375mM Tris pH8.8, 1% SDS, 
10% ammonium persulfate (APS), 0.05% TEMED (tetramethylethylenediamine) and 
ddH2O. Clean gel plates were filled just over three-quarters, topped up with ddH2O, and 
left to polymerize. Once set, the water was poured away and replaced with stacking gel 
(3% polyacrylamide, 50mM Tris pH6.8, 0.08% SDS, 10% APS and 0.06% TEMED). A comb 
was inserted into the stacking gel to create sample wells and left to set. After careful 
removal of the comb, the wells were washed with water and blotted dry with Whatman 
paper. The prepared gel plates were loaded into an electrophoresis tank, which was 
filled with running buffer (25mM Tris base, 190mM glycine, 0.1% SDS, pH 8.3). 
 
2.13.2  Loading samples and running gel 
Protein samples (whole cell lysates) were routinely loaded onto SDS polyacrylamide gels 
in total volumes of 20µl. These comprised protein extracts in lysis buffer (table 2.1) 
mixed with x2 loading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.004% 
bromophenol blue, 0.125M Tris HCl, pH 6.8). Additional preparation steps varied in 
accordance with the solubility/nature of the proteins involved. These included 
sonication, syringe-homogenisation, centrifugation, and boiling.  
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A protein marker ladder (Fermentas), as well as the protein samples were pipetted into 
designated wells, before attaching the electrodes and lid onto the gel tank. The samples 
were run at 150 volts for 1-2 hours, or until the size markers of interest were sufficiently 
separated. 
 
2.13.3  Western blotting 
Following electrophoresis gels were transferred to holder cassettes together with a 
piece of Hybond-P nitrocellulose membrane. These were sandwiched between several 
support layers of sponge and filter paper, pre-soaked in transfer buffer (25mM Tris, 
192mM glycine, and 20% methanol). A foam pad and 3 layers of Whatman (3mm) filter 
paper were firstly placed onto the cassette, followed by the gel. The membrane was 
activated by immersion in methanol and positioned over the surface of the gel with care 
to ensure air bubbles were smoothed out. A second layer of filter paper (x3) and foam 
were placed on top, and the entire stack was secured into the cassette. The cassettes 
were loaded into an electrophoresis tank, with the membrane orientated toward the 
cathode. An ice cooler was also placed into the tank before filling the tank with transfer 
buffer, and securing the electrodes. The transfer was run at 80 volts for 1-1½hours.  
 
After transfer, membranes were incubated with 5% dried milk in PBS-tween buffer 
(2mM Na2HPO4, 0.5mM KH2PO4, 1.3mM KCl, 135mM NaCl, 0.05% Tween 20, pH 7.4), 
which served as a blocking solution prior to washes with antibodies. Membranes were 
inserted into 50ml polypropylene tubes, lying flat against the surface of the tube with 
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attached proteins facing inwards. The tube was filled with blocking solution and placed 
on a tube roller for 1 hour at room temperature.  
 
Thereafter, blocking solution was poured away and replaced with 5ml of 5% dried milk 
in PBS-tween containing specific primary antibodies (table 2.2) diluted according to 
requirements. This was incubated on a tube roller at 4C overnight. 
 
The following day, membranes were washed three times (5 minutes each) in PBS-tween 
on an orbital shaker and replaced to a 50ml polypropylene tube. Specific secondary 
antibodies (table 2.2) were diluted according to requirements in 5ml of 5% dried milk in 
PBS-tween, added to the tube, and incubated (room temperature) for 1 hour on a tube 
roller. 
 
Unbound secondary antibodies were washed away with four washes (15 minutes each) 
of PBS-tween, on an orbital shaker. 
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Table 2.2. Comprehensive list of antibodies used for: immunocytochemistry, immunohistochemistry, western blotting and immunoprecipitation.  
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2.13.4  Developing western blots 
Western blots were developed using a chemiluminescent detection system, which is the 
emission of light and limited amounts of heat as a result of a chemical reaction. 
Secondary antibodies conjugated to horseradish peroxidase (HRP) were used as probes 
in immunoblots, which catalyses the oxidation of luminol in the presence of hydrogen 
peroxide. The light produced by luminol-based systems can be detected on radiographic 
film at short-exposure and ambient temperature. 
 
Prepared membranes were placed protein-side up onto Saran wrap, which was spread 
smoothly over a flat bench. An ECL Plus detection kit (GE Healthcare) which uses an 
acridan-based substrate to produce a chemiluminescent signal was used to label 
western blots for development. Reagent A (25µl) mixed with reagent B (1ml) was 
pipetted evenly over the surface of each membrane and left for five minutes. Excess 
developing fluid was displaced by tapping the edge of the membrane to the bench, and 
the membrane was covered smoothly in Saran wrap. Wrapped membranes were placed 
into a developing cassette, protein-side upward, and secured at the corners with tape. 
 
In a dark room, X-ray film (Kodak) inserted into the cassette was exposed to the 
membranes for time periods ranging from 1 second to several hours. Exposure times 
were adjusted according to signal intensity as per requirements before films were 
developed in an automated X-ray film processor. 
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2.13.5  Quantitative analysis of protein expression values 
A lightbox and high resolution camera connected with Genetools software (Syngene) 
was used for quantitative analysis of expression values following western blot. After 
image capture (GeneSnap, Syngene) of developed blots, absorbance measurements 
(arbitrary units) were taken of individual bands/protein samples. Measurements were 
normalized firstly to background signal from the X-ray film, then to a control 
housekeeping protein (β-actin), measured from the same blot, to account for 
discrepancy in sample loading. Where appropriate, endogenous background protein 
signals were also measured and factored into the final measurements. 
 
2.14.0  Co-Immunoprecipitation  
 
Co-Immunoprecipitation was employed as an experimental measure to detect protein 
interactions in vitro. The principle of this method is to target and purify antigens and 
their potential binding partners from a protein cell lysate using specific antibodies. The 
‘precipitated’ immune complexes can be subsequently analysed by SDS-PAGE 
electrophoresis and western blotting (section 2.13).   
 
The first stage in this procedure involves the introduction of specific antibodies to whole 
cell lysates allowing immune complexes to form between the antibody and target 
antigen. Secondly, agarose beads (Sigma) with immobilized protein A are introduced 
into the mixture as a solid-phase support. Protein A has binding affinity for the Fc region 
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of immunoglobulins through interaction with the heavy chain. This enables protein-
antibody complexes to be captured from the cell lysate. The assumption at this stage is 
that binding partner-proteins will be precipitated together with the targeted antigen. 
Any unbound molecules can then be washed away, before eluting the precipitated 
complexes and verifying the identity of the ‘pulled-down’ partner-proteins. 
 
2.14.1  Pre-clearing cell lysates 
Prior to immunoprecipitation, all protein lysates were pre-cleared with uncoated 
agarose beads. This step allows proteins with affinity to the surface of the agarose to be 
bound and removed, thus reducing later non-specific ‘pull-downs’. 
 
In 1.5ml polypropylene micro-centrifuge tubes, beads were prepared as standard in 40µl 
volumes, and equilibrated in 400µl PBS. The suspension was quickly vortexed and 
centrifuged (13,000rpm) for 2 minutes to pellet the beads. The supernatant was 
aspirated and discarded with a fine-tipped pipette taking care to cause minimum 
disturbance to the beads. 
 
Cell lysis buffer (400µl) was added to the equilibrated beads and tubes were loaded 
onto a rotary mixer for 30 minutes at 4C. The mixture was centrifuged (13,000rpm) 
afterwards for 5 minutes to pellet the beads, and the supernatant carefully aspirated 
and discarded.   
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Cell lysates (400µl) were added to prepared beads and placed on a rotary mixer for 1 
hour at 4C. The pre-cleared lysates were finally harvested by centrifugation at 
13,000rpm for 5 minutes, using a fine-tipped pipette to carefully remove the purified 
supernatant. Aliquots of lysate samples (~30µl) were taken and stored at -20C to 
provide controls for immunoprecipitation inputs. 
 
2.14.2  Immunoprecipitation 
Suitable antibodies (table 2.2) (~10µg) were added to pre-cleared protein lysates and 
incubated overnight at 4C on a rotary mixer. The following day, fresh agarose protein A 
beads (40µl) were equilibrated in PBS and lysis buffer as described in section 2.14.1. The 
protein/antibody composites were incubated with the beads for 2 hours on a rotary 
mixer (4C) to allow capture of the complexes onto the surface.  
 
After this incubation period, the entire contents of the tubes were loaded into Spin-X 
columns (Sigma). Effective separation of supernatant and beads takes place during 
centrifugation for 2 minutes at 13,000rpm. The supernatant flows through a micro-
porous membrane, whilst beads are retained within the column.  
 
Removal of non-specific bound molecules from the agarose beads is assisted by a series 
of washes in lysis buffer. Buffer (400µl) was added to the column with the beads, 
incubated for a period, and washed-through during centrifugation. Standard protocols 
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included three washes, with incubations of 10 minutes on a rotary mixer, although 
stringency of washing was increased in instances of high non-specific protein binding.  
 
2.14.3  Eluting ‘pulled-down’ protein 
Protein-complexes were eluted from protein A beads in x5 sample loading buffer 
suitable for SDS-PAGE electrophoresis (10% SDS, 10mM 2-mercaptoethanol, 20% 
glycerol, 0.0004% bromophenol blue, 0.2M Tris-HCl, pH 6.8). Spin-X columns containing 
washed beads were transferred to clean 1.5ml micro-centrifuge tubes. The beads were 
covered with 30µl loading buffer, and heated for 5 minutes at 95C. Loading buffer 
containing eluted proteins was finally separated from the beads in a 2 minute 
centrifugation at 13,000rpm, and stored at -20C until required for analysis. 
 
2.14.4  Detection of precipitated protein-complexes  
Protein complexes were detected by standard SDS-PAGE and western blotting (section 
2.13). In addition to ‘pull-down’ experimental samples, positive control lysates collected 
after the pre-clearing step (section 2.14.1) were included to confirm samples did contain 
the proteins of interest. Further controls were also carried out to optimise the protocol 
at various stages; collection of samples from IP flow-through, wash steps and post-
elution bead-boil confirmed efficiency of antibody/antigen binding and elution.  
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2.15/2.16  Immunostaining 
 
Immunostaining techniques were used to determine the presence and localisation of 
specific antigens in biological tissue, in whole cell mounts (immunocytochemistry) or in 
tissue sections (immunohistochemistry). Antibodies (table 2.2) conjugated to 
fluorophores were used to target specific proteins/structures, which could be visualised 
under a fluorescent microscope.  
 
2.15.0   Immunocytochemistry (ICC) 
 
2.15.1  Cell culture 
Cells were chiefly cultured and transfected in 10cm tissue culture dishes according to 
standard procedure (section 2.9). Sterile cover slips (22 x 22mm) were placed into 
culture dishes before seeding with cells, which were swirled gently to ensure even 
distribution and adherence.  
 
2.15.2  Fixation  
Following a suitable incubation period, the dishes were removed from the 37C 
incubator and allowed to cool for 5 minutes.  The cover slips were then gently lifted 
from the dish with sharp-edged tweezers, and placed into 24-well plate chambers with 
cells facing upwards. To fix and permeabilise the cells, each slide was covered with 
0.5ml paraformaldehyde (4%) for 15 minutes, which serves as a cross-linking agent to 
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preserve cell structure. Once fixed, the cells were washed three times for 5 minutes in 
PBS (phosphate buffered saline: 137mM NaCl, 10mM Na2HPO4, 1.8mM KH2PO4 and 
2.7mM KCl in H2O at pH 7.4). 
 
2.15.3  Staining 
Cells were incubated for 10 minutes in a solution containing 3% bovine serum albumin 
(BSA) and 0.1% Triton-X in PBS. This was used as a blocking agent against later non-
specific antibody binding.  
 
Antibody diluting buffer was made up with 3% BSA and 0.05% Tween-20 in PBS. Primary 
antibodies (table 2.2) were diluted with buffer to an optimal concentration (anti-WFS1, 
1/100; anti-PDI, 1/350; anti-c-myc, 1/100) and applied to the coverslips for 1 hour at 
room temperature.  
 
Unbound primary antibodies were washed away with 3 washes in PBS (5 minutes each), 
followed by the application of secondary antibodies (table 2.2), diluted in buffer (1/200). 
Alexa fluor dyes (Invitrogen) were the fluorescent probes of choice, since they have 
been proven more photostable, less pH sensitive, and brighter than other standard dyes 
of comparable excitation and emission. Coverslips were incubated in secondary 
antibodies at room temperature, covered with foil and kept in the dark when possible 
henceforth. After 1 hour, excess secondary antibodies were removed with three washes 
in PBS (5 minutes each).  
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2.15.4  Mounting 
Coverslips were mounted onto microscopy slides with DAPI (4',6-diamidino-2-
phenylindole). DAPI is excited under UV light producing a blue-cyan emission (~461nm), 
and binds strongly to DNA, so can be used as an effective cell nucleus marker. 
 
Small drops of DAPI mountant (Vector Labs) were placed onto clean glass microscopy 
slides, with a pasteur pipette. Coverslips were then gently lifted from plate wells with 
sharp-edged tweezers and placed with cells facing downwards over the DAPI, taking 
care to avoid underlying air bubbles. The slides were labelled accordingly and stored at 
4C, allowing the mountant to set prior to viewing. 
 
2.16.0  Immunohistochemistry 
 
2.16.1  Tissue preparation 
Rat pancreata, provided courtesy of Dr S Jacques, Molecular Neuroscience Group, 
University of Birmingham, were excised from animals euthanized by CO2 narcosis. Tissue 
was immediately immersed in increasing gradients of sucrose in PBS (10%, 20% and 
30%) until observed to sink, embedded in OCT mounting medium (Thermo Scientific), 
rapidly frozen on dry ice, and stored at -80C.  
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A Bright 5030 Cryostat (Bright) was used to cut 15µm sections of tissue, which were 
mounted onto charged slides (Surgipath) and stored at -20C. 
 
2.16.2  Fixation and staining 
Frozen sections were warmed to room temperature then fixed in absolute ethanol for 1 
minute. The slides were placed into a Coplin jar and washed twice (5 minutes each) in 
PBS followed by a 10 minute wash in PBS with 0.1% Triton-X-100 to permeate the tissue. 
 
The sections were isolated using a hydrophobic pap-pen (Vector Labs). By drawing 
around the tissue a heat-stable, water repellent barrier was created, which keeps 
staining reagents localised to a particular section, allowing more than one section per 
slide and necessity for much less antibody per section. 
 
Slides were placed in a darkened humidified chamber at room temperature for 30 
minutes covered (100µl per section) in blocking solution (1% bovine serum albumin, 
0.1% Triton-X-100 in PBS). Following gentle aspiration of blocking solution primary 
antibodies (table 2.2), diluted to an appropriate concentration in buffer (3% BSA and 
0.05% Tween-20 in PBS) were then applied to each section (100µl) and incubated in the 
chamber overnight (16 hours) at 4C. 
 
PBS was used to wash the slides three times (5 minutes each) in a Coplin jar. After 
aspiration of the PBS, secondary antibodies (table 2.2) diluted in buffer to an 
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appropriate concentration, were applied (100µl) to each section and incubated for 1 
hour in the chamber at room temperature. 
 
Unbound secondary antibodies were washed off with 3 x 5 minute PBS washes in a 
Coplin jar. Excess fluid was gently aspirated from the sections, a drop of DAPI mountant 
(Vector Labs) was applied over the tissue and a coverslip lain on top. The prepared slides 
were stored in the dark at 4C allowing the mountant to set ready for viewing. 
 
2.17.0  Fluorescent microscopy 
 
An Axioplan 2 microscope with Zeiss Neofluar lenses, an AxioCam HRC Camera and 
Axiovision software (Carl Zeiss Ltd) was used to view slides and capture images. To 
increase the resolving power at high magnification (x1000) immersion oil was placed 
between the specimen and the objective lens. In these instances, the edges of coverslips 
were sealed with varnish to ensure they remained in position. 
 
2.18.0  Measuring protein stability with cyclohexamide 
 
Cyclohexamide (CX), a biochemical produced by bacterium Streptomyces griseus, was 
used to measure the relative differences in protein half-lives between wild-type and 
variants of wolframin. CX is a known inhibitor of eukaryotic protein synthesis and has 
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been shown to block the elongation phase of protein translation by binding to 
ribosomes and inhibiting eEF2-mediated translocation (Obrig, 1971). 
 
HEK293 cells were seeded onto 10cm plates; for each experimental condition/sample, 
one plate was allocated for each time interval. Cells were grown to ~80% confluency 
(section 2.9.0) and transfected (section 2.9.5) with constructs containing wild-type WFS1 
and WFS1-variants. After 24 hours incubation, CX in 200µl pre-warmed DMEM growth 
medium (table 2.0) was added to all plates to give a final concentration of 100µM, which 
were swirled to mix taking care not to disturb the cells. One plate from each 
condition/sample set was harvested in RIPA lysis buffer (section 2.10.1, table 2.1) 
immediately following CX treatment (designated ‘0 hours’) and stored at -80°C. The 
remaining plates were left to incubate (37°C) and harvested at subsequent time 
intervals according to requirements. 
 
Once all plates were harvested, measurements of protein concentration in each sample 
were made (section 2.11), and the samples were loaded equally onto SDS-
polyacrylamide gels (section 2.13.0) and electrophoresed for western blotting (section 
2.13.3). Quantitative analyses of protein expression values were performed using 
Genetools/GeneSnap software (Syngene; section 2.13.5). The stability of each wolframin 
variant was calculated by comparing the expression values at a given time interval 
relative to that at ‘0 hours’, designated 1 (100%). 
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2.19.0  Molecular Cloning 
 
Molecular cloning techniques (summarised in fig. 2.3) were used to generate multiple 
copies of defined DNA sequences, within vectors suitable for inducing protein 
production. Sequences relating to genes/fragments of interest were initially sourced 
from Geneservice (Source Bioscience) or stocks available in the Medical and Molecular 
Genetics Dept., University of Birmingham. Basic cloning principles involve; cutting both 
vector and insert of interest with matched restriction enzymes, ligating the insert into 
the linearised vector, transforming the new ‘clone’ to competent bacteria to enable 
rapid, reliable multiplication, then finally selection of successful transformants followed 
by thorough checks to confirm clones contain the correct insert sequence in the correct 
orientation. 
 
2.19.1  Obtaining and verifying starting material  
Where DNA fragments and gene sequences of interest were available from plasmid 
stocks in the laboratory, full sequencing verification was firstly carried out. Alternatively 
new ‘IMAGE’ clones were purchased from Geneservice. These derive from a collection 
of vectors containing cDNAs representing expressed genes from various organisms. 
Sequence verified clones containing full open reading frames were selected from the 
Mammalian Gene Collection. These were delivered in E.coli cells growing on agar slopes 
containing selection antibiotics and were stored at 4C on arrival.  
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IMAGE clones were grown up on agar plates containing appropriate selection antibiotics 
for specified vectors (section 2.7.2). An inoculation loop was lightly scraped across the 
agar slope to pick up cells, and streaked over the surface of an agar plate. The 
inoculated plate was left to incubate for >16 hours at 37C. Following this period, 
individual colonies were picked and seeded into 5ml LB broth (with antibiotic), and 
cultured overnight at 37C in an orbital shaker. Cells were collected from the culture 
suspension the following day by centrifugation at ~3,000rpm for 5 minutes, which 
served to pellet the cells. After decanting supernatant, plasmids were extracted and 
purified using a Qiagen Spin Miniprep Kit (section 2.7.5).   
 
The purified DNA was sequenced (section 2.4) with primers spanning the start site and 
3’-end of the insert, if full IMAGE cloning data was not provided. Restriction sites 
surrounding the insert were verified for subsequent subcloning steps.  
 
2.19.2  PCR amplification of DNA fragments/genes  
 
PCR amplification of the desired sections was completed with appropriate primers 
(section 2.1.1), electrophoresed on agarose gel and purified (section 2.3.0-1).  
 
Additional restriction sites could be added to existing sequences during the PCR reaction 
if required. The primers for this purpose were designed according to standard protocol 
(section 2.1.1) with additional features: restriction sites were added to the 5’-end of a 
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primer in the appropriate orientation, and a polylinker sequence was also introduced 
upstream of the restriction site to provide structural support for the restriction enzyme 
when binding and cutting DNA (fig. 2.1A).   
 
Only sequence matched bases (not including restriction site and polylinker) were 
included for calculation of primer melting temperature (Tm). Further consideration was 
given to fragments destined for expression vectors containing an N-terminal tag. 
Dependent on the reading-frame of the tag sequence, one or two additional nucleotides 
were added to the primer sequence to ensure ligation of the new gene in the correct 
reading frame (fig. 2.1B). 
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Figure 2.1. Primer design for insertion of restriction sites during PCR. (A) Example primer design for addition of Sal 1 restriction site to 
include polylinker nucleotides to stabilise enzyme/DNA binding for cutting. (B) Primer design for insertion of DNA into tagged (N-
terminal) expression vectors.(i) Example sequence of pCMV-HA vector detailing reading frame and necessity for extra nucleotide to 
maintain correct reading frame of cloned gene. (ii) Primer design including extra nucleotide and polylinker sequence.  
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2.19.3  Restriction digestion/ligation 
Transference of cDNA fragments from one vector to another was achieved using an 
enzyme digestion/ligation technique. The full insert sequence was initially mapped for 
the presence of internal restriction sites using Webcutter (Heiman, 1997). With 
reference to publicly available vector maps or sequencing data generated in the 
laboratory, compatible restriction sites were then identified in both ‘donor’ (containing 
insert) and recipient plasmids. When selecting appropriate restriction enzymes, 
consideration was also given to the efficiency of enzymes in a matched buffer during 
double-digestion, and the possibility of creating unwanted complementary DNA 
overhangs that could anneal incorrectly or in the wrong orientation.  
 
Inserts were cut from a donor vector or purified from a PCR reaction; recipient vectors 
were linearised during digestion. This was typically carried out in 50µl reaction volumes 
comprising: purified plasmid DNA, BSA, restriction enzymes, and suitable buffer 
according to specific manufacturers’ recommendation. Reactions were incubated at 
37C for 2 hours. The digested products were electrophoresed on agarose gel (section 
2.3.0) to separate fragments according to their respective sizes. Using an appropriate 
reference DNA size ladder (Invitrogen) DNA fragments/linearised vectors were 
distinguished, excised from the gel under UV light, and gel purified (section 2.3.1). 
 
Ligation of purified fragments into linearised plasmids was achieved by incubating the 
DNA products together with T4 DNA ligase, and buffer containing adenosine tri-
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phosphate (ATP), an essential cofactor. DNA ligase, derived from the T4 bacteriophage 
catalyses the formation of phosphodiester bonds between juxtaposed 5’ phosphate and 
3’ hydroxyl termini in duplex DNA. This enables digested DNA with complementary ‘free’ 
ends to be joined together. Reactions were carried out overnight at 4C in 0.5ml 
polypropylene tubes, and routinely comprised; 0.1-1M DNA, 4l ligation buffer (x5), T4 
DNA ligase (3 units), and ddH2O up to a final volume of 20l. Optimisation of ligation 
was carried out if necessary with various insert: vector ratios, using the formula below 
as a guideline: 
kb size of insert x ng of vector      =   1: 1 ratio 
                                               kb size of vector 
 
 
2.19.4  Intermediate vectors 
The pGEM-T vector system (Promega) and CloneJet PCR cloning kit (Fermentas) were 
used as high efficiency intermediate vectors in most PCR cloning applications. These 
linearised vectors allow straightforward TA ligation of PCR products, which can then be 
subsequently amplified and subcloned into expression vectors as desired. Available 
multiple cloning sites (MCS) useful for subsequent steps largely influenced selection of 
intermediate vectors (fig. 2.2). 
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pGEM-T 
The pGEM-T vector system was suitable for direct ligation of PCR products generated 
with Taq DNA polymerase. Ligation reactions were incubated for 1 hour at room 
temperature and comprised: 5µl rapid ligation buffer (x2), 1µl pGEM-T vector (50ng), 
insert DNA (variable), T4 DNA ligase (3 units), and DNA/nuclease-free H20 up to a final 
volume of 10µl.  Molar ratios of insert to vector were begun at 1:1, but optimised using 
the following formula as a guideline according to protocol: 
 
ng of vector x kb size of insert         x       insert: vector molar ratio   =   ng of insert 
               kb size of vector 
 
 
 
Figure 2.2. Intermediate cloning vector maps for pGEM-T (Promega) and pJET1.2 (Fermentas).  
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A-tailing reaction 
PCR products generated with proofreading enzymes such as Pfu DNA polymerase 
produce ‘blunt-ended’ products. These require an additional A-tailing modification prior 
to ligation with pGEM-T to add overhanging adenosine residues. A 10µl reaction 
including: 1-7µl DNA, 1µl Taq DNA polymerase buffer with MgCl2 (x10), dATP to a final 
concentration of 0.2mM, 5 units of Taq DNA polymerase, and purified H20, was mixed 
and incubated for 15-30 minutes at 70°C. Up to 2µl of this reaction mixture was used for 
subsequent ligation. 
 
CloneJET 
The CloneJet PCR cloning kit (pJET1.2 vector) is suitable for direct ligation of PCR 
products generated with proofreading Taq polymerase, such as Pfu, which produce 
blunt-ended products. Ligation reactions comprised: 10l reaction buffer (x2), 0.15 pmol 
DNA, 50ng pJET1.2 cloning vector, T4 DNA ligase (5 units) and nuclease-free H2O to a 
total volume of 20l. The mixture was vortexed briefly before incubation for 5 minutes 
at room temperature. 
 
Blunting reaction 
Sticky-ended PCR products generated with non-proofreading DNA polymerases such as 
Taq, required removal of unwanted adenosine overhangs prior to ligation with pJET1.2 
vector. A ‘blunting’ reaction to remove the overhanging nucleotides comprised: 10l 
reaction buffer (x2), 0.15pmol DNA, 1l DNA blunting enzyme (Fermentas) and purified 
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H20 up to a final volume of 20l. Following incubation for 5 minutes at 70°C the reaction 
was chilled on ice. Directly to the blunting reaction, 5 units of T4 DNA ligase and 50ng 
pJET1.2 vector were added, vortexed, then incubated at room temperature for 5 
minutes to ligate.  
 
2.19.5  Transformation, selection and small-scale culture plasmid extraction 
Chemically competent cells were transformed (section 2.7.4) with pUC19 control 
plasmid and products of ligation reactions. Up to 10l of ligation mix was incubated with 
100l -select silver efficiency competent  cells (Bioline), which produce >1x108 cfu/g 
pUC19. Cells with increased efficiency (Bioline -select gold, ~109) were used to increase 
success of problematic transformations.  
 
Recovered cells were grown overnight on suitable selective plates at 37C, and several 
of the resulting colonies were independently picked and seeded for >16 hours in 5ml of 
selective LB broth. Plasmids were recovered and purified from clonal cultures using the 
Qiagen Spin Miniprep kit (section 2.7.5). 
 
2.19.6  Verification of clones  
The purified plasmid DNA preps were checked for the presence of the correct insert 
sequence. Using suitable enzymes each prep was digested (section 2.2) and 
electrophoresed (section 2.3.0). Clones exhibiting the correct digestion pattern were 
then sequence verified if required (section 2.4).   
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2.19.7  Re-transformation, selection and large-scale culture plasmid extraction 
Clones containing the correct sequence inserts were re-transformed (section 2.7.4) into 
E.coli. A typical reaction included 50µl of sub-cloning efficiency chemically competent 
DH5α cells (Invitrogen) mixed with ≤1µg plasmid DNA (miniprep). A 1-5ml starter culture 
was inoculated to 100ml of selective LB broth and grown for ~16hours before plasmid 
extraction using the QIAGEN Maxiprep kit (section 2.7.5). Purified plasmids were again 
sequence verified (section 2.4) prior to transfection or further manipulation. 
CH
A
PTER 2 M
A
TERIA
LS A
N
D
 M
ETH
O
D
S 
 
 
107 
 
             
   
Figure 2.3. Principle steps in molecular cloning  
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2.20.0  Bioinformatics 
Publicly available resources were accessed throughout including: gene and protein 
annotation databases, sequence alignment and primer design software, and 
predictive analysis tools (table 2.3). 
Table 2.3. Bioinformatics resources.  
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CHAPTER 3 
MUTATION ANALYSIS OF WOLFRAM SYNDROME PATIENTS 
3.0  Introduction 
Collection of molecular genetic data is the foundation for understanding any inherited 
disorder. From a clinical perspective, knowledge of the genetic mutations carried by 
patients is essential for both postnatal and prenatal genetic diagnosis, and carrier detection. 
Defining the exact nature of disease causing mutations is also often useful for planning 
treatment and preventing development of complications and may provide access to gene 
therapy should this be available.  
In the laboratory, identifying and associating genetic mutations to phenotype forms the 
basis for elucidating complex pathogenic mechanisms at the protein and cellular level. 
Comparing specific mutation to protein function can help us to identify structurally and 
functionally important protein regions, sometimes relevant to a particular pathway or 
system. In the Wolfram gene for example, heterozygous A716T and K863T variants are 
among a growing number of WFS1 alleles associated with non-syndromic hearing loss 
(Bespalova, 2001: Young, 2001; Fujikawa, 2010), suggesting these regions of the protein are 
particularly important for auditory function. Other WFS1 variants have been linked 
specifically with susceptibility to diabetes (Sandu, 2007; Franks, 2008; Fawcett, 2010) and 
psychiatric illness (Sequeira, 2003; Koido, 2005; Swift, 2005).  
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In Wolfram syndrome (WS), a small number of families from regions in the Middle-east 
(Amr, 2007) have been found to harbour a homozygous missense mutation in WFS2 
(CISD2/ZCD2), although the majority of cases are attributed to mutations in WFS1. A wide 
range of mutations have been described throughout the WFS1 gene with no apparent 
mutational hotspots. Previous attempts to correlate genotype and phenotype have been 
limited by small sample numbers, although there does appear to be some relationships 
between mutation type and disease severity. Several reports suggest that clinical expression 
of WS is more complete in patients harbouring inactivating mutations only (Smith, 2004; 
Cano, 2007; D’Annunzio, 2008) and presentation of clinical features is likely to occur at a 
relatively earlier age (Cano, 2007). Patients carrying one or more missense variants may 
present with a relatively milder phenotype (Van Den Ouweland, 2003; Gasparin, 2009; 
Zymslowska, 2011).  
The West Midlands Regional Genetics Laboratory provides a genetic testing service primarily 
for National Health Service patients within the region, but also carries out testing for private 
consultants and for healthcare institutions nationally and internationally. Part of the service 
offered is genetic diagnosis for Wolfram syndrome and the patient registry currently lists 
approximately 100 individuals, referred to the clinic over the last 20 years. The testing 
methods include MLPA (multiplex ligation-dependent probe amplification) to identify large 
chromosomal abnormalities and mutation detection by direct sequencing analysis. At the 
time of this study a number of listed families (26 probands) had only one heterozygous, or 
no WFS1 mutations identified.  
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3.1  Specific aims and approach 
We aimed to complete the Wolfram patient database by screening all suitable patients for 
WFS1 mutations, before looking to identify potential mutations in other candidate genes. 
Following the mutation screen we planned to add our data to the larger West Midlands 
cohort and search for any genotype-phenotype correlations. We hoped to extend and 
update the current mutational spectrum for WS by completing the mutational and 
genotype-phenotype analysis of the largest single cohort to date.  
DNA samples from WS patients were obtained from the Regional Genetics Laboratory and a 
WFS1 mutation screen was performed by PCR (2.1.0-2.1.1) and direct sequencing (section 
2.4.0).  Primers (appendix 2.1) spanned all coding exons (2-8) and splice sites; exon 8 (2609 
base pairs) was sequenced in 5 overlapping sections (A-E).  
Any patients found to be negative for WFS1 mutations were then screened for possible 
mutation of WFS2, then for mutations in ATP1B1, described in section 3.3.0. Identified 
mutations were confirmed by re-sequencing both forward and reverse complements, and 
novel variants were also sequenced in a panel of normal control chromosomes. 
Results 
3.2.0  Mutation analysis of WFS1 
Following full sequencing of the WFS1 coding sequence, a total of 10 mutations were 
identified in 8 individuals (table 3.0). Nine mutations were found in exon 8, which accounts 
for ~68% of the gene coding sequence, and a single mutation was identified in exon 7.  
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Table 3.0. WFS1 mutations identified. * Denotes novel mutations     
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The majority of WFS1 mutations discovered were missense: C690R, P885L, L804P*, P533S*, 
F247S* and L511P*, including 4 previously undescribed variants (denoted by *) (fig 3.0).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.0. WFS1 mutations. Electropherograms showing missense mutations (L804P, 
P533S, F247S, L511P, C690R and P885L) found in the WFS1 gene matched against normal 
control sequences.  
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A further novel finding was discovered in patient 5, who was compound heterozygous for a 
substitution (IVS7-1G>A) at the splice acceptor site (consensus sequence AG>AA) flanking 
the end of intron 7 (fig 3.1). The likely outcomes of 3’ splice acceptor site mutation are 
either exon skipping or utilisation of an available downstream legitimate or illegitimate 
cryptic splice site (Krawczak, 2007). In the case of our WS patient, this mutation is therefore 
likely to cause partial or complete absence of exon 8. 
 
 
 
 
Deletions were found in patients 4 and 6. The first was a heterozygous 4bp deletion causing 
frameshift and formation of a premature stop codon at position 440, the second was a 
homozygous 3bp (out-of-frame) deletion of nucleotides 1400-1402. Finally, a single 
inactivating mutation (W700X) was found in patient 2 (fig 3.2). 
Figure 3.1. WFS1 mutation. Electropherograms showing a novel splice site mutation (IVS7-1G>A) 
found in the WFS1 gene matched against normal control sequences.  
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The position of all the discovered WFS1 variants are illustrated in figure 3.3, a schematic 
showing the hypothetical amino acid configuration of the wolframin protein (adapted from 
Hardy, 1999). The mutations are spread throughout the length of the protein, with 1 in the 
cytosolic amino-terminal domain, 3 within predicted transmembrane domains, and 4 in the 
endoplasmic reticulum luminal domain (C-terminal). The red star denotes the start of exon 8 
where the splice mutation in patient 5 was found.  
Figure 3.2. WFS1 mutations. Electropherograms showing 2 deletion mutations and a nonsense 
mutation found in the WFS1 gene matched against normal control sequences.  
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3.2.1  Novel WFS1 mutations 
All novel WFS1 variants were screened in a panel of ≥100 normal control chromosomes 
(100-200) and were found to be absent in all cases. A series of bioinformatic analyses were 
also applied to some of these variants looking for any physiochemical data that may or may 
not imply these are functionally important residues. Conservation tracks comparing 
homologous WFS1 sequences in humans, other mammals, birds, zebrafish (Danio rerio) and 
the fruitfly (Drosophila melanogaster) show that all codon variants we found in our patients 
occur in highly conserved amino acids, suggesting these residues have structural or 
Figure 3.3.  Location of mutations across the wolframin protein. Dot diagram of the predicted amino 
acid configuration of wolframin highlighting the location of WFS1 mutations found in our cohort 
(adapted from Hardy, 1999). * Denotes novel findings.  
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functional importance. All codons are conserved in the mammalian and bird species, P553 
and L804 are also conserved in species as phylogenetically distant as zebrafish and fruitflies 
(fig 3.4).  
Programmes predicting the phenotypic effects of amino acid substitution, Polyphen and 
SIFT (Sorting Intolerant from Tolerant), were also applied to the missense mutations. Based 
on assemblage of functional and physiochemical annotations, both sets of results 
independently predicted the phenotypic consequences of the mutations as damaging (table 
3.1).  
 
 
 
 
 
 
 
 
3.2.2  Patient Clinical Data 
Patients were referred on the basis of childhood onset diabetes mellitus and optic atrophy. 
All available patient clinical data are tabulated in appendix 3.  
 
Table 3.1. Predicted phenotypic effects of WFS1 mutations. SIFT and Polyphen predict the phenotypic 
effects of amino acid substitutions according to different sets of physical, chemical and functional data. A 
SIFT score <0.05 is predicted as deleterious. A Polyphen score of <0.5 is predicted as benign. According to 
these parameters, all novel WFS1-mutations discovered in our patients are considered pathogenic. 
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Figure 3.4.  Conservation of WFS1 residues across species (Clustal W). Each of the codons found to carry novel 
mutations are highly conserved residues suggestive of structural or functional significance.  
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3.3.0  Mutation analysis of WFS2 (Zcd2) 
Identification of a homozygous WFS2-E37Q mutation  
Available DNA from listed WS patients who did not screen positive for WFS1 mutations was 
examined for mutations in WFS2 (15 families). All three coding exons were sequenced in full 
(see appendix 2.2 for primer list) and a single individual was found to carry the homozygous 
missense change, E37Q, in exon 2 (fig. 3.5, table 3.2). The same mutation was previously 
reported by Amr et al (2007) in affected members of 3 consanguineous Jordanian families, 
and found to be absent in a large cohort of control chromosomes sourced from both 
matched and unmatched populations. The G>C transversion at nucleotide 109 codes for 
substitution of glutamic acid with glutamine, and disrupts an Xmn1 restriction site, which is 
illustrated in electrophoresed digest products of our patient and normal control DNA (fig. 
3.6). 
 
 
 
 
 
 
 
 
Figure 3.5. Mutation of WFS2.  Electropherogram illustrating 
the WFS2 point mutation (E37Q) found in patient D01.11844. 
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Table 3.2. Genetic data for WFS2-mutation. Patient D01.11844 was found to be homozygous for a WFS2 
mutation (E37Q), which encodes a splice enhancing sequence in exon 2. 
Figure 3.6. Abolition of Xmn1 restriction site by WFS2-mutation. Agarose gel (1.5%) electrophoresis 
of WFS2 restriction fragments digested with Xmn1. PCR amplified genomic DNA from patient 
D01.11844 and 12 control individuals demonstrates abolition of  the unique Xmn1 recognition site  
(GAANNNNTTC) by the E37Q mutation. 
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Reverse-transcription-PCR was performed on RNA from affected individuals from the 
Jordanian cohort by Amr and colleagues (2007) and compared to that of normal individuals. 
Primers encompassing full length WFS2 generated amplicons of expected size in control 
individuals (551bp), whereas products generated from patient WFS2 cDNA were only 336bp 
in length. Sequencing products from patient cDNA showed that exon 2 was completely 
missing from the final transcript. The schematic in figure 3.7 illustrates the consequences of 
this mutation at the transcription level. Panel A represents the normal splicing pattern of 
WFS2. Nucleotide 109 (G) sits 6bp downstream from the intron-exon boundary at the 5’ end 
of exon 2. Following the substitution of G>C exon 2 is skipped during the splicing stage of 
RNA processing (panel B). The remaining exons, 1 and 3, are then joined together (panel C) 
causing a frameshift in exon 3 and creation of a premature termination codon after the first 
8 nucleotides. The result is truncation of ~75% of the protein.  
Intron-exon boundary signals and intronic cis and trans-acting elements are known to direct 
the spliceosome during processing of precursor RNA to mature spliced messenger RNA, 
containing exons only. Other genetic elements embedded within exons, known as exonic 
splice enhancers (ESEs) or silencers (ESS) are also partly involved in either promoting or 
inhibiting the splicing process. These motifs are typically 6-8bp in length (Mersch, 2008) and 
consist of both common and variable sequences which means they are often difficult to 
identify. In WFS2, although the region of exon 2 surrounding the 109G>C substitution does 
not conform to any known ESE sequences, this region has been identified as a functional ESE 
(Amr, 2007).  
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A 
C 
B 
Figure 3.7. Splicing aberration caused by WFS2-mutation. Schematic diagram of splicing aberration in the WFS2 gene introduced by the 109G>C point 
mutation. RT-PCR of patient lymphoblastoid RNA by Amr et al (2007) demonstrated that the mutation causes exon 2 to be completely skipped, 
suggesting nucleotide 109 is part of a functional exonic splice enhancer motif. (A) Nucleotide 109 sits within 6bp of exon 2 splice acceptor site (5’) (B) 
Substitution of G>C at nucleotide 109 causes exon 2 to be skipped (C) Exons 1 and 3 are spliced together resulting in frameshift and creation of a 
premature stop codon, which truncates the protein product by ~75%. 
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3.3.1  Clinical information  
The patient harbouring the WFS2 mutation was a male, 18 years old at the time of report, 
who presented with a typically severe WS phenotype (table 3.3). Diabetes mellitus, optic 
atrophy, hearing loss, diabetes insipidus and renal complications were all diagnosed by the 
age of 11 years. No neurological abnormalities were reported, although these symptoms do 
not typically manifest until the third decade. Unlike the other affected individuals with WFS2 
mutations (El-shanti, 2000; Amr, 2007), this patient has not yet developed peptic ulcers and 
gastrointestinal bleeding tendency, which appears to be a unique feature of WFS2-
associated WS.  
 
 
 
 
Combining clinical information from our patient and the four original affected families 
carrying WFS2 mutations (El-shanti, 2000), we noted the age of diabetes mellitus onset 
ranged from 5-15 years, and optic atrophy from 4-22 years (table 3.4). All affected 
individuals, with respect to age, developed the full spectrum of WS clinical characteristics 
Table 3.3. Age of onset (years) of clinical features in a patient with WFS2-associated WS. Patient 
D01.11844, homozygous for WFS2-E37Q presented with a typical spectrum of WS clinical features including 
the first reported case of diabetes insipidus in WFS2-associated WS. Peptic ulcer disease, a characteristic 
only seen in WS patients with WFS2-mutations, was not diagnosed at the time of this report although the 
patient was only 11 years of age. 
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plus gastrointestinal disease. While suspected in some, none of the original cohort was 
diagnosed with diabetes insipidus, although this feature was present in our patient. 
 
 
 
Little neurological data are available from the original families although central respiratory 
failure was stated as the cause of death in one individual suggesting that neurological 
manifestations are a part of WFS2-associated WS as well. Further support for this comes 
from an independent study by a group at the Saudi Centre for Organ Transplantation 
(Hasan, 2000) who reported an isolated case of WS in a 15 year old boy born to 
consanguineous Jordanian parents. Although no genetic information was available at the 
time, the ethnic origins of this individual combined with the presentation of upper 
gastrointestinal bleeding tendency and duodenal ulcers in addition to the other WS clinical 
features, suggests he may in fact also carry a WFS2 mutation. An ataxic gait pointed toward 
neurological manifestations and following cranial magnetic resonance imaging (MRI) 
generalised brain atrophy and a small sized pituitary gland relative to the patients’ age were 
apparent.  
 
Table 3.4.  Median age (and range) of onset in years of clinical features in WFS2-associated WS families. 
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3.3.2  Haplotype analysis  
All of the WFS2-associated cases of WS have been reported in families of Jordanian descent. 
Previous microsatellite analysis of WFS2 families revealed a common haplotype for markers 
D4S3256, D4S1531, and D4S1564 in all affected individuals across a critical region around 
the WFS2 locus (El-Shanti, 2000), suggesting they may have shared ancestry.  
The WFS2 patient in our Birmingham cohort is also of Jordanian background, so we tested 
whether this individual shared the defined haplotype with the other families. We were 
kindly sent some DNA from a member of the original cohort courtesy of Rita Shiang, Virginia 
Commonwealth University, USA, and genotyped our patient along with this individual and 
an unaffected normal control (section 2.5.0). The results did in fact confirm that our patient 
carries the same haplotype as the other affected families, pointing towards a founder effect 
(see appendix 5 for raw data).  
 
3.4.0  Mutation analysis of ATP1B1 
Since we have ruled out a number of WS patients as carriers of WFS1 or WFS2 coding 
sequence mutations, we investigated the possibility of mutation in an additional candidate 
gene ATP1B1. This 7 exon gene codes for the glycoprotein subunit (β1) of sodium potassium 
ATPase a ubiquitously expressed integral membrane protein, which is responsible for 
maintaining electrochemical gradients of Na+ and K+ across the plasma membrane.  
ATPase is a high energy consumer, closely linked to energy utilisation and glucose uptake 
and inhibition of this enzyme has been linked with apoptosis and neuronal cell death (Lees, 
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2001). The Na+/K+ ATPase β1 subunit has also been shown to directly interact with the C-
terminus of wolframin, and reduced expression of Na+/K+ ATPase β1 subunit seems to be 
linked to mutation or absence of wolframin (Zatyka, 2008a).  
Due to the relatively small size of this gene (2608 bps), the connections it has with WFS1, 
and the functional relevance this protein has to many of the primary systems affected by 
WS, we proposed this gene as a reasonable candidate for mutation analysis. Following direct 
sequencing of ATP1B1 coding exons  (see appendix 2.3 for primers list) however, we ruled 
out mutations in this gene as the causative factor for WS in our patients, as no mutations in 
any of the screened individuals (10 patients) were identified. 
 
3.5.0  Mutation analysis of SLC19A2  
Thiamine (vitamin B1) is an essential nutrient for normal cell function, growth and 
development, and an important coenzyme in intermediary metabolism. Low intracellular 
thiamine levels impair energy production pathways and have been linked to ER and 
oxidative stress, and apoptosis (Wang, 2007). Systemic deficiency is often attributed to 
inadequate dietary intake in developing countries, chronic alcoholism or diabetes mellitus 
and can lead to cardiovascular and neurological disorders. Localised tissue-specific thiamine 
deficiency is associated with the pathology of thiamine responsive megaloblastic anaemia 
(TRMA), a rare, recessively inherited, monogenic disorder.  
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TRMA is primarily characterised by juvenile-onset megaloblastic anaemia, non insulin-
dependent diabetes mellitus, and sensorineural deafness (Rogers, 1969), although other 
clinical findings such as heart, neurological, and retinal defects have also been described in a 
number of cases (Neuwirth, 2009). TRMA patient cells are highly sensitive to thiamine 
depletion, although treatment with pharmacologic dosages of vitamin B1 can ameliorate 
anaemia, arrest hearing loss and delay the onset of diabetes (Mathews, 2009).  
The gene associated with TRMA, designated SLC19A2, was mapped to chromosome 1q 23.3 
(Neufeld, 1997) and codes for a 497 amino acid transporter protein THTR1, which is 
essential for the cellular uptake of thiamine. Loss of THTR1 has been shown to result in 
morphological and oxidative damage, and all known cases of TRMA to date (25 families) 
have been associated with mutational dysfunction of this protein (Neuwirth, 2009). 
During the course of this study, one listed patient on our WS database with no known 
mutations (patient D05.25758), presented with sideroblastic anaemia. This individual was 9 
years of age, and had other clinical features typical of WS including juvenile onset diabetes 
mellitus, deafness and eye disease, although the latter was found to be cone rod dystrophy 
unlike the characteristic optic atrophy seen in WS patients (table 3.5). In light of this new 
development, the clinical diagnosis shifted from what initially appeared to be WS to 
something conforming more closely to TRMA. Our aim was to screen this individual for 
mutations in SLC19A2 to confirm TRMA with a genetic diagnosis. All 6 coding exons of 
SLC19A2 were sequenced in our patient, an affected sibling, and control DNA (see appendix 
2.4 for list of primers). 
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3.5.1  Confirmation of inactivating SLC19A2 mutation in patient with TRMA phenotype 
A c.484C>T point mutation was discovered in both patient D05.25758 from our cohort and 
his affected brother. This mutation substitutes an arginine residue with a termination codon 
at amino acid 162 (R162X), truncating the protein by approximately two-thirds (fig 3.8; table 
3.6). This mutation has been described before in 3 other families of Turkish (Raz, 2000), 
Pakistani, and Japanese origins (Labay, 1999), and possibly reflects a mutational hotspot 
since none of these families appear to share a common ancestor (Raz, 2000).  
 
 
 
 
 
 
 
Table 3.5. Age of onset (years) of clinical features in a patient with SLC19A2-associated TRMA. 
Patient D05.25758, diagnosed with thiamine responsive megaloblastic anaemia (TRMA) presented 
with sideroblastic anaemia at age 9 following initial diagnosis of WS. 
Figure 3.8. Mutation of SLC19A2. Electropherogram illustrating the SLC19A2 
homozygous point mutation (R162X) found in patient D05.25758, diagnosed 
with thiamine responsive megaloblastic anaemia. 
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As already documented, not all TRMA patients present with the same severity of phenotype 
or the typical triad of associated features (Neuwirth, 2009), even when comparing those 
individuals carrying identical SLC19A2 mutations (table 3.7) making diagnosis and detection 
tricky. Depending on the order and presentation of characteristics the spectrum of TRMA 
clinical features can be similar to those in WS. Our patient also had visual abnormalities, a 
feature not always present in TRMA syndrome, further complicating initial diagnosis.  
 
 
 
 
 
 
 
Table 3.7. Age of onset (years) of clinical features associated with SLC19A2-
R162X. Data from three previously reported TRMA families harbouring the same 
SLC19A2 nonsense mutation found in our affected individual (patient 
D05.25758).  
Table 3.6. Genetic data for SLC19A2 mutation. Patient D05.25758, was found to carry a 
homozygous nonsense mutation in SLC19A2 (R162X), confirming a genetic diagnosis of 
thiamine responsive megaloblastic anaemia (TRMA).  
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3.6.0  Sequencing analysis summary 
From a total of 26 probands we have successfully identified 10 mutation types (16 
chromosomes): 8 in the WFS1 gene, 1 in WFS2 and 1 SLC19A2 mutation. Only a single 
heterozygous WFS1 coding sequence mutation was found in several of the listed patients 
and 16 individuals screened negative for any coding sequence mutations of WFS1, WFS2, or 
ATP1B1. However, large deletions and intronic/promoter sequence variants have not been 
ruled out. 
Perhaps revisiting clinical records and observations might suggest an alternate diagnosis, 
since WS does share features common to several other diseases such as maternally 
inherited diabetes and deafness (King, 1992), TRMA and Alstrom syndrome (Alstrom, 1959). 
It is also possible that other, as yet unidentified genes are responsible for WS in these 
patients, as locus heterogeneity is already a known facet of this disorder. 
 
 
 
CH
A
PTER
 3 M
U
TA
TIO
N
 A
N
A
LYSIS O
F W
O
LFRA
M
 SYN
D
RO
M
E PA
TIEN
TS 
 
 
131 
    
Figure 3.9. Summary of WS mutation analysis. From a total of 26 probands (52 chromosomes): mutations were found in 10 individuals, accounting for 16 
chromosomes. WFS1 mutations were found in 8 patients: 2 homozygotes, 2 compound heterozygotes and 4 patients with only one mutation detected. One 
patient was found to be homozygous for a WFS2 mutation and a further patient was homozygous for SLC19A2 mutations. No mutations were detected in 16 
individuals, who were also screened for possible mutation of ATP1B1. 
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3.7.0  Genotype-phenotype correlation  
The West Midlands Wolfram syndrome patient registry to date, lists 93 individuals from 83 
families (appendix 3.0-3.1). Excluding those individuals we found to harbour WFS2 and 
SLC19A2 mutations, we carried out some genotype-phenotype analysis and correlation on 
available data from probands only. 
From a total of 162 chromosomes, 121 mutations have so far been identified in the WFS1 
gene. The most commonly found are missense, nonsense and deletion mutations which 
occur in almost equal frequencies, 31%, 32% and 33% respectively. Insertions, and splice 
mutations account for only 2% of the total and other unique synonymous changes, perhaps 
pathogenic, were discovered in 2% of cases (fig 3.10). One or more WFS1 mutations have 
been found in 67 individuals, where almost half (45%) are compound heterozygotes, 30% 
are homozygous and the remainder have only one mutation detected.  
Where patient clinical data were available the median age of onset was calculated for 
distinct clinical features (table 3.9). From a total of 42 probands, diabetes mellitus presented 
at a median age of 6 years (range 1.5-30) and optic atrophy at 10 years (range 1-18). Of 
those individuals who presented with additional features, the mean ages of onset were: 
deafness at 9.5 years (range 0-39), diabetes insipidus at 13 years (range 2.5-40), renal and 
urinary tract complications at 22 years (range 10-46) and neurological abnormalities at 30.5 
years (range 9-44). Deafness was reported in 61% of cases over 30 years of age, and 
diabetes insipidus and renal/urinary disturbances were found independently in 78% of these 
individuals. 
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In order to relate genotype to phenotype, patients were categorised into three main groups 
according to the mutation-types they carried. The first group were those found to be either 
homozygous or compound heterozygous for inactivating mutations, the second homozygous 
or compound heterozygous for missense changes and the third were compound 
heterozygotes for a missense and an inactivating mutation. Both nonsense and deletion-
frameshift changes were considered ‘inactivating’.  
Figure 3.10/Table 3.8. Proportions of mutation-types found in the West Midlands cohort (n=93). 
Nonsense, missense and deletion mutations occur in almost equal frequencies.  
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Onset of optic atrophy was calculated at a median age of 11, 10 and 8.5 years for each 
group respectively, all of which correlate closely with the overall median age of presentation 
for the whole cohort. The median age of diabetes mellitus onset was 5 years both in group 1 
(n=13) and 3 (n=7), where at least one inactivating mutation was present. Group 2 (n=4), 
carrying missense mutations only, presented with diabetes mellitus at a median age of 10.5. 
When combining groups 2 and 3 (group 4; n=11) to represent all patients carrying at least 
one missense WFS1 mutation, the median age of optic atrophy and diabetes mellitus onset 
was 10 years (table 3.9). 
 
 
 
 
 
 
 
 
 
Our observations follow a similar trend to the findings of Cano et al (2007) who performed a 
meta analysis of combined clinical and genetic data from six independent studies of WS 
patients (n=96). They too found that patients with one or more WFS1 missense mutations 
Table 3.9. Genotype-phenotype correlation in WS. Median age of onset (years) for primary WS clinical 
features between individuals harbouring selected combinations of inactivating and missense WFS1 
mutations. Patients carrying at least one missense mutation present with diabetes mellitus at a later 
median age than those with inactivating mutations only.  
1            n=13                     
2            n=4 
3            n=7 
Group 
(n=number of patients) 
 
 
4            n=11 
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seemed to have a later age of diabetes mellitus onset. Those carrying two missense 
mutations had a median age of onset of 12 years, compared with one missense mutation 
(median age of onset: 9 years) and no missense mutations (median age of onset: 5 years). 
Unlike our study they also noticed a slightly earlier age of optic atrophy presentation in 
patients with one or more inactivating mutations (median: 10 and 11 years respectively) 
compared to those with no inactivating mutations (median: 14 years).  
Despite the relatively small numbers of suitable patients, we compared those individuals 
over 30 years with one or more missense mutations (n=6) to those with inactivating 
mutations only (n=7) to see whether any differences in overall clinical expression of WS 
were apparent (fig 3.11). Interestingly a greater proportion of individuals carrying 
inactivating mutations appeared to have a more complete spectrum of complications with 
71% of patients presenting with deafness and 100% of patients with diabetes insipidus 
compared to those individuals with one or more missense mutations who presented with 
deafness over the age of 30 in only 66% of cases and diabetes insipidus in 44%. Renal and 
urinary tract complications were reported in roughly equal proportions in both groups (83% 
and 86% respectively). Neurological findings were also detailed in all instances except one 
where the patient was only in fact 30 years of age.  
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Figure 3.11. Genotype-phenotype correlation in WS. Comparative presentation of additional WS clinical features 
between individuals carrying inactivating mutations only (group 1, n=13) and those with at least one missense mutation 
(group 4, n=11). Proportion of affected individuals over 30 years of age.  
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3.8.0  Summary and discussion 
Our findings have further completed existing genetic data on the West Midlands Wolfram 
syndrome patient database by uncovering disease-causing mutations in 10 individuals. A 
total of 10 distinct WFS1 variants were found in 8 patients, 5 of these mutations have 
previously been described, and 5 are novel findings. The suspected pathogenicity of these 
novel changes are supported by predictive physio-chemical data, conservation status of 
associated amino acids, and the absence of these mutations in a control panel of normal 
chromosomes.   
We also report the first case of WFS2-associated WS in the UK population. Conforming with 
previously reported families carrying this mutation this individual has a Middle-Eastern 
ethnic background and shares a defined disease-haplotype with other affected individuals, 
suggestive of common ancestry. As the only reported WFS2 mutation to date, this WS-
associated allele perhaps only poses a disease risk to culturally and geographically isolated 
populations of Jordanian-Bedouin background. Contrary to earlier reports, where diabetes 
insipidus was absent in affected individuals (El-Shanti, 2000; Amr, 2007) we also document 
the presence of diabetes insipidus as a feature of WFS2-associated WS. 
One listed individual previously thought to have WS presented with anaemia during the 
course of this study. The clinical diagnosis was re-evaluated and designated as suspected 
Thiamine Responsive Megaloblastic Anaemia (Rogers syndrome). We were able to confirm a 
genetic diagnosis by screening the thiamine transporter gene, SLC19A2, which carries 
mutations in every other reported case of this syndrome. Our patient was homozygous for a 
nonsense change, previously described in several other affected families. 
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Coding exons of the ATP1B1 gene were also sequenced for potential mutation in all 
individuals that screened negative for known WS-gene mutations. This relatively small gene 
was considered a reasonable candidate as a number of interesting links between this gene 
and WS pathology can be made in addition to the direct interaction between the protein 
products of this gene and wolframin. We did not however discover any significant sequence 
changes in ATP1B1, therefore confirming that coding variants in this gene are not 
responsible for WS in our cohort.  
From a total of 93 patients listed on the regional WS database, genetic mutations have yet 
to be identified in 16 patients (4 of which have no more available DNA). We have ruled out 
coding mutations in WFS1, WFS2 and ATP1B1 as causative factors for WS in these cases 
although the presence of intronic or promoter sequence variants or large deletions in these 
genes are a possibility.  
The mutational spectrum of WFS1 is expanded by our findings, bringing the total number of 
unique WFS1 mutations reported to date to over 530. Together with the clinical data 
presented, we further highlight not only the genetic heterogeneity of WS but the 
phenotypic variability of this disease and likeness to other genetically distinct, but 
phenotypically similar disorders such as TRMA. Continued molecular analysis allows us to 
refine the diagnostic criteria for WS and overlapping syndromes sharing similar phenotypes. 
Our results support the notion that correlation between mutation type and disease severity 
may exist. In agreement with earlier comparative analyses we found in our cohort that 
people harbouring inactivating WFS1 mutations present with diabetes mellitus at an earlier 
age (median: 5 years) than those with at least one missense mutation (median: 10 years). 
We did not observe any notable differences in age of optic atrophy onset although patients 
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with two inactivating mutations seem to present with a wider spectrum of additional clinical 
features than those with at least one missense mutation. Taken together with previous 
evidence these trends suggest that some missense mutations may retain partial function.  
3.8.1  Further work 
Making extensive genotype-phenotype correlations in rare disorders is limited primarily by 
sample numbers, but in the case of complex diseases such as WS analyses are further 
complicated by genetic heterogeneity and variability of clinical manifestations. It is 
important to take into consideration patient ages when making correlations between 
groups where possible within the constraints of limited sample sizes. Building on current 
data archives will gradually improve our understanding of WS natural history and continual 
detailed documentation of patient information in the clinic throughout disease progression 
to adulthood will also help us to perform more informative and detailed genotype-
phenotype correlation on larger age-matched groups. 
Those individuals with WS phenotypes but no identified mutations might provide an 
interesting panel for discovering potentially novel WS-causative genes if they exist, although 
DNA from sufficiently large numbers of family members would be necessary for gene 
mapping studies. Due to the functional relatedness of mitoNEET (Cisd1) to WFS2 (Cisd2) we 
propose this gene as an interesting candidate for association with WS. Perhaps ATF6α, 
described in chapter 1 (section 1.5.1) could also be considered due to the regulatory 
relationship wolframin has been shown to have on this important ER-stress sensing protein. 
The application of next generation sequencing technology, which is becoming increasingly 
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more accessible and cost-effective would also allow whole-exome or even whole genome 
capture, which may lead to the discovery of new disease genes.  
Our data suggest that some wolframin variants with WFS1 missense mutations might retain 
some capacity to function, which may be the basis for delayed onset and presentation of 
fewer clinical features in some individuals carrying these types of mutation. From a 
sequencing analysis perspective we may be able to glean some further clues about the 
phenotypic consequences of individual WFS1 missense mutations by gathering and 
comparing the clinical data from patients homozygous for missense mutations with those 
from patients who are compound heterozygous for missense mutations. 
Mechanisms behind phenotypic variability can only be explained by functional analyses of 
the gene product, wolframin. The ultimate correlation would be to determine precise 
functional roles of specific regions of the wolframin protein so that targeted therapies might 
be developed. A selection of wolframin ‘missense’ variants will be characterised in chapter 4 
forming the principle stage of our functional investigation. 
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CHAPTER 4 
CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
4.0  Introduction and aims 
It has been postulated that mutations in the WFS1 gene result in loss of wolframin function. 
Evidence suggests that mutations may cause reduced steady-state protein levels and/or a 
range of alterations to the characteristics and behaviour of wolframin. However, a 
comprehensive understanding of the relationship between WFS1 genotype and resulting 
protein functionality has yet to be reached.  Previous in vitro studies have demonstrated the 
potential for missense mutations to result in wolframin aggregation, instability and mis-
localisation (Hofmann, 2003 and 2006; Yamaguchi, 2004; Fonseca, 2005). Analysis of 
fibroblasts from patients carrying various mutations has also shown in some cases 
significantly lower expression levels of wolframin, or indeed an apparently complete 
absence of wolframin (Hofmann, 2003 and 2006; Philbrook, 2005; Fonseca, 2005), 
suggesting mutations may induce production of unstable, readily degraded proteins. 
If the fate of mutated wolframin may vary depending on the nature of the mutation it is also 
possible that impairment of function may be variable too. Even if all Wolfram syndrome-
associated mutations culminate in similar end-points, ultimately cell degeneration caused by 
uncontrolled ER-stress, the pathogenic mechanisms leading up to the system break-down 
may be different. The select few mutations that have been characterised and analysed for 
function certainly do not reflect the full spectrum of mutations reported in Wolfram 
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patients. Each study also has its own technical and analytical limitations such as 
comprehensive clinical data, detection methods, and adequate controls.  
Our genotype-phenotype data (chapter 3), in concordance with findings from other groups 
(Smith, 2004; Cano, 2007; D’Annunzio, 2008) suggest that WS patients with at least one 
WFS1 missense mutation have a relatively later median age of onset than those patients 
harbouring inactivating mutations and are less likely to present with the full spectrum of 
WS-associated clinical features. These observations, together with reports of relatively 
‘mild’ WS phenotypes in some patients carrying WFS1 missense mutations (Gomez-Zaera, 
2001; Van Den Ouweland, 2003; Gasparin, 2009; Zymslowska, 2011) form the basis of our 
hypothesis that:  
Some wolframin variants may retain partial function. 
From a therapeutic perspective, identifying even limited functional wolframin in some 
patients may be important for future developments in therapeutic intervention, such as 
introduction of targeted chemical chaperones. 
The aims of this chapter were to explore the possibility that selected WFS1 missense 
mutations may still allow some residual wolframin protein function. The foundation of this 
work was to select a representative range of WFS1 mutations for study and to characterise 
these in terms of expression levels, localisation and stability, before looking to investigate 
further any suitable candidates for specific changes in function.   
 
An in vitro ‘over-expression’ model was the approach used in this study for a number of 
reasons. Firstly, this allowed the freedom to select specific WFS1 mutations to investigate, 
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which were not available from any cell or tissue banks at this time. These mutations were 
selected to represent a wider spectrum of WFS1 mutations than previously investigated, 
where clinical data were available from homozygous patients.  Some previous studies have 
been limited by the use of heterozygous models, which are difficult to interpret when 
considering relationship to phenotype. The selection could also be made to reflect a spread 
of mutations found across the WFS1 gene or protein as desired. Using well established cell 
lines and over-expressing our proteins of interest had the advantages of lower technical 
complexity and ease of replication in the laboratory, enabling the generation of more 
efficient and cost-effective preliminary data. Finally, once WFS1 mutations in mammalian 
expression vectors are constructed and characterised, they could be used in a range of 
subsequent functional assays, for which we have already validated cell lines within the 
Birmingham laboratory and well established protocols suitable for our purposes. 
How well a model system such as this one reflects conditions in Wolfram patients is the 
obvious limiting factor when considering a practical experimental approach. Translating any 
information generated in isolated populations of immortalised cells to conditions in vivo is 
tentative. For instance, the demands placed on cells by vastly over-expressing proteins 
could have countless and variable effects on their overall behaviour. We can account in part 
for these effects by making comparisons where appropriate with endogenously expressed 
wolframin, and can also (at least) state with reasonable credence that protein variants over-
expressed in the same conditions as wild-type have the ‘potential’ to behave similarly or 
differently. Although evidence indicates that some wolframin protein variants may be 
undetectable and others expressed at reduced levels in affected individuals, an assumption 
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is made that all of the selected wolframin variants in our panel are expressed to some 
degree in humans, and without tissue from patients this conjecture cannot be confirmed.  
The initial characterisation of our chosen wolframin variants was therefore aimed at 
identifying the ‘potential’ for differences to be observed in vitro, and thus laying a 
foundation on which to build further detail for confident translation to the human 
condition. 
 
4.1.0  Selection of WFS1 gene mutations 
The selection of WFS1 mutations for this study was based on reported phenotype. Assuming 
some wolframin protein variants have residual function we planned to compare mutations 
seen in relatively mild cases of Wolfram syndrome to those reported in severely affected 
patients. If mutations seen in patients with a milder phenotype retain some partial function, 
we might expect to observe fewer abnormalities in their characteristics and function 
compared to mutations found in patients with a severe clinical phenotype. Classification of 
patient phenotype as mild or severe was defined with reference to the median age of onset 
of the primary WS clinical features; juvenile-onset diabetes mellitus (6 years) and optic 
atrophy (10 years) calculated from both our cohort (chapter 3) and from the work of 
Domenech (2004) who reported average ages of diabetes mellitus onset at 5.8 years and 
optic atrophy at 11 years from the combined data of 5 studies (Hardy, 1999; Gomez-Zaera, 
2001; Colosimo, 2003; van den Oweland, 2003; Domenech, 2004). 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
145 
 
We have chosen to concentrate our attention on missense mutations since truncated 
transcripts and proteins resulting from other types of nonsense and frameshift mutations 
are vastly different in character than wild-type and generally found to be highly unstable. 
Attributing a given phenotype to specific mutations is less complex when the individual is 
homozygous for these changes, so the variants selected for investigation here have all been 
reported in homozygous individuals with a clear record of clinical data. Consideration was 
also given where appropriate, to the position of the substitution along the length of the 
protein, in an attempt to include variation found in a range of protein domains. 
 
4.1.1  Clinical information 
Table 4.0 summarises the selection of mutations used in this study and the clinical features 
reported. The chosen amino acid substitutions relating to typical severe WS phenotypes are 
leucine to proline at codon 511 (L511P), and glycine to alanine at codon 736 (G736A). In 
chapter 3, the novel homozygous mutation L511P was discovered in a consanguineous 
Turkish family with 7 affected members under the age of 17, all presenting with a severe 
phenotype. Diabetes mellitus presented at a mean age of 4 years and optic atrophy at 8.5 
years. Other clinical features including sensorineural hearing loss, renal and urinary tract 
abnormalities, and diabetes insipidus were also noted to different degrees in the older 
individuals. The proband listed in table 4.0 was a 10 year old female who presented with 
diabetes at age 3, optic atrophy at 9 years, and had also developed neurogenic bladder, 
chronic renal insufficiency and diabetes insipidus at the time of the report. The second 
‘severe’ homozygous mutation (G736A) was reported in an 8 year old Spanish girl from a 
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consanguineous background (Domenech, 2004). She had developed diabetes mellitus and 
optic atrophy before age 6 and was also diagnosed with possible onset of diabetes insipidus.  
A relatively mild case of WS was reported in a 39 year old Brazilian patient (Gasparin, 2009) 
homozygous for a glutamic acid to lysine substitution at codon 158 (E158K). The onset of 
diabetes and optic atrophy in this individual was during adulthood, 27 years and 19 years 
respectively, and the additional reported clinical features including deafness, urinary tract 
abnormalities, and erectile dysfunction also presented relatively late. Secondly, an arginine 
to histidine change at codon 558 (R558H) was selected for our study since a 38 year old 
French individual homozygous for this mutation also appeared to have milder WS (Cano, 
2007). He developed diabetes mellitus at 29 years and optic atrophy at 35 years of age. 
Although he also presented with neurogenic bladder at 33 years and suffered from 
depression, no other clinical features were identified. A more recently reported case of an 
individual homozygous for WFS1-R558H (Chaussenot, 2011) was another French patient, 40 
years of age. Again, this individual presented with late-onset diabetes mellitus and optic 
atrophy (32 years), but also presented with deafness and neurological complications 
(cerebellar ataxia, nystagmus, dementia and moderate cerebellar atrophy) at 40 years. 
Interestingly R558H has been reported previously in compound heterozygous individuals 
also carrying inactivating mutations. An affected individual from an Italian family was 
compound heterozygous for R558H and a 6bp deletion (p.R178_Q179del) and had a 
typically ‘severe’ spectrum of WS early-onset features (Colosimo, 2003). Another two 
affected sibs (17 and 18 years of age) from a Canadian family compound heterozygous for 
R558H/E864X, had presentation of diabetes mellitus and optic atrophy at 6-10 years and 13-
14 years respectively, but had no other reported complications (Smith, 2004). 
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Table 4.0 Selected WFS1 missense variants and associated clinical features.  
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The variants E737K and R818C have been included in this investigation, although to what 
extent each of these contributes to WS pathogenesis is unknown. The patient listed in table 
4.0 is a 38 year old female of Spanish origin (Gomez-Zaera, 2001). Her parents are first-
cousins and she is homozygous for both of these variants. She had relatively late onset 
primary diagnostic features, but also developed urinary tract and neurological symptoms. A 
sibling with the same genotype also presented with almost identical features and died 
following food aspiration at the age of 42. The authors of this study suggest the causative 
mutation is more likely R818C since this substitution results in more significant chemical 
alteration than E737K, although neither of these variants were seen in control 
chromosomes. An earlier Japanese study (Ohtsuki, 2000) looking at potential links between 
WFS1 variant carrier status and psychiatric illness did discover E737K in 10% of the patients, 
although also noted the presence of this variant in 7% of control individuals. R818C has also 
been documented in other studies (Smith, 2004) but not yet excluded as a benign 
polymorphism. 
Perhaps the most interesting WFS1 variant is codon 611. Although accepted as a common 
single-nucleotide polymorphism, H611 (c.1832G>A) has generated extensive interest as a 
potential susceptibility allele for type 2 diabetes (Minton, 2002; Sandu, 2007; Florez, 2008; 
Franks, 2008). The R611 allele remarkably, has also been highlighted as a possible marker 
for mood disorders (Zalsman, 2009), medication overuse headache (Lorenzo, 2007), and 
type 1 diabetes (Awata, 2000). To date, no functional analysis of this variant has been 
carried out. We therefore aimed to understand more about how this particular WFS1 allele 
could contribute to complex disease, by primarily generating biochemical data about the 
characteristics of this variant, then seeking to identify any obvious limitations in function.  
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4.1.2  Physio-chemical properties of wolframin ‘missense’ variants 
The hypothetical structure of the wolframin protein and location of WFS1 substitutions of 
our interest are illustrated in figure 4.0 (adapted from Hardy, 1999). The tabulated data 
(table 4.1) include the physio-chemical properties of the wild-type and substituted amino 
acids. The N-terminal end of the wolframin protein sits on the cytosolic side of the ER and 
residue 158 is situated in this domain. The substitution of glutamate (E) with lysine (K) 
replaces an amino acid that is negatively charged at a physiological pH with one that is 
positive. The same substitution E>K at residue 737 has been selected, although this amino 
acid is located in the carboxy-terminal portion of the protein, within the ER lumen.  
Leucine (L) is hydrophobic in nature and therefore generally seen in the interior of proteins. 
Amino acid L511 is likely to reside in, or near to the hydrophobic cross-membrane section of 
wolframin. Substitution with proline (P) at position 511 could have a significant impact on 
the overall protein structure, since this is the most rigid of the naturally occurring amino 
acids. This inflexibility is due to linkage between the side-chain and nitrogen atom, and thus 
thought to play an important role in determining protein conformation.   
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Figure 4.0 Dot diagram showing the predicted amino acid configuration of the wolframin protein and 
location of selected sequence variants. Adapted from Hardy (1999).  
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Table 4.1 WFS1 missense variants – Genetic and physiochemical data 
KEY: CD = cytoplasmic domain, TM = transmembrane domain, CL = cytoplasmic loop, LL = luminal loop, LD = luminal domain.  
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The other amino acid thought to be conformationally important is glycine (G). In contrast to 
proline, this small residue lacks a side chain which confers a great deal of flexibility, and is 
often located in turn regions of proteins allowing polypeptide chains to form a tightly 
packed configuration. The residue at position 736 is present in the ER luminal domain and 
has been substituted with alanine, a hydrophobic molecule very different in nature. It is 
interesting to note here that the two amino acids implicated in overall protein conformation 
(leucine and glycine) are those thought to be involved in the pathogenesis of WS in both our 
severely affected patients. 
The arginine (R) to cysteine (C) change found at codon 818 replaces a hydrophilic, charged 
amino acid with a neutral residue. The sulphur groups of cysteines allow the formation of 
disulphide bonds and dimerisation, associated with stabilising protein structure. Again, this 
points toward a particularly significant disruption to the structure and function of 
wolframin, and as mentioned earlier may be more damaging than E737K. 
The final changes, arginine (R) to histidine (H) at 558 and 611 are both thought to be 
positioned in, or close to the transmembrane domains. Being hydrophilic, perhaps residue 
611 is more likely to reside in the cytosolic or luminal loops as opposed to the proposed 
position on the diagram. The substitution R>H does not alter the physio-chemical 
characteristics of the residue drastically, since one basic cation is replaced with another. 
Charged residues can take part in solvent binding and electrostatic interactions with 
complementary ions. It may be that some of these interactions could be hampered but not 
abolished following the above substitutions, which would support our hypothesis that some 
WFS1 mutations may encode partially functioning proteins. This seems a likely situation 
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when considering the H611 allele, attributed to a diabetic predisposition and not WS, but a 
possibility also for the R558H mutation, which has been found in a ‘mild’ case of WS. 
Results 
4.1.3  Bioinformatic analysis of wolframin ‘missense’ variants 
Bioinformatic analyses of sequence variants can provide clues and supporting evidence to 
aid our understanding of protein function. Comparative alignments of nucleic acid and 
protein sequences across a range of species can give us an indication of how functionally 
important a particular sequence is. Those occurring farthest back in the phylogenetic tree 
and conserved despite evolutionary speciation are thought to represent particularly 
important structural and functional elements. 
Alignments of wolframin protein sequences were made using ClustalW (ebi.ac.uk) (fig 4.1). 
Sequences from humans and other mammalian species were compared to zebrafish (Danio 
rerio) and fruitflies (Drosophila). Codons 158, 558, 736, and 737 are identical through all 
species. Codons 511 and 611 differ only in the fruitfly sequence, being substituted 
conservatively at 511. Codon 818 is the least conserved, aligning identically in the 
mammalian species only.  
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Figure 4.1 Conservation of wolframin across species (ClustalW). Amino acid residues selected for study are all 
conserved across mammalian species, some as phylogenetically distant as the fruitfly signifying functional 
importance. 
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SIFT (sorting intolerant from tolerant) and Polyphen (polymorphism phenotyping) are 
programmes designed to predict the probable phenotypic effects caused by gene sequence 
changes.  Multiple sequence alignment, protein function annotation, and information about 
the physical properties of amino acids are combined to analyse a query sequence. 
The resulting output from SIFT is a comprehensive table of possible substitutions at each 
amino acid residue and a normalised probability score from 0-1 representing the predicted 
phenotypic effects of that change. Scores less than 0.05 are more likely to be deleterious, 
and those greater than or equal to 0.05 are predicted to be tolerated. The scores generated 
from our WFS1 substitutions are listed in table 4.2.  All of these changes, with the exception 
of E158K have a score indicative of deleterious phenotypic consequences. E158K, found in a 
mildly affected WS patient, resulted in a SIFT score of 0.08, and is classified as tolerated. 
Polyphen interprets quantitative probability data to produce a qualitative prediction 
outcome of sequence variants on phenotype: benign, possibly damaging, or probably 
damaging. The results from our panel of WFS1 mutations suggest that all 8 variants are 
damaging. L511P has the highest score (2.243) and is predicted with the greatest degree of 
confidence to result in a deleterious outcome of ‘probably’ damaging. The remaining 
variants all produce a score indicative of ‘possibly’ damaging.  
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Table 4.2 Bioinformatic analysis of selected wolframin variants using SIFT and Polyphen. Phenotypic effects of amino acid substitutions are 
predicted according to different sets of physical, chemical and functional data. A SIFT score <0.05 is predicted as deleterious. A Polyphen score of 
<0.5 is predicted as benign.  
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The output from these programmes cannot be directly compared since different parameters 
and data sets are used to calculate the predictions. Both sets of results do however agree 
that all selected WFS1 mutations are likely to have a deleterious effect on phenotype, other 
than SIFT analysis of E158K, which was considered to be tolerated. It is reassuring to note 
that E158K has a relatively lower Polyphen score compared to the other variants, as does 
E737K, supporting our clinical information about the ‘milder’ WS phenotype relating to 
E158K and the previously suggested benign effects of E737K.  
All of the WFS1 mutations in our study may induce adverse phenotypic effects, although to 
variable degrees of severity. It is therefore anticipated that each of the codons in question 
has a crucial role to play in normal structure and/or functioning of wolframin. As expected, 
these amino acids are highly conserved throughout a range of mammalian species, some 
even in more distantly related animals. Additionally, the statistical analyses lend support to 
associations made between genotype and phenotype, predicting (generally) the outcome of 
these substitutions to be deleterious.  
 
4.2.0  Cloning and site-directed mutagenesis of WFS1 
In order to characterise the selected WFS1 mutations in vitro, we prepared some 
mammalian expression vectors containing wild-type WFS1 and the chosen range of variants. 
The vector of choice was pcDNA3.1, which promotes over-expression of untagged proteins. 
Human Wt-WFS1 sequences in pCMV-myc expression vectors were available for our use in 
the Birmingham laboratory (courtesy of Dr Malgosia Zatyka). From these plasmid 
preparations, human WFS1 cDNA was sub-cloned (section 2.19) into pcDNA3.1(+) using 
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EcoR1 and Not1 restriction sites (fig 4.2). Following sequence verification (section 2.4.0), 
WFS1-pcDNA maxipreps (section 2.7.5) were used as templates for site-directed 
mutagenesis (SDM) PCR (section 2.6.0) to generate the sequence variants. Introduced 
mutations were also confirmed by sequencing. Unwanted changes may be introduced to the 
vector ‘backbone’ sequence during the mutagenesis reaction, potentially interfering with 
promoter activity or antibiotic resistance genes. To avoid the arduous task of full 
sequencing, each of the mutated WFS1 sequences were subsequently inserted to fresh 
pcDNA3.1 vectors, which had not been subject to a mutagenesis PCR reaction. For a more 
detailed description of the protocol please refer to section 2.6.0 (primers list in appendix 2). 
Electropherograms depicting wild-type and mutated WFS1 sequences are shown in figure 
4.3 and a comprehensive description of nucleotide and codon substitutions are described in 
table 4.3. 
 
 
 
 
 
 
 
 
 
Figure 4.2 Cloning of human WFS1 into mammalian expression vector pcDNA3.1(+).  
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Figure 4.3 Site-directed mutagenesis of human WFS1. Electropherograms illustrating introduced point mutations.  
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4.3.0  Steady-state expression of wolframin variants 
4.3.1  Specific aims and methods 
The first step in characterising our WFS1 constructs was to examine their relative steady-
state expression. We aimed firstly to verify over-expression of these proteins in our model 
system validating their use in further transfection experiments. Some evidence suggests 
that wolframin expression in WS patients is markedly reduced or entirely absent (Hofmann, 
2003 and 2006; Philbrook, 2005; Fonseca, 2005), therefore our second objective was to 
determine whether our missense mutations result in reduced steady-state expression of 
wolframin. 
HEK293 cells were used in these experiments as they provide a quick-growing, easily 
manipulated, and readily transfected human cell line. Purified WFS1-pcDNA plasmids (1µg) 
were transfected with FugeneHD reagent (Roche) into HEK293 cells grown to 80-90% 
Table 4.3. Site-directed mutagenesis of human WFS1. Amino acid and codon substitutions  
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confluency (section 2.9.5). Following a 24 hour incubation period, the cells were harvested 
in lysis buffer (2.10.1), sonicated on ice (2 x 10 seconds), and centrifuged for 30 minutes 
(4°C) at 14,000rpm. The supernatant was harvested and measured for protein concentration 
on a BioRad 750nm Microplate Absorbance Reader (section 2.11.0). Samples (10µg/lane) 
were electrophoresed on SDS-PAGE gels and western blotted (section 2.13.0). Semi-
quantitative absorbance measurements of the resulting blots were then calculated using 
GeneSnap/GeneTools software (Syngene; section 2.13.5).  
The influences of technical variability, particularly transfection efficiency, were minimised by 
repeating the experiment a number of times.  
4.3.2  Steady-state expression of wolframin variants harvested in RIPA buffer 
The first set of transfections (n=4) were harvested in RIPA buffer for western blotting. 
Wolframin protein was detected with polyclonal α-WFS1 antibody (Proteintech) and 
variance in gel protein loading was corrected for with measurements of β-actin, detected 
with α-β-actin antibody (Sigma). Figure 4.4A is a representative blot illustrating steady-state 
expression of wild-type wolframin and selected variants following transfection into HEK293 
cells. Variation between the wolframin mutants is apparent, and variability between 
experiments was also observed to different degrees. Figure 4.5 shows the mean expression 
values corrected for β-actin from all of the experimental repeats and standard error. The 
corresponding quantitative measurements are detailed in table 4.4 (see appendices 7 and 8 
for raw data). The figures show that aside from WFS1-L511P, the steady-state expression of 
all the wolframin variants fall into a range between 73.4% (± 24.6%) and 118.9% (± 26.7%) 
relative to wild-type wolframin. The mean expression level of WFS1-L511P however, is only 
46.2% (± 19.0%) relative to wild-type. Despite considerable deviation from the mean value, 
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consistently lower levels of protein were detected from WFS1-L511P throughout all 
conditions, indicating that this variant may give rise to depleted steady-state expression of 
wolframin.  
Two-tailed t-tests comparing wild-type-WFS1 with each of the wolframin variants lend 
support to our initial observations. Statistically significant differences (p.=0.047) could be 
found between the steady-state expression levels of wild-type-WFS1 and WFS1-L511P. 
 
 
Figure 4.4 Steady-state expression of wolframin variants harvested in RIPA buffer. Clone set 1. (A) Typical 
SDS-PAGE immunoblot analysis of samples probed with anti-WFS1 Ig (Proteintech) and anti β-actin 
(Sigma). (B) Selected samples re-run and probed with an alternative anti-WFS1 Ig (courtesy, Dr S. 
Hofmann) and β-actin (Sigma). Comparative signal detection suggests that mutations do not influence 
antibody binding efficiency.  
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Figure 4.5 Mean steady-state expression wolframin variants relative to wild-type (n=4). Clone set 1 harvested in RIPA buffer.  
Mean steady-state expression of WFS1-L511P is significantly lower than wild-type (Wt) WFS1 (p.=0.047). The remaining variants 
show no significant differences in expression. 
* 
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Testing possible confounders of low expression detection 
4.3.3  Antibody specificity 
To confirm that our observations were a realistic reflection of expression levels, we aimed 
to explore a number of other possible influencing factors. The first consideration was 
whether or not introduced WFS1 mutations affect the binding capacity of the antibody. For 
example, the L511P mutation may alter the epitope site, resulting in reduced binding 
efficiency and a weaker signal following immunoblotting. To address this question we re-ran 
a selection of the samples on SDS-PAGE gels and blotted using a second polyclonal anti-
WFS1 Ig (Hofmann, 2003) raised to a slightly different range of target peptides (amino acids 
Table 4.4 Mean steady-state expression wolframin variants relative to wild-type (n=4) in 
arbitrary units. Clone set 1 harvested in RIPA buffer.  T-Tests comparing differences in expression 
of wolframin variants to wild-type. 
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1-285). The resulting blots corresponded well with the initial findings (fig 4.4B), where the 
only significant difference in expression was seen in WFS1-L511P. Thereafter our initial 
antibody of choice was assumed appropriate for subsequent experiments.   
 
4.3.4  Quality of plasmid DNA preparations 
To ensure the quality of the DNA preps had no bearing on transfection efficiency or 
expression levels we produced fresh maxipreps (see section 2.7.5) from master stocks. The 
subsequent sets of experiments were direct repeats of the initial transfections and protein 
harvest in RIPA buffer. Relative steady-state expression of wolframin variants (n=3) were 
measured once again and the resulting data substantiated our earlier findings (fig 4.6, table 
4.5). Again, WFS1-L511P differed significantly in steady-state expression relative to wild-
type WFS1 (11% ±7.2%, p.=0.004).  
There was a considerable degree of variation between experiments, particularly notable in 
WFS1-R611H, which deviated from the mean significantly. We additionally found that WFS1-
R818C expression was significantly lower than wild-type WFS1 in this set of experiments 
(59% ±7.9% p.=0.024). The discrepancies found here, also notable for WFS1-L511P, where 
the steady-state expression of clone set 2 was found on average to be ~35% lower relative 
to wild-type wolframin than clone set 1, perhaps highlight the importance of further 
controls to account for differences in transfection efficiency.  
Despite these fluctuations, none of the results refuted our initial findings, and moreover we 
were able to confirm independently in our system that WFS1-L511P expression levels differ 
significantly relative to wild-type WFS1 (see appendices 9 and 10 for raw data). 
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Figure 4.6 Mean steady-state expression wolframin variants relative to wild-type (n=3) in arbitrary units. Clone set 2 harvested in 
RIPA buffer. Mean steady-state expression of WFS1-L511P and WFS1-R818C is significantly lower than wild-type (Wt) WFS1 (p.=0.004 
and p.=0.024 respectively). The remaining variants show no significant difference. 
* * 
* 
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4.3.5  Differences in wolframin solubility 
Finally, we investigated potential differences in protein solubility, which could result if 
mutations sufficiently alter the physio-chemical characteristics, and overall conformation of 
a protein. It is conceivable that our introduced WFS1 mutations could change the chemistry 
of the protein such that the proportion of total wolframin content released to the 
supernatant during sample preparation may differ significantly between variants, obscuring 
the accuracy of our results. We endeavoured to address this issue by firstly comparing the 
amount of wolframin in the insoluble fraction of cell debris following protein harvest in RIPA 
Table 4.5 Mean steady-state expression wolframin variants relative to wild-type 
(n=3). Clone set 2 harvested in RIPA buffer. T-Tests comparing differences in 
expression of WFS1 variants to wild-type. 
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buffer. Secondly we directly repeated the earlier transfection experiments, this time 
harvesting the protein in an alternative lysis buffer (Laemmli).    
 
4.3.6  Crude measures of wolframin solubility in RIPA buffer 
Steady-state wolframin expression was measured in both the soluble and insoluble fractions 
of samples harvested in RIPA buffer (n=3). The soluble proteins were prepared for western 
blotting as before following sonication and centrifugation. The insoluble fraction of cell 
debris, which forms a small pellet after centrifugation, was resuspended in RIPA buffer and 
mixed with vigorous pipetting. Despite the technical limitations of homogenising and 
loading insoluble material accurately, this method was intended to give a crude indication of 
any major inconsistencies in solubility between the variants. 
Mean expression of each wolframin variant relative to wild-type was calculated over three 
repeat experiments for both soluble and insoluble fractions (table 4.6) and the resulting 
figures were compared (fig 4.7). No significant differences in solubility were found between 
wild-type WFS1 and any of the variants: L511P, R611H, G736A, E737K, or R818C. However, a 
significantly smaller proportion of insoluble WFS1-E158K (p.=0.026) and WFS1-R558H 
(p.=0.002) proteins were measured in comparison to wild-type.  
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Figure 4.7 Relative steady-state expression of wolframin variants in both soluble and insoluble fractions of RIPA buffer lysates (n=3), 
measured in arbitrary units. WFS1-E158K and WFS1-R558H expression levels in insoluble fractions were found to be significantly lower 
than wild-type (Wt) WFS1 (p.=0.026 and p.=0.002 respectively). The remaining variants show no significant difference. 
* 
* 
* 
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Although rudimentary, these findings give credence to our earlier observation of lower 
WFS1-L511P steady-state expression by providing evidence that this variant is not obscured 
from detection in an insoluble fraction of cell debris. Representative immunoblots (figs. 4.8A 
and B) highlight the relatively low expression of WFS1-L511P relative to wild-type.  These 
data also raise a question about the ‘actual’ steady-state expression levels of WFS1-E158K 
and WFS1-R558H, given that relatively smaller proportions of these mutant proteins were 
detected in the insoluble fraction compared to wild-type. When looking at the mean 
measurements for these variants in the soluble state, we observed equal or slightly higher 
levels of protein expression compared to wild-type of no significant difference. If a larger 
proportion of total wolframin is soluble in the case of these two variants, our calculation of 
steady-state expression levels could be over-estimated (see appendix 11-13 for raw data).  
Table 4.6 Mean steady state expression of wolframin variants in soluble and insoluble fractions 
relative to wild-type wolframin measured in arbitrary units. Transfected HEK293 cells were harvested 
after 48 hours in RIPA buffer. 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
171 
 
 
 
 
4.3.7  Steady-state expression of wolframin variants harvested in Laemmli buffer 
Harvesting our wolframin variants in Laemmli buffer allowed us to further assess the 
potential differences in solubility. Unfortunately we were unable to produce such ‘clean’ 
western blots with cells lysed in this buffer compared to those in RIPA buffer. Nevertheless, 
we repeated transfections three separate times and compared the average expression of 
the wolframin variants relative to wild-type looking for any obvious differences (figs. 4.9 and 
Figure 4.8 Steady-state expression wolframin variants in the soluble and insoluble fractions of RIPA 
buffer lysate. Typical SDS-PAGE immunoblot analysis of samples probed with anti-WFS1 Ig 
(Proteintech) and anti β-actin (Sigma).  
A 
B 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
172 
 
4.10, table 4.7). An appreciable degree of variation between experiments was observed, 
likely attributed in a large part to the poor quality of the blots. Within the limits of our data, 
we could however see general expression trends correlating with our earlier experiments 
using RIPA buffer. 
 
 
 
 
Distinctly lower levels of WFS1-L511P expression relative to wild-type were measured in all 
three experiments, just above the threshold of statistical significance (31% ±23%, p.=0.069). 
Steady-state expression measurements for the remaining variants in Laemmli did not differ 
significantly from those of wild-type wolframin, falling into a relative range of 61%-97%. In 
contrast to the crude solubility data (section 4.3.6), we recorded no marked differences in 
the expression of WFS1-E158K or WFS1-R558H. 
Figure 4.9 Steady-state expression wolframin variants harvested in Laemmli buffer. Typical SDS-
PAGE immunoblot analysis of samples probed with anti-WFS1 Ig (Proteintech) and anti β-actin 
(Sigma) demonstrating reduced steady-state expression of WFS1-L511P.  
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Together these findings reinforce our earlier observations in RIPA buffer, further reducing 
the likelihood of solubility having a confounding effect on our initial results. Most 
importantly, we have provided additional evidence indicating that the WFS1-L511P variant is 
expressed at a lower steady-state level than wild-type (see appendices 14-15).  
 
 
 
 
 
 
Table 4.7 Mean steady-state expression wolframin variants relative to wild-type (n=3) in HEK293 cells 
harvested in Laemmli buffer. T-Tests comparing differences in expression of wolframin variants to wild-
type. 
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Figure 4.10 Mean steady-state expression wolframin variants relative to wild-type (n=3) harvested in Laemmli buffer.   
* * 
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4.3.8  Summary and discussion 
In contrast to the findings of Hofmann et al (2006), these experiments provide the first 
evidence that steady-state levels of some over-expressed wolframin ‘missense’ variants, 
even those representing relatively severe WS phenotypes, are comparable to those of wild-
type. The majority of our selected mutants demonstrated the capacity for normal 
expression in vitro. One variant, associated with a severe WS phenotype (WFS1-L511P) was 
expressed at a significantly lower level than wild-type. These findings suggest that some, but 
not all mutations result in reduced expression of WFS1. This supports the hypothesis that 
loss of wolframin function in WS may result from a range of pathomechanisms dependent 
on genotype.   
We substantiated our initial results by ruling out a number of possible influential factors 
including DNA quality, efficiency of antibody binding, and solubility. We also performed 
experiments from the stage of transfection a sufficient number of times (n=10) to minimise 
the effects of variable transfection efficiency.  
Each of these additional lines of investigation could be taken further in a number of ways. 
The wolframin variants could be cloned into tagged expression vectors for the purposes of 
confirming antibody specificity, although we did perform experiments with two different 
antibodies reaching the same results. Attempts could be made to measure differences in 
solubility more accurately by applying a range of buffers and treatments to insoluble 
proteins. Since we do not attempt to make comments on wolframin solubility in 
physiological conditions, but merely validate our steady-state observations, we are satisfied 
that our crude data about relative solubility support our findings and follow a comparable 
trend. The question of transfection efficiency could also be addressed using quantitative 
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measures such as the bicistronic reporter assay. In this system the gene of interest (eg 
WFS1) is cloned into an expression vector containing an internally controlled reporter gene, 
such as GFP (green fluorescent protein). Both genes are expressed equally from the same 
promoter, so that measurements taken from the reporter gene give us quantitative 
transfection efficiency information about the gene of interest.  
The next step in this investigation is aimed at understanding the mechanisms behind low 
WFS1-L511P expression by firstly looking at relative protein stability. Previous study of 
selected wolframin missense variants revealed that all of the mutants investigated did have 
lower steady-state expression than wild-type, which was attributed to a reduction in protein 
stability (Hofmann, 2006). For this reason we shall firstly compare relative stability of WFS1-
L511P to wild-type wolframin before considering other potential mechanisms for reduced 
expression such as transcription disruption, or translation inefficiency due to codon bias. We 
will additionally seek to further characterise the remaining wolframin variants in readiness 
for future functional assays.  
 
 
 
 
 
 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
177 
 
4.4.0  Comparative stability of wild-type wolframin and selected variants 
Background and aims 
Earlier studies revealed that wild-type wolframin is a stable protein with a half-life of 
~24hours (Yamaguchi, 2004; Hofmann, 2006). Pulse-chase experiments showed that 
mutations can reduce the stability of wolframin to various degrees, and that cellular 
depletion of wolframin is mediated by proteasomal degradation. Hofmann et al (Hofmann, 
2006) demonstrated that wild-type wolframin was stable for a chase period of 6 hours, 
whereas WFS1-P504L and WFS1-P724L were reduced to 50%. Other missense and nonsense 
mutants (R629W, P885L, W700X and F883X), degraded at an even greater rate, closer to 
background levels after a 6 hour chase period.  
Interestingly, the results of these stability assays did not correlate well with the steady-state 
levels of the same mutants, where WFS1-P724L for example, was shown to be one of the 
most stable variants, yet was detected at comparably low steady-state levels in relation to 
the others. All of the mutants studied by Hofmann et al (Hofmann, 2006) however, were 
reportedly expressed at lower steady-state levels than wild-type, and all of these products 
were shown to be relatively unstable. The authors therefore suggested that protein 
instability is the basis for loss of wolframin function in WS, which is supported by the lower 
levels of wolframin detected in patient fibroblasts.  
In contrast to these findings, only one variant from our panel of WFS1 mutants (L511P) 
appears to result in lower steady-state protein expression. Consequently we expect that the 
majority of our mutants may differ in stability also and reflect a more ‘normal’ pattern of 
degradation. With consideration to our hypothesis, we predict mutations relating to mild 
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WS phenotypes and/or those retaining a degree of function to resemble wild-type 
wolframin more closely. We anticipate that the most likely variant to engender protein 
instability from our selection is WFS1-L511P, and perhaps a rapid rate of degradation 
explains the lower expression levels observed in our earlier experiments. It is possible 
however, that other candidates from our panel are equally, or even more unstable, but 
perhaps expression levels are compensated by enhanced protein production, undetectable 
by observing steady-state alone.  
This section of work investigates the relative stability of our selected wolframin variants. We 
aim to further characterise our mutants for possible future functional assays, under the 
hypothesis that some variants have residual function. We also wanted to investigate further 
the underlying mechanisms behind the reduced steady-state expression levels seen in 
WFS1-L511P to ascertain whether this observation was in fact due to a reduction in protein 
stability.  
4.4.1  Specific methods and approach 
To measure relative differences in protein half-life between our WFS1 variants, we used 
cyclohexamide in a time-course experiment followed by western blotting. Cyclohexamide 
(CX), produced by the bacterium Streptomyces griseus, inhibits protein biosynthesis in 
eukaryotic organisms. By targeting specifically the 60S subunit of ribosomes, CX blocks 
protein translation allowing measurements of protein to be made without the confounding 
effects of continuing protein synthesis.  
This chemical is inexpensive, works rapidly, and has been used extensively in biomedical 
research for measuring protein degradation, including some work on wolframin (Fonseca, 
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2010). Although toxic, the application of CX in our experiments eliminates the need for 
harmful radioactivity, which is necessary for the alternative ‘pulse-chase’ method, and the 
protocol itself is less technically complex. 
Plates of HEK293 cells were transiently transfected (section 2.9.5) with variants of WFS1-
pcDNA3.1 (1µg). After 24 hours incubation the cells were treated with CX (section 2.18.0), 
and harvested in RIPA buffer at time intervals for western blotting. The first samples were 
harvested immediately following treatment and regarded as time ‘zero’. All subsequent 
harvest intervals could then be measured against time ‘zero’ to calculate relative 
degradation of protein over time. Samples were frozen immediately following harvest until 
the time-series was completed, then sonicated and centrifuged in preparation for western 
blotting (section 2.13.0). Western blots were probed for WFS1 with anti-WFS1 Ig 
(Proteintech, table 2.2), and also anti-β-actin Ig (Sigma, table 2.2) to enable calculation of 
equal protein loading. The resulting blots were measured using GeneSnap/GeneTools 
software (Syngene) to obtain semi-quantitative figures of absorbance (see appendix 16-23 
for raw data). For each WFS1 variant, levels of wolframin over the time course, corrected for 
endogenous wolframin expression, were compared to levels at time ‘zero’ to establish the 
relative degradation. Results from the mutants were compared to those of wild-type WFS1 
to determine any differences in protein stability.  
Optimising the protocol to suit our system required a number of pilot experiments to 
ascertain appropriate time intervals, treatment, and transfection conditions. 
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4.4.2  Pilot experiments and method development 
We harvested protein in a series of initial experiments at time intervals up to 48 hours 
following transfection with wild-type WFS1 and treatment with CX at varying 
concentrations. The earlier reports of Yamaguchi (2004) and Hofmann (2006) showed wild-
type wolframin to be stable for at least 6 hours, and reduced to 50% by around 24 hours. 
Both of these data sets were generated with the pulse-chase method and we therefore 
aimed to establish a pattern of wild-type wolframin degradation following CX treatment.  
Treated cells were firstly harvested at intervals of 0, 2, 4, 6, 12, 24 and 48 hours to give a 
considerably wide set of intervals from which to gauge an appropriate time range. We 
expected to observe stable wild-type wolframin between 6 hours and 24 hours, but also 
wanted to explore the potential for these experiments to run over extended periods in the 
event that some WFS1 variants may prolong the half-life of wolframin, or that we may 
observe more subtle differences in protein stability beyond the 24 hours chase-period. 
To ensure our over-expression system was a valid model, we compared the effects of CX on 
cells both untransfected and transfected with wild-type WFS1-pcDNA. We also carried out a 
range of experiments where cells were transfected with serial dilutions of wild-type WFS1 
plasmid DNA to establish an appropriate level of induced over-expression. We wanted to 
ensure the differences between endogenous wolframin and over-expressed wolframin 
could be distinguished, whilst confirming that enhanced protein expression was not 
sufficient to ‘overcome’ the action of CX. Additional preliminary experiments compared cells 
treated with a range of CX concentrations from 50µM to 500µM to look for balance 
between effectiveness and toxicity. Previous published works of CX assays (Blackinton, 
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2005; Fonseca, 2010) and manufacturers recommendations (Sigma-Aldrich) were used as 
guidelines.  
A negative control experiment was conducted using a myc-tagged construct containing 
WFS1-N-terminal domain (amino acids 1-321) provided courtesy of Dr Malgosia Zatyka. This 
represented a nonsense mutation producing severely truncated products, which were 
expected to be highly unstable. Full length WFS1-myc was also included here to allow valid 
comparisons with the same probe (anti-myc Ig, Sigma). 
4.4.3  Pilot Results 
Together the pilot studies enabled us to devise a suitable protocol for observing stability of 
over-expressed WFS1 in HEK293 cells following 100µM CX treatment. We were able to 
demonstrate clear differences in WFS1 expression levels between transfected and 
untransfected HEK293 cells following western blotting (fig 4.11) but also corresponding 
patterns of degradation in endogenous wolframin  and over-expressed wild-type wolframin 
(fig 4.12).  
Figure 4.11 Cyclohexamide pilot experiments over a 48 hour chase period. Example immunoblots of 
wolframin expression in untransfected and transfected HEK293 cells showing clear differences in signal 
intensity between endogenous and over-expressed WFS1. Blots developed after identical exposure time. 
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In subsequent experiments we could therefore confidently conclude that endogenous 
protein signals do not interfere with those of our introduced WFS1 variants, and WFS1-
pcDNA provides a suitable ‘over-expressed’ positive control. In agreement with earlier 
studies these initial experiments suggested that wild-type wolframin remained relatively 
stable beyond 6 hours. 
 
 
 
 
As predicted, our preliminary results indicated that the WFS1-N-term products were highly  
unstable, reduced to background levels after 6 hours and wild-type WFS1-myc behaved 
similarly to untagged wild-type-pcDNA, remaining stable for periods exceeding 6 hours (fig 
4.13). 
Figure 4.12 Cyclohexamide pilot experiments over a 48 hour chase period. Example immunoblots of 
wolframin expression in untransfected and transfected HEK293 cells showing comparable patterns of 
stability. Blots developed after different exposure times. 
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For the most part, extending the time-course up to 48 hours proved inappropriate as in 
most instances cells incubated with CX for this period did not survive (appendix 16A-B). We 
also found a marked degree of fluctuation even at a 24 hours chase-period in repeat 
experiments treated in the same conditions. Since the action of CX halts the translation 
process, the proteins necessary for cell survival and more importantly those involved in 
protein degradation may be the limiting factor. We speculate that this influencing factor 
may be responsible for the large variations we observed. 
 
 
These inconsistencies in our pilot data generated over a 48 hour chase-period suggested 
that a CX assay over this length of time is unsuitable for our system. We have successfully 
repeated control experiments up to 6 hours however, observing consistent stability of wild-
type wolframin and degradation of our highly unstable negative control products. Further 
investigation of WFS1 variants was therefore conducted over a 6 hour time course where 
we could compare the relative stability of our missense variants to that of an unstable 
truncated mutant (WFS1-N-term). The earlier work of Hofmann et al (2006), who reported 
Figure 4.13 Cyclohexamide pilot experiments over a 48 hour chase period. Example immunoblots of 
myc-tagged wild-type and truncated WFS1 showing complete degradation of WFS1-N-term after 6 
hours. 
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significant differences in the stability of missense wolframin variants at a 6 hour chase-
period, further supported the suitability of our option for a 6 hour time-course. 
Pilot assays including the full range of our wolframin variants were carried out although in 
light of the ‘normal’ levels of steady-state expression we observed in previous experiments 
we expected most of the mutants to display stability similar to that of wild-type wolframin. 
Figure 4.14 (table 4.8) shows the relative stability of wolframin variants (n=2/3) over a 6 
hour chase-period observed in our preliminary experiments (see appendix 17 for raw data). 
None of these variants appeared to match the high degree of instability seen in the negative 
control (WFS1-N-term) or that of previous mutants examined in earlier studies (Hofmann, 
2006). These observations, combined with the steady-state data we have generated, initially 
indicate that none of our selected wolframin variants result in production of highly unstable 
proteins. Even with an assay conducted over a limited chase-period we can at least report 
no protein instability of the magnitude measured in previously investigated wolframin 
missense variants.  
Unlike the mutations studied by Hofmann et al (2006), all of our selected WFS1 mutants 
except WFS1-L511P, appeared to confer ‘normal’ steady-state levels of protein expression, 
and perhaps as expected, our preliminary experiments revealed no significant differences in 
stability of these variants over 6 hours either. Significantly lower levels of WFS1-L511P 
steady-state expression were observed in our earlier experiments (section 4.3.0) so we 
considered this mutation the most likely candidate to cause protein instability. We 
therefore performed more detailed analysis of WFS1-L511P over a 6 hour time course to 
confirm our pilot data and included WFS1-R611H also due to the relevance of this variant to 
our future experiments and inconsistency of preliminary data. 
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Figure 4.14 and Table 4.8 Pilot data (n=2/3) of the relative stability of wolframin variants after 6 hours. HEK293 cells transfected with WFS1 constructs 
were treated with 100µM cyclohexamide and harvested at time intervals of 0 hours and 6 hours. Following SDS-PAGE and western blot analysis the 
relative stability of each variant was calculated by comparing protein levels (measured in arbitrary units) at 0 hours and 6 hours post-treatment. 
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4.5.0  Relative stability of wolframin variants  
4.5.1  There are no significant differences in stability between wild-type wolframin, WFS1-
L511P and WFS1-R611H 
The first sets of control experiments confirmed that there were no significant differences in 
stability between endogenous wolframin and over-expressed wild-type wolframin (tagged 
and untagged) (figs 4.15, 4.18, 4.19). We did not observe any degradation up to 6 hours, and 
unexpectedly measured slight increases in wolframin. We ruled out over-expression as a 
cause for the observed increases, since we also measured endogenous wolframin in the 
same range. These measurements were therefore accepted as reasonable experimental 
variation. 
Significant differences (p.=0.02) were observed between wild-type wolframin and our 
negative control, which represented a nonsense mutation (WFS1-N-term). WFS1-N-term 
was reduced to 16%±6% after a 6 hour chase-period (figs 4.16, 4.18, 4.19) correlating with 
measurements reported for other WFS1 nonsense and some missense variants (Hofmann, 
2006).  
Following treatment with CX, the experimental samples WFS1-L511P and WFS1-R611H 
remained stable up to 6 hours chase, and no significant differences were observed between 
these missense variants and wild-type wolframin (figs 4.17-4.19). Corresponding 
immunoblots and a summary of the relative protein levels of WFS1 variants after 6 hours 
chase period are illustrated in figures 4.18 and 4.19 (see appendices 18-21 for raw data). 
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Figure 4.15 Relative stability of endogenous and over-expressed tagged and untagged wolframin (n=3). Immunoblot analysis of wolframin 
in HEK293 cells over a 6 hour chase period following 100µM cyclohexamide treatment. Expression measured in arbitrary units (AU) relative 
to time 0 (designated 1). 
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Figure 4.16 Relative stability of over-expressed myc-tagged wild-type wolframin and WFS1-N term only mutant (n=4). Immunoblot analysis of 
wolframin in HEK293 cells over a 6 hour chase period following 100µM cyclohexamide treatment. Expression measured in arbitrary units (AU) 
relative to time 0 (designated 1). 
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Figure 4.17 Relative stability of over-expressed wild-type wolframin and wolframin variants (n=3). Immunoblot analysis of wolframin in 
HEK293 cells over a 6 hour chase period following 100µM cyclohexamide treatment. Expression measured in arbitrary units (AU) relative to 
time 0 (designated 1). 
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Figure 4.18. Stability of wild-type and mutant wolframin. Immunoblot analysis of wolframin in HEK293 
cells over a 6 hour chase period following 100µM cyclohexamide treatment. (A) Untransfected cells 
demonstrating stability of endogenous wolframin after 6 hour (blot developed with prolonged film 
exposure). (B-D) Cells transfected with untagged Wt-WFS1, WFS1-R611H and WFS1-L511P constructs. 
(E) Myc-tagged Wt-WFS1 detected with anti-myc Ig (F) Cells transfected with a myc-tagged negative 
control construct coding for the N-terminal domain (residues 1-321) of wolframin only, detected with 
anti-myc Ig. 
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Figure 4.19 Relative expression of wolframin variants 6 hours following cyclohexamide treatment (n=3/4).  Expression measured in 
arbitrary units (AU) relative to time 0 (designated 1). T tests compare the differences in expression between variants 6 hours post treatment. 
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4.5.2  Summary and discussion 
We have developed an over-expression system in HEK293 cell lines where we can examine 
the relative stability of wolframin variants over a 6 hour period. Over-expressed wild-type 
wolframin proved to be stable over 6 hours, in agreement with previous pulse-chase 
(Yamaguchi, 2004; Hofmann, 2006), and CX experiments (Fonseca, 2010). Also correlating 
with earlier findings, we demonstrated the relative instability of a severely truncated WFS1 
product (WFS1-N-term), representing a nonsense mutation. This ‘negative control’ protein 
was reduced to 16% ±6% after 6 hours, significantly different to the relative stability of wild-
type WFS1 after the same chase-period (p.=0.02). 
The data generated from our CX assays reveal that the stability of WFS1-L511P and WFS1-
R611H does not differ significantly from that of wild-type. Contrasting with earlier studies of 
WFS1 mutants (Yamaguchi, 2004; Hofmann, 2006), our results indicate that some WFS1 
missense variants code for stable wolframin protein products.  
This study has enabled us to compare the stability of wolframin missense variants to that of 
severely unstable protein. Unfortunately we were unable to examine the fate of these 
variants over extended periods using our system of CX treatment, and therefore cannot 
comment on any differences in stability up to 24 hours, which may have been revealed. We 
have however, demonstrated the capacity for some variants (WFS1-L511P and WFS1-
R611H) to remain stable for periods in excess of 6 hours, which is in contrast to the 
behaviour of truncated (nonsense) products, or of other reported missense variants.  
Our choice of a CX assay conducted in a human cell line (HEK293) differs from the pulse-
chase methods in primate derived cell lines (COS7) used in previous study of wolframin 
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stability. It is consequently difficult to make direct comparison of results. Since we found our 
negative control protein (WFS1-N-term) produced corresponding patterns of degradation to 
nonsense mutants examined with the pulse-chase method, we felt that making general 
comparisons between the results generated by these two methods was reasonable.  
Consideration must be given, as for any chosen assay, to the effect that introduced 
chemicals such as CX or transfection reagents might have on the folding capacity of the 
experimental proteins, which would also vary between protocols. We are assuming here 
that the effects of mutation would cause loss of molecular interactions and not gain, 
anticipating that proteins with substitutions are more likely to be ‘unfolded’ and exposed to 
chemical denaturation, as opposed to more tightly folded and potentially long-lived. 
Furthermore, based on our physio-chemical data we expect different amino acid 
substitutions to have varying effects on overall protein conformation; some ‘milder’ changes 
in protein folding may affect degradation less markedly, necessitating very sensitive assays 
covering a longer time-scale.  
Detailed analysis of the stability of our mutants over a longer time-course could potentially 
be carried out by radio-labelling and pulse-chase techniques in order to investigate both of 
these eventualities. The pulse-chase method has the advantage that translation is not 
‘switched off’ as it is in CX assays, meaning that the cellular machinery required for normal 
activities such as protein degradation are not exhausted once translation stops. This in 
theory allows cells to live longer, assuming radioactivity exposure is not sufficient to cause 
premature cell death, so we can observe activity over a longer period.  
The accuracy of our findings could also be further improved with the introduction and 
measurement of reporter genes such as GFP (green fluorescent protein) at the transfection 
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stage to correct measurements of protein at each time interval for variation in transfection 
efficiency (section 4.3.8).   
Since only one wolframin variant in our panel demonstrated lower steady-state expression, 
we anticipated the majority of our mutants to be relatively stable. Surprisingly, although 
expressed at a reduced steady-state, WFS1-L511P remained stable up to 6 hours. This could 
imply that any relative differences in protein stability caused by this variant may only be 
detectable beyond 6 hours. Alternatively, reduced protein expression could result from 
aberration at the RNA level.  
This work provides further information about the characteristics of our chosen wolframin 
variants, suggesting that not all missense mutations reduce wolframin protein stability. 
Apart from WFS1-L511P, corresponding to a severe phenotype, our panel of WFS1 
mutations have shown expression characteristics in vitro correlating to those of wild-type, 
increasing the likelihood of some protein functionality. Our data support the notion that loss 
of wolframin function in WS could be due to several mechanisms, not all of which relate to 
protein instability and low expression.  
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4.6.0  Comparative mRNA levels of wild-type-WFS1 and WFS1-L511P 
4.6.1  Background and aims 
Previous study of WFS1 missense mutants revealed a reduction in steady-state wolframin 
expression levels, which was attributed to protein instability (Hofmann, 2006). We have also 
found a novel WFS1 missense mutation (L511P) that induces low steady-state protein 
expression in vitro, but does not however appear to be markedly unstable. To explain the 
possible causes for low expression, we postulate that this mutation may instead cause 
perturbation at the stage of RNA synthesis or processing. To explore this possibility we 
compared RNA levels of over-expressed wild-type-WFS1 and WFS1-L511P. If the differences 
we observed in protein steady-state were a consequence of aberration at the RNA level, we 
expected to see relatively lower RNA in samples transfected with WFS1-L511P relative to 
those transfected with equal amounts of wild-type WFS1. 
4.6.2  Specific methods and approach 
Real-time PCR (Q-PCR; section 2.1.3) was used to quantify and compare RNA extracted from 
HEK293 cells transiently transfected with wild-type WFS1 or WFS1-L511P. The Taqman 
based detection system (Applied Biosystems) was the method of choice due to a number of 
technical advantages over alternative Q-PCR protocols such as SYBR Green. The Taqman 
system uses fluorogenic probes that detect specific amplification products as they 
accumulate during PCR. This serves to minimise the generation of false-positive signals, a 
major limitation of traditional protocols using intercalator dyes, which bind any double-
stranded DNA.  
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
196 
 
Applied Biosystems offer a range of pre-designed Taqman assay probes, which have been 
optimised and validated. We selected FAM-labelled human WFS1 primers, specific for a 
sequence in the region of exon 4, which amplify 81bp products (Applied Biosystems, ref. 
Hs00903605_m1). We deliberately avoided probes covering exon 8, since the substitution 
relating to codon 511 (nucleotide 1532) is situated in this area, and could interfere with the 
reaction, skewing results. 
HEK293 cells were grown to 80-90% confluency and transfected (FugeneHD, Roche; section 
2.9.5) with either wild-type WFS1 (pcDNA3.1), WFS1-L511P (pcDNA3.1), or an empty 
pcDNA3.1 control vector. After a 24 hour post-transfection incubation period, total RNA was 
harvested with TRIzol (Invitrogen; section 2.10.2), reverse transcribed to cDNA (section 
2.1.2), and measured (section 2.12.0). Equal amounts (8.75ng) of cDNA, mixed with Taqman 
Q-PCR mastermix and WFS1 probes were then cycled on a 7500 Real Time PCR machine and 
software (Applied Biosystems). Relative measurements of WFS1 RNA were calculated 
according to the delta-delta Ct method (section 2.1.3). 
4.6.3  Results 
To minimise the effects of transfection efficiency the experiment was repeated 6 times 
including independently generated plasmids before average fold-changes between different 
sets of conditions were calculated (appendix 24-26). Internal controls were also made within 
replicates, where several sets of RNA were harvested per transfection, two independent 
sets of cDNA were synthesised from each sample of RNA, and two ‘identical’ samples from 
each cDNA prep were simultaneously run in the real-time reaction. We were able to take 
mean measurements from across these controls, minimising experimental error at each 
stage of the procedure. By analysing several corresponding samples we could gauge the 
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accuracy of RNA/cDNA measurements and pipetting, giving an indication of how reliable our 
end results were. 
Mean fold-changes between different pairs of sample sets were calculated from average 
delta ct values over 6 transfections (2x cDNA for each). Also for each condition, all twelve 
sets of delta ct values were applied in pairs to a two-tailed t-test to compare the differences 
(fig. 4.20). As expected, we found the mean expression of WFS1 RNA in samples transfected 
with a control empty vector (pcDNA3.1) was not significantly different from endogenous 
levels of WFS1 in untransfected controls, with a fold change of 1.074±0.10. Also the samples 
over-expressing both wild-type WFS1 and WFS1-L511P had significantly higher WFS1 RNA 
compared to background levels, with mean fold changes of 155.20±20.88 and 94.03±17.27 
respectively. Analysis of the experimental samples revealed significantly lower levels of 
WFS1 RNA in cells over-expressing WFS1-L511P compared to wild-type (p.=0.026), with an 
average overall reduction of ~37% (fold change=0.63±0.10) (fig. 4.21).  
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Figure 4.20 Relative mRNA expression of WFS1 variants (n=12) measured by Real-time PCR. WFS1 expression in 
cells transfected with: wild-type WFS1, WFS1-L511P and an empty control vector (pcDNA3.1) relative to 
untransfected cells. Two-tailed students t-tests compare sets of 12 del-ct values (from 6 transfections) confirming a 
significant reduction in WFS1-L511P compared to wild-type WFS1 (p.0.026). 
* 
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Figure 4.21 Relative mRNA expression of wild-type and mutated WFS1 measured by Real-time 
PCR (n=12). Significantly lower levels of WFS1 mRNA (p.=0.026) were measured from samples 
derived from cells carrying WFS1-L511P, which showed an average overall reduction in WFS1 
expression of 37% compared to wild-type control samples. 
* 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
200 
 
4.6.4  Summary/conclusions 
Due to the massive upregulation of gene expression following transfection, we should 
perhaps expect a significant degree of mRNA variation when measuring levels with sensitive 
quantitative assays. We did observe fluctuations in WFS1 RNA both within and between 
experiments, despite the accuracy of sample preparation and measurements assured by 
consistency of β-actin measurements. This variation could be explained by differences in 
transfection efficiency, which we aimed to minimise by conducting several direct repeat 
experiments with more than one independent preparation of plasmid-DNA. An additional 
improvement we may consider in future is the analysis of an internal control gene, present 
on the expression vector (eg. neomycin), which could be used to normalise for transfection 
efficiency more accurately.   
Overall these data suggest that less WFS1 mRNA is generated from the L511P variant 
compared to wild-type WFS1, and provides a possible explanation as to why the L511P 
variant has significantly lower steady-state protein expression than wild-type wolframin. 
The basis for reduced WFS1-L511P mRNA could be related to hindrance of the transcription 
process resulting in relative inefficiency and synthesis of fewer mRNA molecules per unit of 
time. Alternatively the transcript itself may be less stable than wild-type, the mutation 
conferring increased susceptibility to RNase degradation, a feature common to the 
development of other diseases such as cancer, inflammatory and autoimmunity disorders 
(Knapinska, 2005). 
This study provides the first evidence that missense variants may reduce normal WFS1 
mRNA levels, proposing this mechanism as a feature of WS pathogenesis. 
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4.7.0  Localisation of wolframin variants 
4.7.1  Background and aims 
Immunofluorescence microscopy analysis (Hoffman, 2003; Fonseca, 2005; Takeda 2001; 
Osman, 2003) and sub-cellular fractionation studies of mouse brain (Philbrook, 2005) and 
human fibroblasts (Takeda, 2001) reveal that wolframin is predominantly situated on the 
endoplasmic reticulum (ER) membrane. Although the precise function is still unclear, 
wolframin is implicated in a number of pathways including protein trafficking, calcium 
homeostasis, and the ER stress response. In any given role we can reasonably assume 
correct positioning of the protein is crucial for the propagation of normal cell signal 
transduction and molecular interactions. Confirmation of appropriate sub-cellular 
localisation of wolframin variants is therefore an important prerequisite to future functional 
studies. 
Earlier work examining localisation of selected wolframin variants showed that some 
mutations (WFS1-P724L and WFS1-G695V) appear to cause a degree of protein aggregation, 
and form relatively insoluble, higher-molecular weight complexes compared to wild-type 
wolframin (Fonseca, 2005). Interestingly these variants both involve changes to proline and 
glycine residues, which as mentioned earlier, are thought to be conformationally important 
amino acids. Contrasting results were reported by another group (Yamaguchi, 2004), who 
found their mutated WFS1 constructs (N663D and N748D*) produced proteins with a 
‘normal’ ER pattern of expression seen under the microscope.  Taken together, these 
studies suggest the fate of mutated WFS1 products may vary depending on genotype. 
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The aim of this section was to investigate the sub-cellular localisation of our panel of 
wolframin variants. We expect any proteins with at least partial function to localise 
correctly, and if this can be demonstrated, we may have grounds to explore the 
impairment/loss of function in more detail.  
Our general hypothesis states that some missense WFS1 mutations may allow partial 
wolframin function. From the spectrum of reported mutations, those associated with milder 
WS phenotypes (E158K and R558H), or non-syndromic diabetes susceptibility (R611H) are 
most likely to retain some functionality so consequently, we anticipate these variants are 
the most likely candidates to localise normally.  
4.7.2  Specific methods 
We used immunocytochemical analyses to look at cells overexpressing our variants of 
interest (section 2.15.0). Cell lines were transfected with WFS1-pcDNA or WFS1-myc 
plasmids containing the sequence variants, incubated for 24 hours, then fixed onto glass 
microscope slides with 4% paraformaldehyde. The localisation of wolframin was determined 
with a combination of anti-WFS1, anti-myc, and anti-PDI (ER marker) antibodies (table 2.2).  
Results 
4.7.3  Pilot experiments  
A series of preliminary studies were conducted to ascertain appropriate experimental 
conditions. These included choosing suitable cell lines, antibody optimisation, and 
determining acceptable conditions for cell growth, transfection and fixation. 
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4.7.4  Choice of cell line 
The obvious choice of cell lines for our localisation experiments were HEK293 and COS7. 
Both of these cell lines are easily grown and manipulated in the laboratory. HEK293 cells 
have already been successfully transfected with our WFS1-pcDNA constructs in earlier 
experiments and being derived from humans, have the advantage of providing perhaps a 
more accurate model for studying human WFS1. Earlier wolframin immunocytochemical 
studies (Yamaguchi, 2004; Fonseca, 2005; Hoffman, 2006) alternatively used COS7 cell lines, 
which originate from monkeys (Chlorocebus pygerythrus). COS7 cells are larger and rounder 
than HEK293 cells (approx 30 µm and 13µm respectively) making it comparably easier to 
distinguish their substructures under the microscope. These cells are also readily 
transfected and are most appropriate for making direct comparisons between our findings 
and those previously published by other groups. 
Initially, HEK293 and COS7 cell lines were cultured, fixed, probed for wolframin and protein-
disulphide isomerise (PDI) independently, and viewed under the fluorescent microscope. A 
range of antibody concentrations were used, selected as per manufacturers 
recommendation (Proteintech, Stressgen). We aimed here to detect endogenous wolframin, 
and to detect endogenous PDI, which is a ubiquitously expressed ER resident protein 
intended for use as an organelle marker. We also wished to determine which of the cell 
lines was most fitting for subsequent experiments.  
A rabbit polyclonal anti-WFS1 Ig (Proteintech) was used as a primary antibody for the 
detection of wolframin, followed by an anti-rabbit secondary Ig conjugated to Alexa-Fluor 
488 (green). The presence of PDI was detected with a mouse monoclonal anti-PDI Ig 
(Stressgen), followed by an anti-mouse secondary Ig conjugated to Alexa Fluor-594 (red). 
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Examples of the wolframin and PDI staining patterns are shown in figure 4.22 (x40mag). 
Endogenous levels of both proteins were detected in COS7 cells (left panels) and HEK293 
cells (right panels), correlating well with expected staining patterns detailed in the 
literature. The differences in cell morphology were also immediately apparent (fig 4.23). The 
COS7 cells grew in a more uniform monolayer making them easier to distinguish from each 
other, whereas the HEK293 cells had a tendency to form clumps. The larger size and circular, 
flattened shape of the COS7 cells also enabled better visualisation of the sub-structures, 
compared with the small, angular HEK293 cells with less obvious features. For these 
reasons, COS7 cells were the cell line of choice used for all our subsequent localisation 
experiments.   
 
 
Figure 4.22 Cells fixed and stained with anti-PDI or anti-WFS1 Ig (x40 mag). TOP PANELS: COS7 (left) 
and HEK293 (right) stained with anti-PDI Ig demonstrating detection of endoplasmic reticulum. 
LOWER PANELS: COS7 (left) and HEK293 (right) stained with anti-WFS1 Ig demonstrating detection of 
wolframin. 
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4.7.5  Antibody optimisation and transfection 
Fixed COS7 cells were stained with dilution series of anti-WFS1 and anti-PDI Igs to establish 
optimum concentrations. Three dilutions of each primary antibody were made in 
increments from the upper, middle, and lower range recommended by the manufacturers. 
Anti-WFS1 Ig was applied to slides at concentrations of 1:200, 1:100, or 1:50 (appendix 27). 
Anti-PDI Ig was applied to slides at concentrations of 1:500, 1:350, or 1:200 (appendix 28). 
Optimal concentrations of antibodies were determined with consideration to specificity and 
signal to noise ratio.  
The optimum cell confluency for efficient transfection was 80-90%. Following a 24 hour 
incubation period in these conditions the high density of tightly packed cells were difficult to 
distinguish from each other to capture a clear image. A compromise was therefore made by 
lowering the confluency at transfection to ~60-70%, which reduced the transfection 
efficiency but enabled visualisation of single cells after incubation and staining. 
Figure 4.23 COS7 and HEK293 cell lines fixed and stained with anti-WFS1 Ig (x40 mag), contrast 
adjusted. LEFT PANEL: Evenly distributed COS7 cells stained with anti-WFS1 Ig demonstrating a typical 
ER pattern of staining with signal most concentrated in an area to one side of the nucleus (blue) and 
spanning out to the periphery of the cell. RIGHT PANEL: HEK293 cells stained with anti-WFS1 Ig; Cells 
forming a clump, with indistinguishable cells. 
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4.7.6  Detection of endogenous and over-expressed wolframin 
A range of transfection experiments were conducted using wild-type WFS1-pcDNA. The first 
aim was to detect cells over-expressing WFS1, and distinguish these from untransfected 
cells, with endogenous levels of WFS1 expression. This exercise was important groundwork 
for later experiments using the WFS1 mutants, to ensure any observed effects could be 
confidently attributed to the mutations and not complicated by endogenous WFS1 signals.  
We also aimed to make comparisons between untransfected and transfected cells to verify 
normal localisation of over-expressed wild-type WFS1, ruling out any potential effects of 
‘over-expression’ itself.  
Following transfection, cells over-expressing WFS1 were distinctly apparent when viewed 
under the fluorescent microscope. The green (Alexa-Fluor 488) signal intensity 
corresponding to wolframin was significantly higher than that produced by endogenous 
WFS1 expression alone, as seen in untransfected cells (fig 4.24). To confirm the initial 
observations we were able to capture images under the (green) filter of endogenous 
wolframin then reduce the exposure to just below detection levels. Using the same 
exposure settings we could confirm the ‘over-expression’ of WFS1 by detecting a clear signal 
in transfected cells, thus enabling distinction between endogenous and over-expressed 
WFS1. 
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Figure 4.24 COS7 cells stained with anti-WFS1 Ig (1:100). Images captured at same exposure 
settings demonstrating the clear differences between over-expressing cells and untransfected cells. 
In all subsequent experiments untransfected cells were identified, then exposure times were 
reduced until the signal became non-visible. This enabled clear determination of transfected cells, 
minimising any confounding signals from endogenous wolframin. 
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The distribution of over-expressed wild-type WFS1-pcDNA was consistent with endogenous 
wolframin, co-localising with PDI in the ER to produce an orange overlapping signal (fig 
4.25), validating our wild-type WFS1-pcDNA positive control. An obvious reticular 
distribution, characteristic of the ER was observed, predominantly to one side of the nucleus 
and fanning out the cell membrane. Obtaining comparable signal intensity of wolframin 
(green) and PDI (red) at the same exposure was not possible in cells over-expressing WFS1 
as the abundance of wolframin protein produced a disproportionately high signal 
‘swamping’ that of PDI, which was only present at endogenous levels. For this reason 
exposure of red channel was prolonged to enable clearer representation, justified by our 
qualitative experimental aims to simply observe a phenomenon.  
4.7.7  Negative control experiments 
Severely truncated WFS1 products do not localise correctly to the ER membrane 
We have now established a system in COS7 cells where over-expressed wild-type WFS1 
(pcDNA3.1) can be shown to localise correctly. Before introducing WFS1-mutants and 
interpreting our findings, we carried out a series of negative control experiments to 
demonstrate the possibility of identifying mis-localisation using our method. We predicted 
that severely truncated wolframin was potentially incapable of localising to the ER 
membrane correctly. We used a number of human WFS1 constructs with various deletions 
(provided courtesy of Dr Malgosia Zatyka) to investigate their suitability as negative 
controls. The vectors contained: WFS1 N-terminal domain only (amino acids 1-321); WFS1 C-
terminal domain only (amino acids 652-890), and WFS1 minus the N-terminal domain 
(amino acids 322-890). To enable antibody detection, these sequences were cloned into 
myc-tagged pCMV expression vectors. 
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Figure 4.25 Co-staining of COS7 cells with anti-WFS1 and anti-PDI Igs (x100mag), contrast adjusted. (A) Untransfected cells demonstrating a typical ER 
pattern of wolframin localisation. (B) Over-expressed wild-type WFS1 produces an identical pattern of distribution.     
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Full length wild-type WFS1-myc was firstly transfected and over-expressed in COS7 cells, 
and compared to wild-type WFS1-pcDNA. We observed consistent ER localisation between 
both tagged and untagged wolframin (fig 4.26), validating the use of myc-tagged proteins 
and anti-myc Igs for our control experiments.  
The WFS1 ‘deletion’ constructs, previously shown to induce over-expression of the correctly 
sized products by western blotting (Zatyka, 2008a) were then transfected into COS7 cells for 
immunostaining (section 2.15) with mouse anti-myc primary Ig (table 2.2), followed by anti-
mouse secondary Alexa-594 (red; table 2.2). Figures 4.27A-B illustrates the typical patterns 
of localisation exhibited by each of the negative controls and wild-type WFS1-myc. The 
results confirmed our hypothesis that these severely truncated wolframin proteins did not 
localise correctly.  
Previous data indicate the C-terminal domain of wolframin lies on the luminal side of the ER 
membrane and the N-terminal domain on the cytosolic side. Based on our knowledge about 
the structure of wolframin we assume our corresponding truncated mutants do not contain 
transmembrane domains and are therefore unlikely to anchor to the ER membrane. 
Over-expressed WFS1-C-term products appear to be concentrated in clusters around the 
nucleus, perhaps forming aggregates within the ER, the main bulk of which lies in this 
region. The WFS1-N-term products look homogenously spread throughout the body of the 
cell, possibly indicating dispersal throughout the cytoplasm. The mutant containing the 
transmembrane domain and C-terminus (WFS1-del-N-term) produces a pattern primarily of 
ER co-localisation, but with additional punctuate wolframin staining suggestive of 
aggregation. This pattern is similar to the staining observed by Fonseca et al (2005) when 
investigating the missense mutations P724L and G695V.  
CH
A
PTER
 4 CH
A
RA
CTER
ISA
TIO
N
 O
F SELECTED
 W
FS1-V
A
RIA
N
TS 
 
211 
  
Figure 4.26 COS7 cells over-expressing tagged (myc) or untagged WFS1 (x100 mag), contrast adjusted. Co-immunostaining for ER with anti-PDI Ig and 
WFS1 with anti-WFS1 or anti-myc Igs. Appropriate localisation of tagged wolframin proteins to the ER validates negative control experiments using tagged 
mutant proteins.  
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Figure 4.27A COS7 cells fixed and co-stained with anti-WFS1 and anti-myc Igs (x100mag), contrast adjusted. (A) Over-expressed wild-type WFS1 
demonstrating a typical reticular ER pattern of wolframin localisation. (B) Over-expressed WFS1-C-terminal mutants appear to cluster around the 
nucleus, in the region of the main body of the ER, possibly within the ER lumen.  
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Figure 4.27B COS7 cells fixed and co-stained with anti-WFS1 and anti-myc Igs (x100mag), contrast adjusted. (C) Over-expressed WFS1-N-
term mutants produce a diffuse, homogenous signal suggestive of localisation throughout the cytosol. (D) Over-expressed WFS1-Del-N-term 
mutants do demonstrate a predominantly reticular pattern of ER localisation, but with punctuate staining characteristic of protein 
aggregation. 
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We have speculated about the localisation of our negative controls, although further 
investigation would be necessary to confirm these suggestions. With respect to the current 
study aims, our negative control data confirm our system as an effective means of detecting 
mis-localisation of wolframin. 
4.7.8  Localisation of wolframin variants 
The WFS1-L511P variant appears to cause a degree of protein aggregation in vitro whereas 
other selected wolframin missense variants have the capacity to co-localise correctly to 
the ER. 
Each of the WFS1-variants was transfected and over-expressed in COS7 cells for 
immunostaining. We repeated the transfections three times, using two independent DNA 
preparations. For each repeat we observed at least two separate slides of fixed and stained 
cells under the fluorescent microscope for each condition. The slides were scanned by eye 
systematically and representative images of typical cells were captured.  
We observed apparently normal ER localisation of all our missense wolframin variants 
except for WFS1-L511P. The majority of the variants exhibited clear co-localisation with PDI 
(fig 4.28-31), illustrated by the orange staining (merged images), and obvious reticular ‘net-
like’ pattern, which can be seen more clearly in larger images. The WFS1-L511P proteins 
were noticeably different from the others, and despite co-localising with PDI to some 
extent, did have the propensity to produce punctuate staining patterns (fig 4.32, appendices 
29 and 30). Again, this may suggest the formation of protein aggregates. 
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Figure 4.28 COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (x100), contrast adjusted. (A) Over-expressed wild-type WFS1 
(B) Over-expressed WFS1-E158K.  
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Figure 4.29 COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (x100), contrast adjusted. (A) Over-expressed WFS1-R558H (B) Over-
expressed WFS1-R611H.  
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Figure 4.30 COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (x100), contrast adjusted. (A) Over-expressed WFS1-G736A (B) Over-
expressed WFS1-E737K.  
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Figure 4.31. COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (x100), contrast adjusted. Over-expressed WFS1-R818C.  
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Figure 4.32 COS7 cells fixed and co-stained with anti-WFS1 and anti-PDI Igs (x100), contrast adjusted. Over-expressed WFS1-L511P produces reticular, 
punctuate staining suggesting localisation to the ER with tendency for aggregation.  
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4.7.9  Summary and discussion 
We have demonstrated in vitro that large deletions severely disrupt the normal ER 
distribution of wolframin as expected. In agreement with an earlier study (Fonseca, 2005) 
our data also suggest that some WFS1 missense mutations may alter the sub-cellular 
localisation of wolframin potentially causing aggregates as illustrated by the distribution of 
WFS1-L511P (see appendix 29 for comparisons). The majority of wolframin variants on our 
selected panel did however co-localise correctly to the ER, suggesting that loss of wolframin 
function caused by missense mutation is not necessarily a consequence of protein mis-
localisation. In an over-expression system we provide evidence that a number of wolframin 
disease-associated missense variants have the potential to properly localise to the ER in 
vitro. 
Interestingly, although we have observed the tendency for WFS1-L511P to form what looks 
like aggregates, it is not clear from our data whether this may occur due to the solubility of 
the proteins or to a propensity for these particular variants to form multi-homodimers. No 
significant differences in solubility were observed when we performed our earlier steady-
state experiments (section 4.3.6), although more thorough examinations of relative 
solubility would be necessary to explore this in more detail. Furthermore, conditions in vivo 
may in fact result in differences not readily detectable in lysed and homogenised cells.   
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4.8.0  Chapter summary 
The overall aim of this investigation was to explore WS pathogenesis caused by WFS1 
missense mutation, attempting to further define the pathomechanisms leading to loss of 
function. This study was approached with consideration to phenotype and sought firstly to 
characterise a panel of WFS1 missense variants, associated with both mild and severe 
phenotype.  
A number of WFS1 missense mutations were selected, cloned and characterised in terms of 
protein expression, stability and sub-cellular localisation. From a panel of seven variants, 
only one mutant (WFS1-L511P), representing severe WS, demonstrated the potential to 
significantly reduce protein expression at the transcription level, and cause mis-localisation. 
No significant differences were observed between wild-type wolframin and the remaining 
WFS1 variants, including those associated with severe WS.  
These findings support our hypothesis that loss of wolframin function in WS could be due to 
several different mechanisms, depending on genotype. In contrast to previous 
investigations where all WS-associated missense variants studied showed significant 
‘physiochemical’ abnormalities (Hofmann, 2003 and 2006; Yamaguchi, 2004; Fonseca, 
2005), we provide the first evidence that some wolframin missense variants have expression 
and localisation characteristics comparable to wild-type protein. We postulate that some 
missense variants, particularly those corresponding to a relatively mild WS phenotype, may 
have residual function and the incentive to explore this idea further is strengthened by our 
data, since the majority of our selected wolframin variants display normal physiochemical 
characteristics. Our evidence suggests that the underlying loss of function caused by some 
missense WFS1 mutations may arise from impairment of more specific molecular 
CHAPTER 4 CHARACTERISATION OF SELECTED WFS1-VARIANTS 
 
222 
 
interactions or functions, which is a possibility we intend to address with more detailed 
functional analyses. 
 
4.8.1  Functional analysis of wild-type and mutant wolframin  
Building on our characterisation data we can now begin to investigate the impact these 
missense variants have on specific wolframin functions. The common biochemical feature 
associated with WS is ER-stress mediated apoptosis. Wolframin has been shown to play an 
important role in a controlled UPR, but is also implicated in a range of other biological 
systems including calcium homeostasis, insulin secretion, and protein folding and 
maturation. It is still unclear whether the perturbations in ER-stress caused by WFS1 
mutation are only directly related to the transduction of UPR signalling, or if disruption of 
other functions such as protein processing could indirectly result in the same outcome. 
A top down approach is proposed for future functional analysis of our missense variants, 
examining firstly the overall effect our selected mutants have on ER stress and apoptosis, 
before considering a step back to more specific molecular mechanisms including insulin 
secretion and chaperone activity (see general discussion).  
An important role for wolframin in ER stress management is the negative regulation of 
ATF6α (Fonseca, 2010). This particular interaction, mediated by HRD1, was shown to be 
impaired in selected variants (WFS1-P742L, WFS1-G695V), mutations associated with 
protein aggregation.  We intend to investigate the potential for our panel of wolframin 
mutants to perform this function, given the differences we have discovered during our 
characterisation experiments. In accordance with previous studies, we anticipate that WFS1-
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L511P, which shows a propensity to aggregate, may have an impaired interaction with 
ATF6α. The other variants in our panel, which demonstrate normal ‘characteristics,’ may 
have the capacity to carry out this function more efficiently. 
In addition to ATF6α, comparing the binding capacity of wild-type and mutant wolframin to 
other molecular partners could provide more specific information about biochemical 
differences associated with particular mutations that result in loss of wolframin function. 
Certainly if all WS-associated mutations prove to have little or no function, we still hope to 
learn more about the R611H variant and provide the first functional data about how the 
diabetes ‘risk’ allele H611, relates to normal and pathological β-cell conditions.  
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CHAPTER 5 
IDENTIFYING WOLFRAMIN MOLECULAR PARTNERS 
 
5.0  Introduction 
Complex networks of biochemical interactions are the fundamental components of any 
living system. Virtually every cellular process including DNA replication, gene expression, 
protein modification and secretion, signal transduction, cell cycle control and apoptosis is 
coordinated by very specific protein-protein interactions (PPIs).  
The nature of PPIs are diverse, and largely governed by the location and relative 
concentrations of the interacting participants within the cell at a given time, in combination 
with the structural and physio-chemical properties of the interacting proteins. Associations 
between protein partners may be stable, forming core complexes, or transient, as is often 
seen in regulatory interactions (Ruffner, 2007). These are determined in part by the relative 
binding strength or specificity of the constituent proteins, and the location of the interacting 
segments. Many protein complexes are necessary for function, and therefore disruption of 
these vital associations is an important contributor to the onset of disease. 
Much research effort is focused on identifying and understanding PPIs and gathering 
information about these associations is an important step for understanding disease 
pathogenesis and developing new therapeutic approaches. 
CHAPTER 5 IDENTIFYING WOLFRAMIN MOLECULAR PARTNERS 
 
 
225 
 
Depending on experimental aims, identifying and understanding PPIs can be approached in 
a number of ways. Some methods are principally concerned with discovering new 
interactions, and others may be directed at understanding the dissociation kinetics between 
known interacting pairs. Well established high throughput screening methods for identifying 
potential PPIs include surface-anchored protein arrays and two-hybrid assays. Once 
identified, protein pairs can be examined more closely using affinity purification techniques, 
or fluorescence resonance energy transfer (FRET) analysis.  
5.0.1  The yeast two-hybrid system 
GAL4 is a transcriptional regulator that mediates expression of most genes involved in the 
uptake and metabolism of galactose in yeast (Traven, 2006). It has two distinct functional 
domains that must be in physical proximity for the factor to function, one that promotes 
DNA binding and another that activates transcription. 
The yeast two-hybrid system exploits the modular properties of transcription factors such as 
GAL4 for the detection of unknown molecular interactions. Genes regulated by GAL4 for 
example, contain upstream activating sequences (UAS) in their promoter regions to which 
GAL4 binds (Bram, 1986), and these UAS are artificially introduced upstream of reporter 
genes in the yeast two-hybrid system.  
Yeast cells can be transformed with selected plasmids conferring expression of a protein of 
interest fused to a GAL4 transcription factor DNA binding (DBD) domain and a library of 
cDNAs for unknown proteins which are fused to the complementary GAL4 activation 
domain (AD) (fig 5.0A). The known protein is used as ‘bait’ to screen for potential partners 
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from the library ‘prey’ proteins. When the partners associate and bring the two 
transcriptional domains together, expression of a target gene is triggered which acts as a  
reporter (fig 5.0B). A functional GAL4 transcription factor for example, activates expression 
of the MEL1/LacZ gene (α/β-galactosidase), which enables transformed yeast/bacteria to 
metabolise colourless X-Gal and produce a blue insoluble product (fig 5.0C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.0. Principles of the yeast two-hybrid assay.  (A) Yeast cells are co-transformed with vectors 
containing a known gene of interest fused to a transcription factor DNA binding domain (DBD), and a library 
of potential molecular partners fused to the same transcription factor activation domain (AD). (B) When 
binding partners associate, the transcription factor is activated by close proximity of the functional domains, 
triggering expression of a reporter gene (e.g. MEL1). (C) Reporters such as MEL1 allow ‘blue-white’ selection.  
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Due to significant amplification of reporter gene expression, the yeast two-hybrid assay is 
useful for detecting transient or weak interactions, although this sensitivity does result in a 
higher number of ‘false-positive’ results, which need to be examined further and 
discounted. For investigation of mammalian protein interactions, yeast also have the 
advantage of providing a host background environment more closely resembling that of a 
higher eukaryote compared with bacterial or in vitro assays. This method is however limited 
when protein-protein interactions require post-translational modification such as 
glycosylation or phosphorylation, which do not occur in yeast systems.  
Overall a relatively large number of potential protein-partners can be screened in vivo using 
this technique to isolate a number of novel candidates for further investigation. Questions 
arising about the biological relevance of any protein associations detected in yeast can then 
be addressed by more detailed analysis in mammalian systems. 
5.0.2  Molecular partners of wolframin 
A number of wolframin molecular partners have been identified in previous studies, helping 
to improve our understanding of wolframin function.  
Calmodulin (CaM) was determined as a wolframin partner-protein by affinity 
chromatography purification (Yurimoto, 2009) and is an important modulator in a large 
number of Ca2+ dependent signal transduction pathways. Intracellular Ca2+ fluctuations 
affect a wide range of processes including protein secretion, gene expression and cell 
division all of which share links with proposed wolframin function. 
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In the Birmingham laboratory, the wolframin (WF) -C-terminal domain was used as bait in a 
yeast two-hybrid screen with a human brain cDNA library (Zatyka, 2008a). The β1 subunit of 
Na+/K+ ATPase (ATP1B1) was isolated, and confirmed as a molecular partner of wolframin by 
endogenous co-immunoprecipitation. This enzyme, also known as the Na+/K+ pump, is 
situated on the plasma membrane and assists in membrane transport and maintenance of 
cell volume as well as functioning as a signal transducer, regulator of mitochondrial reactive 
oxygen species production and intracellular calcium homeostasis; all of these pathways have 
connections with observed sub-cellular features in Wolfram syndrome models.   
GRP94, an ER molecular chaperone from the heat shock protein 90 (HSP90) family, has also 
been shown to associate with wolframin (Kakiuchi, 2009). Interesting links can be made 
between this interaction and clinical manifestations of Wolfram syndrome; GRP94 is 
strongly linked to bipolar disorder in the Japanese population (Kakiuchi, 2007) and the 
complex between wolframin and GRP94 is modulated in neurones by valproate, a standard 
drug treatment for mood stabilisation.   
The identification of other wolframin-partners including ATF6α, Hrd1 (Fonseca, 2010) and 
Smurf1 (Guo, 2011) define more clearly the role wolframin plays in UPR signalling. A 
functional complex between wolframin and the E3 ligase Hrd1, is thought to target ATF6α 
for proteasomal degradation, so having a negative regulatory effect on the ER stress 
response. The E3 ligase Smurf1 has been shown to interact with, and target wolframin for 
ubiquitination and degradation, which demonstrates at least one mechanism of WFS1 
regulation. Selected WF-mutants expressed ectopically also seem to exhibit resistance to 
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the action of Smurf1 and could potentially result in pathological inhibition of ATF6α and 
disruption of the UPR. 
5.1  Specific aims and methods 
The specific aim of this section was to isolate novel wolframin molecular partners to extend 
current knowledge about the functional pathways of wolframin, in particular interactions 
taking place in the pancreas, which have special relevance to WFS1 and its involvement in 
diabetogenesis. Identifying new molecular partners would additionally increase the scope 
and novelty of our proposed future functional work with WF-variants (chapter 4). 
A yeast two-hybrid assay performed by Dr Christopher Ricketts, Dept. Medical and 
Molecular Genetics, University of Birmingham, formed the foundation for this work. A 
Human Pancreas Matchmaker cDNA library (Clontech) was screened for potential 
interactions with the WF-N-terminal domain (amino acids 1-321) using the MATCHMAKER 
GAL4 Two-hybrid System 3 (Clontech). WFS1-N-terminus, cloned into pGBKT7 vectors 
(EcoR1/Xho1) was transformed into yeast (AH109) and checked for protein expression. 
Positive yeast clones (containing pGBKT7-WFS1-N) were then co-transformed with mixed 
pACT2 plasmids containing a pancreatic cDNA library and grown on selective media ((QDO + 
X-α-Gal) section 2.8.2) to isolate potential interactors (fig 5.2).  
As described in section 5.0.1, the association of the bait and prey proteins can be detected 
by expression of MEL1 and X-α-Gal metabolism (blue/white screening). Selection stringency 
for interaction is increased further still in the AH109 yeast strain, minimising false-positive 
results by growing co-transformed cells on media lacking adenine and histidine, known as 
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quadruple drop out (-TRP/-LEU/-ADE/-HIS). The nutritional reporters ADE2 and HIS3, are, 
like MEL1, under the control of distinct GAL4 upstream activating sequences, and only 
transcribed if bait and prey proteins are in close proximity.  
Each positive clone isolated and identified from the two-hybrid screen resulted in growth of 
blue AH109 colonies. Colonies were evaluated according to strength of blue product (X-α-
Gal metabolites), which was hypothesised to reflect strength of interaction. Putative 
positive clones were selected, numbered and stored (-80°C). 
This work was continued firstly by extraction of plasmids and identification of ‘prey’ proteins 
from positive yeast clones. Plasmids were purified from yeast using the Yeastmaker Yeast 
Plasmid Isolation Kit (Clontech; section 2.8.5), and T7/3’ DNA-AD vector primers (appendix 
2.7) used to PCR amplify (section 2.1.0) across the region containing the ‘unknown’ library 
gene. PCR products were electrophoresed (section 2.3.0), purified from agarose gel (section 
2.3.1) and sequenced (section 2.4.0). By applying results to a BLAST search tool (NCBI), the 
identity of captured ‘prey’ proteins from the library was determined. 
Following sequence analysis, positive clones were verified by ‘one-to-one’ co-
transformation of yeast (section 2.8.4) with both bait (WF-N-terminus) and known prey 
plasmids to confirm expression of MEL1, thus signifying potential protein interaction. 
Selected candidates were then investigated further in mammalian cells by over-expression 
and co-immunoprecipitation (fig 5.1). 
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Figure 5.1. Methods workflow for identifying and verifying protein-protein interactions following a yeast 
two-hybrid screen.  Plasmids containing unknown library gene sequences were extracted from ‘positive’ 
yeast clones and sequenced. Genes of interest, coding for potential wolframin partner proteins, were 
identified using the BLAST sequence alignment search tool (NCBI). Plasmids containing positively identified 
‘partners’ were then reintroduced to yeast with WFS1 to confirm initial findings. Finally, each of the 
candidate gene sequences and WFS1 were cloned into mammalian expression vectors for co-transfection 
and immunoprecipitation experiments in human cell lines. 
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Results 
5.2  Isolation and identification of DNA from positive yeast two-hybrid clones  
Following sequencing analysis, a number of putative wolframin partner-proteins were 
identified from the pancreatic cDNA library screen: protease serine 2, pancreatic lipase and 
cofactor colipase, regenerating islet-derived 1 alpha (REG) protein, alpha amylases 2A/2B, 
and carboxypeptidase B1 (table 5.0).  
These secretory proteins are components of the pancreatic juice, produced and exported 
from the exocrine pancreas and with the exception of the REG protein, most are thought to 
be principally involved in digestion.  
Protease serine 2 
Protease serine 2 (PRSS2) or trypsinogen, is a 247 amino acid zymogen secreted by acinar 
cells (Emi, 1986). In the small intestine cleavage by enteropeptidase activates the enzyme 
(trypsin, 223 amino acids), which stimulates autocatalysis. Trypsin functions to hydrolyse 
peptide bonds, reducing proteins to their constituent amino acids for efficient absorption by 
the body. 
Pancreatic lipase 
Pancreatic lipase (PNLIP) is a carboxyesterase that catalyses hydrolysis of intraduodenal long 
chain fatty acids and glycerol esters, which are then able to enter the circulation through 
the lymphatic system (Lowe, 1989). Secreted in its mature form together with a signal 
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sequence (465 amino acids), pancreatic lipase only becomes active when associated with 
colipase (CLPS) in the small intestine.  
PNLIP belongs to a lipase protein superfamily related by tertiary structure (Wong, 1992). 
Other members of the lipase family can be found in a variety of tissue types as well as the 
pancreas, functioning amongst other things in the metabolism of circulating lipoproteins 
and tissue supply of fatty acids (Olivecrona, 1993).  
Colipase 
Colipase (CLPS) is secreted in coordination with pancreatic lipase and is a vital cofactor for 
lipase activity. Proteolytic cleavage of procolipase in the gut lumen activates this co-enzyme, 
enabling it to bind the C-terminal domain of lipase. This interaction prevents the inhibitory 
effects of bile salts on lipase, thus initiating lipase activity. The immature colipase 
prepropeptide is comprised of 112 amino acids (Lowe, 1990), 1-17 forming the signal 
sequence, and 18-22 the activation sequence, otherwise known as enterostatin. In addition 
to the pancreas, the procolipase gene is also expressed in the stomach, duodenal mucosa 
(Okada, 1993), and regions of the brain (Lin, 2002).  
Enterostatin appears in the circulatory system and lymph following food intake and has 
been shown to relay satiety signals to the brain (Erlanson-Albertsson, 1997). The metabolic 
effects of enterostatin are associated with reduction in fat intake, maintenance of 
bodyweight (Silvestre, 1996), and decreased insulin secretion (Park, 2009). 
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Table 5.0. Clones identified from initial yeast-two hybrid screen using wolframin N-terminus as bait in a pancreatic cDNA library.  
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Regenerating protein  
The REG protein (REG1A) also referred to as; the pancreatic stone protein, lithostathine, 
thread-protein and protein X, is a non-enzymatic secretory glycoprotein (Terazono, 1988). 
The precursor protein of 166 amino acids consists of a 22 amino acid signal peptide, 
susceptible to proteolytic cleavage. The mature C-terminal product (133 amino acids) 
displays a tendency to precipitate at physiological pH and forms the predominant 
component of pancreatic stones and fibrils (De Caro, 1979).  
REG1A belongs to the REG gene family, which includes REG1B, REGL and PAP. These genes 
are found tandemly clustered on chromosome 2p12 (Miyashita, 1995), possibly arising by 
duplication of a common ancestral gene. Upregulated expression of these genes occurs in 
response to damage, inflammation and stress in a variety of tissues (Ashcroft, 2004). Some 
members of the REG family have been associated with motor neuron regeneration (Livesey, 
1997) and Alzheimer’s disease (Ozturk, 1989).  
More specifically, REG1A has been shown to act as a growth factor, playing a role in the 
inflammatory response in gastroenterological organs (Dieckgraefe, 2000; Lawrance, 2001), 
and is expressed in regenerating islet β-cells (Terazono, 1988; Watanabe, 1994). 
Amylase 2A/2B 
Pancreatic alpha amylases (AMY2A/AMY2B) begin the process of polysaccharide digestion 
by acting on the α-1-4 glycosidic bonds in dietary starch and sugars. The full protein is 511 
amino acids including the signal sequence and requires one essential calcium ion to form 
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the correct tertiary structure (Steer, 1974) and chloride ions to stimulate activity (Levitzki, 
1973). 
Carboxypeptidase B 
Carboxypeptidases are a widely distributed family of hydrolytic enzymes that remove C-
terminal residues from proteins. Performing a variety of functions throughout the body 
carboxypeptidases are associated with protein maturation and secretion (Fricker, 1988), 
digestion (Beck, 1973), coagulation and inflammatory pathways (Song, 2011), and 
development (Reznik, 2001). A particularly interesting member of this family with respect to 
Wolfram syndrome pathology is carboxypeptidase E (CPE), which shares 15-20% sequence 
homology with CPB1 (Skidgel, 1988). This protein has been shown to provide an important 
link between diet-induced hyperlipidemia, ER stress-mediated islet β-cell apoptosis and type 
2 diabetes (Kharroubi, 2004; Jeffrey, 2008). 
The pancreatic exocrine carboxypeptidases (A1, A2 and B) are protease enzymes that cleave 
amino acids from proteins during digestion. Like other digestive enzymes carboxypeptidase 
B1 (CPB1) is also secreted as an inactive propeptide to protect the pancreatic tissue from 
damage (417 amino acids), and activated in the gut lumen by trypsin to a mature, active 
protein of 307 residues.  
Summary of initial screen 
Unexpectedly we did not isolate any potential WF-interacting partners typically expressed in 
β-cells, which would be the most relevant to WS pathology, although the vast majority 
(~90%) of pancreatic tissue is exocrine. The proteins identified from a yeast two-hybrid 
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screen are predominantly associated with digestion but some of these also have additional 
functions in the brain and links with insulin secretion and β-cell apoptosis, which relates 
them more specifically with systems primarily affected by WS. There are no gastrointestinal 
symptoms reported in WFS1-associated WS but cells producing digestive enzymes are 
overburdened with protein synthesis and susceptible to ER stress. The role of wolframin in 
the UPR may suggest a function for this protein in the exocrine pancreas and perhaps the 
absence of disease manifestation in these cell-types is due to pathway redundancy? 
 
5.3  Confirming protein interactions in yeast 
Positive interactions were re-tested in yeast cells. Electrocompetent E.coli were used to 
produce large volumes of purified bait and prey clones in preparation for re-transformation. 
Yeast-extracted plasmids were electroporated individually into bacterial cells and cultured 
(section 2.7.4). Plasmids were harvested using maxiprep kits (QIAgen; section 2.7.5) and 
sequence verified (section 2.4.0). Bait vectors (pGBKT7-WFS1-N) together with pACT2 
containing a known partner protein sequence (from table 5.0) were then co-transformed 
(section 2.8.4) on a ‘one-to-one’ basis into competent yeast cells and grown on selective 
medium (fig 5.2). 
According to the same basic principles as the initial screen in yeast (section 5.0.1), selective 
markers were used for verifying the presence of each plasmid and the interaction of bait 
and prey. Blue colonies produced from co-transformations plated on a QDO-X-α-Gal 
substrate signified an active GAL4 transcription factor indicative of bait-prey interaction. 
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Figure. 5.2. MATCHMAKER GAL4 Two-Hybrid System 3. (A) Fusion vectors containing WFS1-N term as bait in pGBKT7 and a pancreatic cDNA library 
in pACT2 are prepared.  (B) Each vector contains unique selection markers. (C)  Following co-transformation, yeast are able to grow on minimal 
media; the presence of WFS1 is associated with growth on –TRP1, the presence of a library protein is associated with growth on –LEU2.  An 
interaction between the two proteins produces a functional GAL4 transcription factor, which induces expression of ADE2 and HIS2 for more stringent 
nutritional selection in addition to MEL1 expression enabling blue/white screening on X-α-Gal substrate.  
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Control samples of cells transformed with a single bait or prey vector did not result in colony 
formation on QDO-X-α-Gal agar (data not shown). However, each positive clone (pACT2-
prey) identified from the two-hybrid screen (table 5.0) did result in growth of blue yeast 
colonies on QDO-X-α-Gal when independently co-transformed with WFS1-N term/pGBKT7 
(fig. 5.3). These results confirm our initial findings and justify further investigation of these 
candidate WF-partners.  
 
 
 
 
 
 
 
Figure 5.3. Re-testing positive interactions in yeast. Co-transformation of competent AH109 yeast with 
WFS1-N term/pGBKT7 and each of: PRSS1, CLPS, PNLIP, REG1A, AMY 2A/2B and CPB1 in pACT2 produced 
blue colonies when grown on quadruple drop-out yeast minimal medium with X-α-gal, confirming 
positive selection from an initial library yeast two-hybrid assay.  
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5.4.0  Expression of WFS1 in exocrine tissue 
Consideration must be given to the biological significance of interactions detected between 
foreign fusion-proteins introduced into yeast. False-positive results may occur as a 
consequence of incorrect protein folding and altered stability, and other molecular 
associations may be dependent on formation of larger complexes involving multiple 
proteins. Whilst these possibilities can be largely investigated in mammalian cells, it is 
important to firstly ensure the protein partners in question are likely to co-exist both 
spatially and temporally in an endogenous environment.  
Although interactions with wolframin were initially detected from a pancreatic library, it is 
feasible that in reality they may occur in one or several other locations, perhaps other sites 
specific to the activities of our candidate proteins such as the intestine, brain (CLPS) or islet 
cells (REG1A). To justify further analysis of our proposed protein-couples we decided to 
examine WFS1 expression in exocrine acinar cells as a starting point since each of our 
selected ‘partner’ proteins, in the pancreas, are predominantly expressed and secreted from 
this cell type.  
WFS1 expression in acinar cells has not previously been demonstrated 
Earlier studies in fact suggest that WFS1 is not expressed in exocrine tissue (Ishihara, 2004; 
Philbrook, 2005; Xu, 2009). The absence of WFS1 however remains somewhat inconclusive 
since none of the aforementioned studies were primarily focused on exocrine tissue and did 
not seek to confirm their observations with suitable controls. We suggest it may be possible 
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that wolframin could be present, but in much lower concentrations than in islets, where 
WFS1 is known to be strongly expressed (Philbrook, 2004; Ueda, 2005). 
Two complementary approaches were taken to determine WFS1 expression in exocrine 
tissue: examination of WFS1 mRNA and protein levels in a pancreatic exocrine cell line, and 
immunohistochemical analysis of whole rat pancreatic tissue sections 
 
5.4.1  Analysis of WFS1 mRNA and protein in rat acinar cells  
A rat pancreatic AR42J acinar cell line was purchased from the European Collection of Cell 
Cultures (HPA, 2011) and cultured according to supplier recommendations (table 2.0, 
chapter 2).  
The RNeasy kit (Promega) was used to extract RNA from samples of ≤1 x 107 cells (section 
2.10.2). Sample concentrations were measured on a Nanodrop 2000 spectrophotometer 
(Thermo Scientific; section 2.12.0) and 1µg of DNase treated RNA subsequently reverse 
transcribed with random primers and Reverse Transcription System reagents from Promega 
(section 2.1.2). Successful cDNA synthesis was verified on agarose gel (section 2.3.0), before 
standard PCR amplification with selected primers (section 2.1.0). 
Primers spanning exons 6 and 7 of rat WFS1 were designed to produce 241bp products from 
mRNA (cDNA) if present. A positive control house-keeping gene, rat-ACTB, was also analysed 
with primers spanning a 380bp region of cDNA (see appendix 2.13 for primer sequences) 
plus negative controls containing no reverse transcriptase. The results (fig 5.4), analysed by 
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agarose gel electrophoresis (section 2.3.0), confirmed the presence of WFS1 expression in 
Acinar AR42J cells.  
 
 
 
 
 
 
 
 
 
 
 
Protein was harvested from AR42J Acinar cells in RIPA lysis buffer (section 2.10.1) for SDS-
PAGE and immunoblotting (section 2.13.0). Positive control whole cell lysates were taken 
from both: MIN6 cells, a mouse pancreatic β-cell line known to express WFS1, and 
transfected COS7 cells over-expressing WFS1 (section 2.9.5).  
Figure 5.4. Expression of WFS1 RNA in exocrine cells. Reverse-transcription PCR products derived from 
rat Acinar AR42J RNA demonstrating expression of WFS1 and positive control gene ACTB. Clear lanes for 
negative control samples, WFS1-mock and ACTB-mock, cycled without reverse-transcriptase, indicate 
the absence of genomic DNA or other amplicon contamination. 
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Qualitative analysis using anti-wolframin antibody (Hofmann, 2003; table 2.2) revealed that 
wolframin protein is present in rat exocrine AR42J cells (fig 5.5). Re-probing blots with anti-
β-actin (ACTB) antibody (table 2.2), a ubiquitous house-keeping gene, provided a crude 
indication of total protein loaded.  
 
 
 
Due to the potential differences in antibody specificity to proteins derived from different 
species a direct comparison of WFS1 expression levels between cell lines cannot be made. 
These differences perhaps explain the relatively weak WFS1 signal in COS7 cells ‘over-
expressing’ WFS1. A rat pancreatic β-cell line, such as INS-1 may provide a useful 
comparison for semi-quantitative analysis of WF protein expression between endocrine and 
exocrine tissue. 
 
Figure 5.5. Qualitative analysis of WFS1 expression in exocrine cells. TOP PANEL: Western blot 
demonstrating detection of wolframin in rat Acinar AR42J cells alongside positive control samples 
derived from: COS-7 cells over-expressing WFS1 and untransfected MIN6. BOTTOM PANEL: Signals 
from blots re-probed for β-actin (ACTB) provide an indication of total protein loaded for crude 
comparison.  
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5.4.2  Immunohistochemical analysis of rat pancreata 
Direct analysis of tissue samples is perhaps a more pragmatic approach for investigating 
gene and protein expression as primary cells have not been subject to immortalisation or 
prolonged culture and handling in the laboratory, which may influence the expression 
profile of cells. Therefore, to substantiate our findings in AR42J cells, immunohistochemical 
analyses were used to assess WF protein expression in rat pancreata.  
Whole rat pancreata were provided courtesy of Dr Steven Jacques, Molecular Neuroscience 
Group, University of Birmingham. Tissue was excised from two animals immediately 
following CO2 narcosis (for other purposes), embedded, sectioned and immunostained 
(section 2.16.0). Anti-WFS1 antibody (Proteintech; table 2.2) was used to detect the 
presence of wolframin and anti-insulin antibody (Invitrogen; table 2.2) was used to confirm 
the location and morphology of islets (β-cells). Fluorescently-labelled secondary antibodies 
conjugated to different fluorophors (table 2.2) enabled stained sections to be viewed on an 
Axioplan 2 microscope with Zeiss Neofluar lenses and Axiovision software (Carl Zeiss Ltd). 
Experimental optimisation 
A number of tissue sections were used in preliminary experiments to optimise and verify the 
antibody specificity and concentration. Negative control samples were prepared according 
to protocol (section 2.16.0) with omission of primary antibodies. Images were captured 
from the microscope using a series of exposure settings to assess background, non-specific 
staining with secondary Alexa Fluor antibodies. An antibody dilution series was also applied 
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to tissue sections to optimise concentrations for minimal signal to noise ratio. (appendices 
31-34).  
Histology of the pancreas 
The bulk of the pancreas (~90%) is composed of exocrine tissue, from which secretions flow 
into a network of ducts leading ultimately to the duodenum. The exocrine secretory units, 
acini, are pyramid-shaped cells with basally located nuclei arranged into tubules to allow 
protein secretions passage directly from cells to ducts (fig 5.6A-C). Dispersed within the 
exocrine tissue are Islets of Langerhans, distinctive clusters of hormone-secreting endocrine 
cells including α, β, δ and PP (pancreatic polypeptide) cells (fig 5.6A).  
 
 
Figure 5.6. Histology of the pancreas. (A) Hematoxylin and eosin (H&E) stained human pancreas illustrating 
the arrangement and morphology of exocrine and endocrine tissue. DNA/RNA is stained purple and 
cytoplasmic structures pink (B) A magnified image of H & E stained acini, a small ball of pyramid-shaped 
epithelial cells with a tiny central lumen (white labelled cell boundaries). (C) Section of rat pancreas (x100 
mag) stained with anti-WFS1 and Alexa-Fluor 488 antibodies showing the characteristic clusters of acini. 
CHAPTER 5 IDENTIFYING WOLFRAMIN MOLECULAR PARTNERS 
 
 
246 
 
Detection of wolframin in exocrine cells 
Rat pancreas sections stained with anti-insulin (INS) antibody (red) clearly demonstrated the 
location of islets (fig 5.7A). As expected, islets also gave rise to a strong signal (green) when 
probed for the presence of wolframin, known to be abundant in pancreatic β-cells (fig 5.7B 
and 5.8). The surrounding exocrine tissue also produced a less pronounced, but evident 
green signal (fig 5.8), suggesting that wolframin may additionally be expressed in acini. It is 
unclear at this stage whether the signal observed is specific, relatively weak expression of 
WFS1 in acini, or if in fact the signal is only due to background staining.  
Confirming these observations requires a suitable blocking peptide as a primary antibody 
absorption control and a WFS1-null negative control, both of which were not available at 
this time.  
Immunoblot analysis of primary pancreatic tissue is an alternative method that could be 
used to substantiate WFS1 expression patterns, but does require accurate separation of 
islets and acini to avoid cross contamination of cell-types. A number of techniques such as 
fluorescence-activated cell sorting (FACS) or laser-capture microdissection (LCM) could be 
employed for this purpose, but do pose a risk of chemical or mechanical injury to the cells, 
perhaps causing changes to normal characteristics and gene expression. 
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Although our immunostaining data remain inconclusive at this stage, they do not contradict 
results obtained in rat AR42J acinar cells showing WFS1 expression at RNA and protein 
levels. Overall our findings indicate that WFS1 is expressed in exocrine tissue, supporting the 
notion that physical proximity of digestive zymogens and wolframin is possible in this tissue. 
Further investigation of yeast-isolated candidate proteins (table 5.0) as molecular partners 
to wolframin is therefore justified. 
 
 
Figure 5.8. Immunohistochemical analysis of rat pancreas sections (x100 mag). A closer look at anti-
WFS1 detection in islets (outlined in white) and the staining pattern observed in the surrounding 
acinar cells.   
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5.5.0 Cloning genes for proposed wolframin partners to mammalian 
expression vectors 
To confirm WF interactions primarily identified in yeast, more detailed analysis was carried 
out in mammalian cells. From those isolated in the two-hybrid screen (table 5.0), several 
candidate ‘partner’ proteins were initially selected: lipase, colipase, REG protein and 
carboxypeptidase B1.  
Sequence verified IMAGE clones were purchased from the European Collection of Cell 
Cultures (ECACC). These vectors containing cDNA sequences for the specified genes were 
used for cloning to HA-tagged mammalian expression vectors, pCMV-HA (Clontech), using a 
range of restriction sites and intermediate vectors as appropriate (section 2.19.0). Table 5.1 
lists the chosen genes/proteins and their relating unique IMAGE clone reference ID number, 
the cloning vectors used and MCSs. 
Details of the final expression vectors are illustrated in figure 5.9. WFS1 cloned into a myc-
tagged expression vector (pCMV-myc) was provided courtesy of Dr Malgosia Zatyka, Dept. 
Medical and Molecular Genetics, University of Birmingham.  
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               Table 5.1. Cloning methods for selected WFS1-partner candidates. IMAGE clone ID (Geneservice), intermediate cloning vector and cloning 
sites used for ligation to pCMV-HA expression vectors.  
Figure 5.9. Cloning methods for selected WFS1-partner candidates. N-tagged expression vectors for cloning/transfection of WFS1 and 
proposed partners: (A) colipase, pancreatic lipase, stone protein and carboxypeptidase were cloned into pCMV-HA . (B) WFS1 (courtesy 
of Dr M Zatyka) was cloned into pCMV-Myc  
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5.6.0TTTransfection and over-expression of wolframin and candidate 
partner-proteins in mammalian cells 
Plasmids containing HA-tagged; CLPS, PNLIP, REG1A, CPB1, and Myc-tagged WFS1 were 
transfected and co-transfected into mammalian cells (section 2.9.5). Experiments were 
aimed at over-expressing each protein for the purposes of co-immunoprecipitation. A series 
of directions were taken for protocol optimisation, summarised in figure 5.10, 
encompassing transfection, sample preparation and detection. 
5.6.1  Method Development 
Pilot 
Preliminary experiments began with transfection of COS7 cells with 1µg plasmid DNA and 
Fugene6 transfection reagent (Roche). Transfection mixes containing each of the chosen 
‘partner’ genes and WFS1 respectively were prepared according to standard protocol 
(section 2.9.5) and incubated for 15 minutes before adding to cells at 70-80% confluency. 
Protein was harvested in RIPA buffer after a 24 hour incubation period (section 2.10.0), and 
samples were prepared for SDS-PAGE by sonication (2x 10 seconds), centrifugation for 30 
minutes (14,000rpm), and collection of supernatant. Samples were mixed with x2 sample 
loading buffer, electrophoresed on SDS-polyacrylamide gel and immunoblotted (section 
2.13.0) using anti-HA/anti-Myc antibodies (Sigma; table 2.2). 
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Transfection 
Transfection conditions were the first set of parameters optimised for detection of protein 
over-expression. Cell lines routinely used to support reliable over-expression of a wide 
range of proteins were used. Both COS7 and HEK293 cells were transfected at a range of 
densities and manipulations were made with: DNA concentration, and DNA to Fugene6 
ratio, incubation times for transfection mix and for cells post-transfection. FugeneHD 
Figure 5.10. Method development. Three primary approaches for optimisation of CLPS, PNLIP, REG1A, 
and CPB1 over-expression relating to: transfection, protein harvest and sample preparation for western 
blotting, and signal detection.  
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(Roche), a ‘next generation’ transfection reagent was also incorporated into the protocol to 
improve transfection efficiency. The quality of plasmid DNA was verified with fresh 
preparations, which were measured and independently transfected. 
SDS-PAGE  
The next stage of method development was concerned with protein harvest and 
preparation for polyacrylamide gel electrophoresis. Transfected cells were harvested in a 
range of lysis buffers (table 2.1) and subject to various pre-treatments prior to western 
blotting including: sonication and syringing, sample boiling, resuspension and attempted 
homogenisation of pelleted debris following centrifugation. A more concentrated sample 
loading buffer (x5) was also included enabling larger sample volumes to be loaded on gels.     
Detection 
Finally, the effectiveness of protein/signal detection was explored using alternate antibodies 
(table 2.2) and dilution series. Signal detection was maximised with high sensitivity ECL plus 
detection reagents (Amersham), reflective developing cassettes with high sensitivity X-ray 
film, and increasing film exposure times. 
 
5.6.2  Over-expression of WFS1 and proposed molecular partners (CLPS, 
PNLIP, REG1A, CPB1) 
We were able to demonstrate over-expression of WFS1-Myc and HA-tagged; CLPS, PNLIP, 
REG1A and CPB1 in mammalian cells following single and co-transfection experiments.  
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CLPS-HA and WFS1-Myc were used in preliminary time-series transfection experiments, 
where protein was harvested at intervals from 12-72 hours. Results indicated that the 
highest concentrations of colipase protein could be collected from cells 48 hours post-
transfection following our protocol (fig. 5.11A). WFS1 expression continued to increase at 
each time interval up to 72 hours post-transfection, although suitably high levels of protein 
were detectable after 48 hours (fig. 5.11B) suggesting this as the most appropriate time-
scale for subsequent co-transfection experiments. HEK293 and COS7 cells were transfected 
with WFS1 and CLPS and found equally able to support over-expression of both proteins (fig. 
5.12).  
 
 
 
Figure 5.11. Method development - Testing different post-transfection incubation times. Western blot 
analysis of HEK293 cells co-transfected with CLPS-HA and WFS1-myc harvested at time intervals, showing 
optimal time for good expression of both at 48hours.  
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Colipase (CLPS) was the first candidate randomly selected for transfection and 
immunoblotting experiments. Figure 5.13 demonstrates a good level of WFS1-myc 
expression at ~100kDa and CLPS-HA at ~14kDa both singly and co-transfected into HEK293 
cells. Protein was harvested for SDS-PAGE in RIPA lysis buffer according to standard protocol 
(section 5.6.1) 48 hours post-transfection. However, detection of CLPS-HA over-expression 
Figure 5.12. Method development – Comparison of protein over-expression in host cell lines. 
Qualitative western blot analysis of CLPS-HA and WFS1-Myc over-expression in HEK293 and COS7 cells 
showing both cell lines equally support over-expression of WFS1 and CLPS. Co-transfections of CLPS and 
WFS1 (CLPS/WFS1) or each with empty negative control vectors (WFS1/HA, CLPS/Myc) were carried out 
in duplicate. Anti-β-actin Ig was used to give an indication of protein loading. (A) CLPS detected with anti-
HA Ig (B) WFS1 detected with anti-Myc Ig. 
A 
B 
1             2              3              4              5              6 1             2              3              4              5              6 
HEK293 COS7 
KEY 
CLPS - HA-tagged CLPS, WFS1 – Myc-tagged WFS1, HA- empty HA vector, Myc- empty Myc vector, ATBC - β-actin   
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following immunoblot was inconsistent despite large numbers of repeat experiments in 
seemingly identical conditions. We tried a wide range of method modifications for 
transfection, SDS-PAGE and detection although none of these conditions improved the 
consistency of the results (data not shown).   
 
 
 
 
 
 
 
 
 
 
The remaining three candidates; pancreatic stone protein (REG1A), carboxypeptidase B1 
(CPB1) and pancreatic lipase (PNLIP) were also transfected and over-expressed in HEK293 
cells. Proteins of appropriate size were observed on western blots probed with anti-HA Ig, 
but again these results proved difficult to replicate reliably. 
Figure 5.13. Expression of WFS1 and CLPS in HEK293 cells.  Qualitative western blot analysis of CLPS-
HA and WFS1-myc over-expression from single and co-transfections. Cells were harvested in RIPA 
buffer after 48 hours and lysate supernatant was collected following sonication.  
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Pancreatic stone protein over-expression in HEK293 cells was detected at 19kDa by anti-HA 
Ig. Samples prepared according to standard protocol in RIPA buffer supernatant are shown 
in figure 5.14A with corresponding samples probed for WFS1-Myc in the lower panel. 
REG1A-HA protein was found in samples derived from all combinations of transfection; 
REG1A alone, with WFS1, and with an empty control vector, although co-transfections with 
WFS1 produced significantly lower levels of REG1A, with signals barely visible even after 
extended film exposure. 
Figure 5.14B shows protein harvested from the same transfection as those in figure 5.14A, 
but collected from insoluble material following centrifugation (section 2.10.1). Cell debris, 
usually spun into an insoluble pellet and discarded following sample preparation was 
resuspended in a small volume of RIPA buffer (table 2.1) and repeatedly pipetted up and 
down in an effort to homogenise. This material was then immunoblotted with anti-HA Ig to 
reveal the presence of a substantial amount of REG1A protein in this fraction of the lysate. 
Large amounts of WFS1-Myc (lower panels) were also present in the insoluble portion of cell 
lysates.  
After discovering relatively abundant REG1A protein in the insoluble fraction, we performed 
a range of experiments with the aim of solubilising REG1A. A range of lysis buffers were 
used to harvest protein (table 2.1). Other means of releasing REG1A from (aggregated) 
pelleted material were also attempted including further sonication, syringe homogenisation 
and boiling samples. For the purposes of co-expression with WFS1, maintaining optimal 
conditions for wolframin was found to be a principle limitation to these methods of sample 
preparation.  
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Interestingly, we were only able to determine carboxypeptidase B expression in the 
insoluble fraction of RIPA buffer lysates (fig 5.15). Although transfection, harvesting and 
immunoblotting conditions were kept consistent between samples we observed little or no 
CPB1 expression from the crude ‘resuspended’ material used for western blot when co-
transfected with WFS1-Myc, yet clear signals with anti-HA Ig (46kDa) from CPB1 samples 
transfected alone or with control vectors. The possible biological significance of this 
observation remains to be investigated. 
Figure 5.14. Method development- Comparison of REG1A expression in lysate supernatant and pellets. 
Qualitative western blot analysis of HEK293 cells transfected and co-transfected with combinations of 
REG1A-HA, WFS1-myc and empty control vectors. (A) Supernatant from cell lysates in RIPA buffer prepared 
according to standard protocol. (B) Resuspended pellets from insoluble material following lysis in RIPA 
buffer. More REG1A protein was detected in the insoluble fraction than in supernatant.  
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Pancreatic lipase was detected at 51kDa, again only detectable in the insoluble fraction of 
RIPA buffer lysates (fig 5.16). Although samples were not measured quantitatively here, 
obvious inconsistencies in expression levels were observed between both different and 
duplicate samples. In this instance, each of the PNLIP transfection combinations does 
produce a low intensity signal although some positive samples (e.g WFS1/PNLIP 1) clearly 
have comparably higher concentrations of PNLIP.  
 
 
 
 
Figure 5.15. Method development – Expression of CPB1-HA in HEK293 cells. Qualitative western blot 
analysis of HEK293 cells transfected and co-transfected with combinations of CPB1-HA, WFS1-myc and 
empty control vectors. Insoluble pellets resuspended in RIPA buffer, vigorously mixed and boiled in 
loading buffer. CPB1-HA was only detectable in insoluble portion of cell lysates; a good level of expression 
was observed in cells transfected with CPB1-HA alone or with an empty control vector but little or no 
expression was detectable when co-transfected with WFS1-Myc. 
CHAPTER 5 IDENTIFYING WOLFRAMIN MOLECULAR PARTNERS 
 
 
260 
 
 
 
 
 
Closer consideration was therefore given to solubility as a factor influencing the inconsistent 
observations we made of our ‘partner’ proteins following immunoblotting. Samples 
harvested in a number of buffers were also subject to a range of pre-treatments prior to 
SDS-PAGE, and efforts to resuspend material from pelleted cell debris were made. These 
experiments are ongoing. 
Summary of section 
We have demonstrated consistent over-expression of WFS1-Myc in mammalian cell lines 
and over-expression of single and co-transfected HA-tagged: CLPS, REG1A, CPB1, and PNLIP 
with variable degrees of success. We have observed good expression of CLPS-HA in the 
Figure 5.16. Method development - Expression of PNLIP-HA and WFS1-Myc in HEK293 cells. Qualitative 
western blot analysis of HEK293 cells transfected and co-transfected with combinations of PNLIP-HA, WFS1-
myc and empty control vectors. PNLIP-HA was only detectable in insoluble portion of cell lysate; pellets were 
resuspended in RIPA buffer, vigorously mixed and boiled in loading buffer.  
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soluble fraction of RIPA buffer cell lysates, but these results are inconsistent between 
experiments. The remaining proteins (REG1A, CPB1 and PNLIP) have been detected in the 
insoluble fraction only, again with inconsistency between experiments. A notable 
observation was the expression level of CPB1-HA, which was detectable in the absence of 
WFS1-Myc only, although this finding must be verified.  
To date, our co-transfection experiments have been based on modifying our established 
‘optimal’ wolframin harvesting and preparation conditions to accommodate the presence of 
selected ‘partner’ proteins. It is apparent that optimal conditions for reliable WFS1 over-
expression and immunoblot detection are not comparable to those required for our chosen 
molecular partners. 
Previous studies have successfully demonstrated these proteins using western blotting 
techniques (Crenon, 1994; Cavard, 2006; Ventura, 1999; Lowe, 1992), furthermore, ‘ready 
to load’ prepared protein lysates are commercially available (Abcam, Origene). Consulting 
relevant literature enables us to ascertain the alternate harvesting and preparation 
conditions used for application in our own work. We intend to explore and adapt these 
protocols further with the aim of reaching sufficient, if compromised, conditions for 
adequate solubilisation of wolframin and ‘partner’ proteins together. Despite the method 
development needed for reliable WF-partner co-expression, we took forward the available 
protein we were able to effectively produce to co-immunoprecipitation experiments. 
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5.7.0  Co-immunoprecipitation of over-expressed wolframin and proposed 
molecular partners  
Co-immunoprecipitation (Co-IP), a technique used to isolate protein-protein interactions in 
vivo, was used to purify WF-partner complexes from mammalian cell lysates. By targeting 
wolframin or a partner-protein with specific antibodies, it is possible to physically isolate 
(pull-down) from a solution not only the targeted antigen, but also any proteins that are 
bound to it, which can be analysed by SDS-PAGE and western blot.  
5.7.1  Specific methods 
An indirect capture method was employed using agarose A beads as a solid phase substrate 
(section 2.14.0). Agarose beads are highly porous, microscopic resin slurries with surfaces 
suitable for binding antibodies. When specific antibodies are immobilised onto agarose 
beads, this support scaffold is used to pull-down not only target antigens but entire protein 
complexes from solution (fig 5.17). The targeted antigen (e.g. wolframin) and its associated 
partners were firstly incubated with specific antibodies to allow antibody-antigen binding.  
Agarose beads were then added to the mix to immobilise and ‘pull-down’ complexes. Beads 
with attached proteins were then isolated and washed to remove unwanted non-specifically 
bound molecules before the targeted antigen (e.g. wolframin) and its associated partners 
were released from the beads and analysed. 
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Figure 5.17. Principles of indirect co-immunoprecipitation. (A) Cells are co-transfected with both 
potential partner proteins. (B) Cells are lysed to release proteins. (C) Lysates are incubated with 
antibodies specific to a target antigen, e.g. one of the partners. (D) Agarose beads are added to the 
mixture to provide a solid-phase support for ‘pulling-down’ the entire complex as antibodies have 
affinity to the surface of the beads. (E) Immobilised complexes are purified from solution ready for 
analysis by western-blot. 
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Whole cell lysates, containing over-expressed proteins of interest were used for Co-IP. 
Experiments were initially performed using anti-Myc Ig for pull-down, which served to 
target WF-Myc, and anti-HA Ig for detection of any associated HA-tagged partner-proteins. 
Where material was available, the pull-down was carried out in reverse, using anti-HA 
antibody for isolation of potential partners, and anti-Myc for detection of any coupled WF-
Myc protein. 
Following pull-down, agarose beads (with attached proteins) were washed 3 times for 10 
minutes in RIPA buffer (table 2.1). The stringency of this step was experimentally modified 
in attempts to minimise non-specific protein binding to beads and remove background 
staining of subsequent western blots; wash duration was increased and alternate buffers 
were applied. 
5.7.2  Co-IP of WFS1-CLPS 
The largest numbers of protein samples were generated from CLPS constructs, enabling a 
series of alternative IP experiments to be performed. Using anti-Myc Ig for targeting 
wolframin we were able to repeatedly detect the presence of ‘pulled-down’ CLPS-HA at 
14kDa with anti-HA Ig (fig 5.18A), suggesting an association between WFS1-CLPS could be 
legitimate. The validity of our findings however, remains in question due to the recurrent 
‘pull-down’ of CLPS-HA observed in our negative control, which comprised empty pCMV-
Myc vector and CLPS-HA. The same experiment was carried out in reverse using anti-HA to 
target CLPS (fig 5.18B). We found that WF-Myc was pulled-down as expected, but again a 
clear signal was present in the negative control (WFS1/empty pCMV-HA).  
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Since agarose is able to bind some proteins and cellular components, non-specific 
interaction and pull-down of off-target molecules directly with beads may be the cause for 
unwanted background signals. The pre-clearing step where lysates are incubated with beads 
alone is designed to minimise this outcome by collecting and removing non-target 
molecules, although increasing the stringency of washes following IP can further lessen this 
occurrence. 
 
Figure 5.18. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and colipase (CLPS-HA), 
harvested from HEK293 cells in RIPA buffer.  Pull-down of protein complexes was performed with 
(A) anti-Myc Ig, specific to WFS1, and (B) anti-HA Ig, specific to CLPS.  
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We repeated WFS1-CLPS Co-IP experiments, modifying the stringency of washing. Our aim 
was to maintain binding of desired specific proteins but strip away non-specific interactions. 
Increased number and duration of washes with RIPA buffer (fig 5.19A-B), and alternate 
buffers with variable concentrations of salt (NaCl) and detergents were applied (fig 5.20A-B), 
although detection of protein in the negative control samples persisted.  
 
 
 
 
 
 
 
Figure 5.19. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and colipase (CLPS-HA), 
harvested from HEK293 cells in RIPA buffer.  Pull-down of protein complexes was performed with 
anti-Myc Ig, specific to WFS1, and washed with RIPA buffer for: (A) 2 x 20 min (B) 3 x 20 min.  
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Figure 5.20. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and colipase (CLPS-HA) harvested 
from HEK293 cells in RIPA buffer.  Pull-down of protein complexes was performed with anti-Myc Ig, specific to 
WFS1, and washed in: (A) high salt buffer (table 2.1) (B) low detergent buffer (table 2.1).  
 
Generation of additional protein extracts suitable for Co-IP will enable us to continue along 
this line of investigation. Increasing buffer NaCl concentration to as much as 1M may disrupt 
any electrostatic or ionic attractions although some physiological interactions can also be 
lost at salt concentrations above 300mM, higher stringency can also be achieved by 
changing detergents and raising concentrations. Further reduction of non-specific protein 
binding may be achieved with more rigorous ‘blocking’ of beads with an irrelevant protein 
such as bovine serum albumin (BSA), which serves to reduce the available surface area for 
attachment of superfluous proteins. We confirmed the specificity of anti-Myc Ig 
immunoprecipitation by stripping a membrane of anti-HA Ig using 0.2M NaOH (sodium 
hydroxide) and reprobing it with anti-Myc Ig (fig 5.21). 
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Immobilising antibodies/protein-complexes onto alternative supports may provide another 
solution to non-specific pull-down. Materials such as acrylamide and cellulose resins, 
magnetic beads, polystyrene particles and controlled pore glass (Thermo Scientific) are all 
popular options for IP protocols.  
 
5.7.3  Co-IP of WFS1-REG1A 
Preliminary Co-IP was also carried out with WFS1-REG1A combinations, collected from both 
soluble and insoluble lysate material. Pull-down of complexes was achieved with anti-Myc 
Ig, specific to WFS1-Myc. We were able to detect a positive REG1A signal in each sample set 
(fig 5.22A-B), but as before a clear signal in negative controls also. 
Figure 5.21. Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and colipase (CLPS-HA), 
harvested from HEK293 cells in RIPA buffer.  TOP PANEL: Pull-down of protein complexes was 
performed with anti-Myc Ig, specific to WFS1. BOTTOM PANEL: The membrane was probed with anti-
HA Ig, specific to CLPS, then stripped with 0.2M NaOH and reprobed with anti-Myc Ig to verify correct 
binding pattern of WFS1 constructs and specificity of anti-Myc Ig.  
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Although providing a useful starting point, the use of material not fully dissolved does 
interfere somewhat with the precipitation process, where protein aggregates often stick to 
beads randomly. Proteins of interest may perhaps be isolated in this instance by binding of 
another unrelated protein, which happens to form part of the composite. 
 
 
 
 
 
 
Supernatant (A) 
Pellets (B) 
Figure 5.22 Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and pancreatic stone 
protein (REG1A-HA). Over-expressed proteins harvested from HEK293 cells in RIPA buffer (A) 
supernatant and (B) insoluble material. Pull-down of protein complexes was performed with anti-
Myc Ig, specific to WFS1.  
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5.7.4  Co-IP of WFS1-CPB1 
The only CPB1 protein detected so far was observed in resuspended insoluble material from 
RIPA buffer lysates. We attempted to Co-IP CPB1-HA and WFS1-Myc with anti-Myc Ig 
despite limitations imposed by partial insolubility. Very faint signals following immunoblot 
were captured both in sample inputs and pull-downs (fig 5.23), although appropriately sized 
bands were visible at 46kDa when probed with anti-HA, specific for CPB1-HA. Again signals 
were also detected in negative control samples. 
 
 
 
Section summary  
Our earliest attempts to confirm proposed WF-partner interactions in mammalian cells have 
been carried out with a limited supply of material. To date we have been able to confirm the 
‘potential’ for CLPS, REG1A and CPB1 to form a complex with WFS1 using Co-IP although 
experiments are still at the stage of method development. 
Figure 5.23 Co-immunoprecipitation of tagged wolframin (WFS1-Myc) and carboxypeptidase B1 (CPB1-
HA). Over-expressed proteins harvested from HEK293 cells in RIPA buffer (pellets). Pull-down of protein 
complexes was performed with anti-Myc Ig, specific to WFS1.  
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5.8  Ongoing and further work  
5.8.0  Protein solubilisation 
Since proteins with different physio-chemical properties are not easily amenable to the 
same treatment, it is difficult to study these on a systems level in a lab controlled 
environment. Our first goal is to define appropriate conditions for WF-partner co-expression 
for analysis by SDS-PAGE. A number of options remain open for optimising solubilisation of 
these proteins together, including varied lysis buffers and pre-treatments.  
 
Export of secretory proteins and cleavage of signal peptides is known to play an important 
role in proper protein folding, formation of disulphide bonds and tertiary structure (Vitale, 
1999; Phillips, 1996). Taken together with successful isolation of lipase and 
carboxypeptidase proteins from cell culture medium as well as cell pellets in earlier studies 
(Lowe, 1992; Reverter, 1998; Ventura, 1999), we hypothesise that our solubility issues may 
arise from incorrect folding of our candidate proteins, which all naturally pass through the 
secretory pathway. We may turn our attention to collection and purification of over-
expressed proteins from culture medium, although perhaps isolating WF-partner pairs 
together in this way may not be possible. Conceivably, a potential interaction with 
wolframin may be necessary for correct folding or export of selected secretory proteins. 
 
An in vitro transcription-translation method is another approach we could consider for 
tackling issues of combined protein solubility. Cell-free systems of synthesising target 
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proteins from DNA/RNA templates, have been employed successfully for study of cytotoxic 
products or those tending to aggregate or form inclusion bodies. Extracts containing the 
basic translational machinery including ribosomes, initiation factors, tRNAs and ATP can be 
used to generate proteins for a limited period. A number of commercial kits are available 
with components derived from prokaryotic and eukaryotic organisms, including human, 
which deliver functional proteins. 
5.8.1  Optimising Co-IP conditions  
Following successful production of our desired proteins we can concentrate on improving 
the specificity of our Co-IP experiments. A number of repeat experiments would enable 
modifications to be made to the stringency of pre-clearing lysates and wash buffers. Wash 
buffers containing increasingly higher concentrations of denaturants should serve to break 
non-specific interactions until a point is reached where all proteins bound to 
beads/immobilised antibodies are removed. In order to verify a positive association, under 
these conditions we would expect to maintain WF/partner pull-downs but observe a 
disappearing signal from the negative control pull-down.  
Another approach we could try is direct Co-IP, which has proven more efficient in certain 
biological systems. Antibodies are immobilised onto a solid phase support such as beads 
before incubating with lysates. Antigen-antibody complexes are allowed to form before 
purification of these partners from solution with agarose beads already conjugated to 
antibodies. 
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Assuming adequate solubilisation of both proteins, we could also attempt Co-IP with one or 
more endogenous proteins. Endogenous wolframin, known to be expressed in COS7 and 
HEK293 cells, could be used to pull-down HA-tagged ‘partner-proteins’ with anti-WFS1 Ig 
(and vice versa). In light of our earlier data (section 5.4) we may ultimately perform Co-IP of 
purely endogenous proteins found in acinar cells if possible. 
 
5.8.2  Alternative approaches for confirming protein interactions in mammalian systems 
If suitable conditions for solubilising both wolframin and our proposed partners (CLPS, 
PNLIP, REG1A and CPB1) together are not ascertained, we may consider an alternative 
approach for confirming/eliminating our findings from yeast in a mammalian system. 
An altogether different method of producing proteins and investigating their interactions in 
vitro was described by Suzuki et al (Suzuki, 2004). Instead of using tagged proteins for Co-IP 
experiments, the target proteins are synthesised and biotinylated or radiolabeled through in 
vitro transcription-translation. Although not without drawbacks, this system produces 
proteins more likely to be soluble and eliminates the need for traditional fusion-tags. 
In vivo protein-interaction assays such as FRET (fluorescence resonance energy transfer) and 
more recently BiFC (biomolecular fluorescence complementation) allow analysis of protein 
associations in a more physiologically relevant context. FRET technology is based upon 
constructing fusion-proteins with coupled fluorophores, which transfer energy when in 
close proximity. When energy is transferred from excited donor to acceptor, a change in 
fluorescence will take place that can be visualised with an inverted fluorescent microscope. 
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BiFC (Morell, 2008) involves the construction of fusion-proteins where proteins of interest 
are linked to complementary unfolded fragments of a fluorescent reporter. If the proteins 
interact, the reporter is able to reform its three-dimensional structure and emit a 
fluorescent signal, detectable under an inverted fluorescent microscope. FRET and BiFC are 
useful techniques that not only allow detection of interaction sites within live cells, but are 
also highly sensitive, enabling capture of short-lived or weak associations.  
 
5.9  Summary and discussion 
A number of potential wolframin molecular partners, proposed to interact with the 
cytoplasmic N-terminal domain of wolframin, have been detected from a yeast two-hybrid 
assay. WFS1-N was used as bait to screen a pancreatic cDNA library (Dr C. Ricketts) and from 
those positive yeast clones collected we have isolated and identified: AMY2 A/B, CPB1, CLPS, 
PNLIP, PRSS2, and REG1A, all of which encode secretory proteins synthesised in the exocrine 
pancreas. These interactions were all confirmed by ‘one-to-one’ reintroduction to yeast. 
 
Before verifying these findings in a mammalian system, we firstly sought to provide 
evidence that these interactions could be biologically relevant, where both wolframin and 
proposed partner-protein may be present in the same locality. Since each of the candidate 
‘partners’ are produced and secreted by exocrine cells, we considered this a reasonable 
place to look for the presence of wolframin, which has never previously been shown in this 
tissue type. A rat exocrine acinar cell line (AR42J) was used for this purpose, and we were 
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able to demonstrate the expression of WFS1 on both RNA and protein levels. 
Immunohistochemical analyses of whole rat pancreas sections also provided inconclusive 
support for these observations but requires WFS1 negative tissue as a control. 
Four candidates were selected: CLPS, PNLIP, REG1A and CPB1, and corresponding cDNA 
sequences were cloned into HA-tagged expression vectors. Together with WFS1-Myc, each 
of the candidate partners was transfected and over-expressed in mammalian cells. Finding 
conditions for abundant, reproducible protein expression was problematic. Following a 
series of optimisation experiments, we found the most obvious obstacle was protein 
solubility, in particular preparing both wolframin and a designated ‘partner’ for immunoblot 
analysis in conditions suitable for both proteins.  
A series of preliminary Co-IP experiments were carried out from the limited material we 
were able to generate. We demonstrated pull-down of CLPS, REG1A and CPB1 using WFS1-
myc Ig although adequate controls are needed to substantiate these early findings. Our 
initial results do not discredit the idea that wolframin has the ‘potential’ to bind each of the 
selected partners (CLPS, PNLIP, REG1A, CPB1) however, more work is needed to prove that 
the interaction is specific. 
Limitations  
Conditions in vivo may well allow interactions to take place that are technically complex or 
impractical to reproduce in the laboratory. The most challenging problem we have 
encountered is concerned with creating compatible conditions for solubilising WF-partner 
pairs for further analysis. Secondly, an issue that may in fact be related to solubility is the 
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need for further optimisation of Co-IP protocols. It has yet to be determined whether the 
observed non-specific pull-down during Co-IP results from improper folding of secretory 
proteins. 
Alternative in vitro methods provide options for dealing with problems of protein solubility 
and purification although techniques such as FRET analysis may allow us to tackle both 
problems together, whilst providing a credible and biologically relevant means of confirming 
our proposed interactions in vivo. 
Conclusions 
Our findings suggest that wolframin may function in some capacity in the production or 
activity of one or more digestive enzymes and exocrine secretory proteins. The preliminary 
data show that the N-terminal domain of wolframin, sitting on the cytoplasmic side of the 
endoplasmic reticulum (ER), may interact with a number of previously unidentified 
pancreatic protein-partners. 
It may be that possible wolframin interaction with our identified proteins could take place in 
regions other than the exocrine pancreas, perhaps in the gut or in the case of REG1A, in 
regenerating β-cells, which opens an interesting link with WS pathology. Indeed if 
interactions do occur endogenously in human systems, the regions of these proteins 
associated with wolframin are also important to understand. For example, pancreatic 
carboxypeptidases (CBP) do share 15-20% sequence homology with other CBP family 
members (Skidgel, 1988), which could hypothetically share a region of binding affinity to 
wolframin. This possibility could open a whole array of novel functions for wolframin. 
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In the case of CLPS, we would be interested to learn whether wolframin is able to interact 
with amino acids 18-22, which constitute the enterostatin pentapeptide, found in the brain 
as well as the digestive system. Of particular interest is the role of enterostatin in regulation 
of insulin secretion and whether a potential interaction of this peptide or its precursor CLPS, 
with wolframin has any significance.   
Although wolframin expression is shown to be primarily localised to the ER membrane 
(Osman, 2003; Philbrook, 2005), a number of studies provide evidence that it may also 
engage in activity with plasma membrane proteins (Zatyka, 2008a) and is expressed in β-cell 
secretory granules (Hatanaka, 2011; Ishihara, 2004). Defining the sub-cellular location and 
understanding the context of these interactions is therefore difficult and the requirement of 
other associate-proteins or bridging molecules for complex formations has not been ruled 
out.  
The likely nature of WF-interaction with our proposed candidates is therefore open to 
interpretation and further investigation, although we speculate that wolframin could be 
involved in the folding and processing of these proteins, since earlier evidence proposes 
wolframin as a molecular chaperone (Fonseca, 2005). 
Our primary objective is to validate our preliminary findings from the yeast screen to 
demonstrate one or more of our candidates as an authentic wolframin molecular partner. 
We intend to incorporate any such novel findings in further functional study of WFS1 
variants (see chapter 6). 
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CHAPTER 6 
GENERAL DISCUSSION, CONCLUSIONS AND FURTHER WORK 
6.0  Thesis summary 
The work presented in this thesis further highlights the genetic and phenotypic 
heterogeneity of WS, by initially expanding the mutational spectrum of WS patients. A 
number of individuals in our cohort were found to carry previously undescribed WFS1 
mutations, and together with the listed patients registered on our West Midlands database, 
comprise the largest single UK cohort to date. The first WS patient in the UK populace to 
harbour mutation of WFS2 is also reported. Our data suggest this mutation (WFS2-E37Q) 
originates from a founder of Jordanian-Bedouin background, as all individuals found to carry 
this mutation, including our own, appear to share a common ancestor. 
Possible causative mutations were not found in a number of WS patients included in our 
study despite full direct sequencing of all coding regions of WFS1 and WFS2. This may be a 
consequence of undetected chromosomal abnormalities, large deletions, or important non-
coding WFS1 variants, or may alternatively suggest the existence of additional WS disease-
loci. The phenotypic variability associated with WS complicates interpretation, as a number 
of other disorders share clinical characteristics with WS. This is underlined in our study by 
the discovery of a homozygous SLC19A2 mutation (R162X) in one of our patients, who only 
presented with anaemia following a diagnosis of WS. We were therefore able to confirm a 
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genetic diagnosis of TRMA. Clinical profiles of remaining patients should perhaps be re-
evaluated. 
One or more WFS1 mutations have been found in 67 of the listed patients on the 
Birmingham WS patient database. Of 121 identified mutations, approximately equal 
proportions (31-33%) of missense, nonsense and deletion mutation-types were found in 
WFS1. The remainder was accounted for by insertion, splice and synonymous changes. 
All available clinical information compiled from a total of 42 patients revealed median ages 
of diabetes mellitus and optic atrophy onset of 6 years and 10 years respectively. Further 
genotype-phenotype correlation performed on patients grouped according to mutation-
types, showed that individuals carrying inactivating WFS1 mutations present with diabetes 
mellitus at an earlier median age (5 years) than those with at least one missense mutation 
(median: 10.5 years). A greater proportion of patients with inactivating mutations also 
appear to develop a more complete spectrum of WS-associated complications. Our findings 
are consistent with those of earlier studies (Smith, 2004; Cano, 2007; D’Annunzio, 2008; 
Zmyslowska, 2011) and suggest that patients carrying inactivating mutations are 
predisposed to develop a relatively more severe phenotype than those with missense 
mutations. In support of these observations are the reports of ‘mild’ cases of WS where 
patients develop a markedly later onset of clinical features (Van Den Ouweland, 2003; Cano, 
2007; Gasparin, 2009). These patients have always harboured WFS1-missense mutations. 
Single nucleotide variants in WFS1 range from those considered as common benign 
polymorphisms to those associated with disease, including WS of variable severity, type 2 
diabetes (Voight, 2010), non-syndromic deafness (Young, 2001; Bespalova, 2001), and 
psychiatric illness (Furlong, 1999; Torres, 2001; Swift, 2005; Zalsman, 2009). Perhaps 
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previously uncharacterised variants of WFS1 are responsible, at least in part, for a number 
of other disorders of the visual, auditory or nervous systems and the clinical manifestations 
associated with this gene have a wider spectrum than previously thought? As more 
information comes to light, we may find a clearer relationship between genotype and 
phenotype and an understanding of wolframin function in general terms or specific to 
various biological systems.  
We hoped to contribute to this end by functional analyses of selected wolframin variants, 
and intended to focus our efforts from the perspective of diabetogenesis, both an integral 
part of the WS phenotype and a prevalent, complex disease of an indeterminate molecular 
basis.  
A selection of representative wolframin variants were characterised in mammalian over-
expression systems and we provided the first evidence that correctly localised, stably 
expressed wolframin protein may be produced by WFS1 harbouring some WS-associated 
mutations. The first molecular characterisation of the type 2 diabetes associated allele 
WFS1-H611 is also presented, laying the ground-work for further functional analyses. A new 
perspective on the effects of WFS1 mutation was taken by comparing missense variants 
relating to phenotypes of variable severity. Our data, together with knowledge of variability 
in WS clinical presentation, support the hypothesis that some WFS1 mutations may allow 
production of partially functional wolframin protein. We intend to test this idea further by 
assessing the relative ability of wild-type and mutant wolframin to function in a series of 
assays. 
To broaden functional understanding of wolframin and enhance the scope of our 
prospective plans we have identified several new potential molecular partners of wolframin 
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in the pancreas, which have yet to be verified. A number of interesting candidates are 
described, all of which are components of exocrine pancreatic secretions, mostly associated 
with digestion, although some have other additional systemic functions perhaps relating to 
wolframin pathways. Our evidence that WFS1 is expressed in exocrine cells raises the 
possibility for novel wolframin interactions to take place in acinar cells, potentially 
mediating synthesis or secretion of digestive enzymes.  
The wide spectrum of reported WFS1 mutations associated with WS by definition all result 
in presentation of diabetes mellitus and optic atrophy. What differs between affected 
individuals is the relative age of disease onset and the number of additional clinical features 
that present. We do not yet understand whether variability in disease severity and 
characteristics is solely dependent on background genetics, or whether the type of 
mutations involved play a large part in prognosis.  
WS-associated diabetes is thought to be caused by ER stress-mediated apoptosis of 
pancreatic β-cells and mounting evidence suggests other WS clinical features may arise due 
to similar mechanisms (Yoshida, 2007). Unsurprisingly wolframin seems to have an 
important role in regulation of the UPR, and when this function is impaired an uncontrolled 
stress response results, ultimately culminating in execution of apoptosis.  
Many specific links have been shown between wolframin and various components of stress 
response pathways (Yamada, 2005; Ueda, 2005; Fonseca, 2010), although it is unclear 
precisely how WFS1 mutation disrupts the normal UPR. Complete absence of wolframin 
would clearly abolish all related molecular interactions, but the question is whether all or 
only some of these interactions are critical for cell survival and adaptation to stress 
conditions? If some missense mutations confer at least a degree of function, it is possible 
CHAPTER 6 GENERAL DISCUSSION 
 
 
282 
 
that depending on genotype, only specific molecular interactions and downstream cascades 
are negatively affected. Could this partly explain the variation in WS phenotype, where not 
all wolframin pathways are disrupted allowing cells to cope with stress conditions for longer 
periods before the system breaks-down?   
A lack of wolframin protein is the likely cause of ER stress in patients carrying nonsense or 
frameshift mutations as these types of gene aberrations are known to result in unstable 
products. Previous studies suggest that the effects of missense mutations are less clear. 
Absence or depleted expression of wolframin has been documented in patient fibroblasts 
carrying selected WFS1 mutations (Philbrook, 2005). In vitro experiments have also shown 
that some WFS1 mutations may cause reduced steady-state protein expression as a result of 
instability (Hofmann, 2006), and provide evidence that some mutants may be susceptible to 
aggregation (Fonseca, 2005). If the effects of different mutations are variable on a molecular 
level an important question is raised: do WFS1 mutations directly contribute to ER stress, 
reduce the capability of a cell to effectively deal with stress conditions, or both? These 
outcomes may be dependent on the mutation-type. 
The majority of research efforts are focused on WFS1 knock-out or knock-down models, 
which draw parallels to situations of partial or complete deficiency in wolframin. This 
approach is fundamental for understanding what wolframin actually does by allowing a view 
of the system as a whole where wolframin function is totally abolished. Since WFS1 
missense mutations present not only in 31% of Wolfram syndrome patients (see section 
3.7.0) but in several other disease states, it might also be prudent to view the disruption of 
wolframin function from a genotypic perspective, which may shed light on the phenotypic 
heterogeneity of WS and the role of WFS1 in specific physiological systems, such as the 
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auditory or neuroendocrine systems. Although some functional studies have included a 
select few wolframin variants (Osman, 2003; Fonseca, 2005; Hofmann, 2006), they do not 
cover an extensive range of mutations, particularly missense changes, and also fail to 
correlate the functional data with associated physio-chemical characteristics and phenotypic 
effects of the mutation in question.  
Genetic (locus/allelic) heterogeneity in WS suggests that one of many perturbations in the 
complex system of cellular stress management results in the same eventual outcome, an 
inability to adapt to stress conditions resulting in cell-death. Although uncontrolled 
apoptotic cell-death is the common molecular feature of WS, the patho-mechanisms leading 
to this break-down and presentation of parallel clinical features are clearly different 
between WFS1 and WFS2 associated WS. It seems then very reasonable to suggest that 
different mutations in WFS1 could disrupt the function of wolframin in a number of ways 
with the same eventual outcome. If selected mutations do allow partial protein function, 
rather than abolishing protein function entirely, only specific molecular interactions may be 
interrupted, broadening the scope for therapeutic intervention in these cases.  
 
6.1.0  Future directions 
For comparative wild-type and mutant wolframin functional analyses an appropriate model 
system must firstly be developed. We intend to focus on cell types primarily affected in WS 
such as β-cells, neuronal cells, or retinal cells and compare wild-type with those carrying 
nonsense or missense WFS1 mutations. Producing cell lines with suitable genotypes is the 
important first stage of this process, and can be accomplished in a number of ways. The 
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overall aim is to replace wild-type WFS1 with variants of interest and is routinely 
accomplished by either temporarily or permanently ‘turning-off’ wild-type WFS1, then 
replacing this gene with an alternative copy harbouring a mutation.  
6.1.1  Wolframin-depletion 
Transient or stable WFS1 knock-down can be achieved in vitro with the application of siRNA 
technology. Alternatively, whole animal or organ specific WFS1 knock-out cells can be 
derived from selectively bred and genetically modified animals. Mutant copies of WFS1 can 
then be reintroduced by means of transfection or infection with lentiviral or adenoviral 
delivery vectors.    
RNA interference (RNAi) is a natural mechanism of gene silencing conserved in plant and 
mammalian cells, thought to play an important role in battling viral infection, fine tuning 
normal cellular gene expression and suppressing the movement of mobile genetic elements 
within the genome (McManus, 2002). The protein machinery comprising the RNAi pathway 
recognises double-stranded RNA and degrades it into smaller segments using an enzyme 
called dicer. These segments, known as short interfering RNAs (siRNA) are typically 21-23 
nucleotides in length and are subsequently used in an enzyme complex (RISC) as templates 
to prevent expression of complementary sequences of single-stranded RNA (Ketting, 2001). 
These can be engineered in the laboratory to complement specific gene sequences, and 
used to transiently induce gene knock-down following transfection into living cells (Fire, 
1998). They are particularly useful as a research tool because they are highly specific, 
versatile and efficient. To increase the short half-life of synthetic RNAi, eukaryotic 
polymerase III promoters can be employed to drive expression of siRNA from expression 
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cassettes, to produce small hairpin RNA (shRNA) structures (Paddison, 2002). This method 
allows more ‘stable’ gene silencing as the vectors are usually passed on to daughter cells.    
The greatest challenge for RNAi-based technology, is delivering these molecules to the 
cytoplasm of target cells as unmodified RNA cannot penetrate lipid plasma membranes. A 
number of techniques, each with their distinct advantages and limitations, are used to 
overcome this problem including: viral and bacterial delivery, liposomal and nanoparticle 
packaging, high-pressure injection and chemical modification. 
Stable knock-down of WFS1 in both mouse pancreatic (MIN6) and human neuroblastoma 
(SKNAS) cells are currently under development in the Birmingham laboratory. A selective 
murine breeding programme is also in place to create lines with conditional knock-out of 
WFS1 in pancreatic β-cells using a Cre-Lox recombination system. LoxP sequences contain 
specific binding sites for Cre, a DNA recombinase enzyme, which serves to splice specific 
target genes in vivo. A recombination event can take place in the cells of transgenic animals 
containing LoxP sites, when they also express Cre. Inversion, deletion or translocation of 
DNA segments may occur depending on the orientation of the LoxP sites. Two mouse lines 
are used to achieve targeted deletion of WFS1, one that is genetically modified to contain 
‘floxed WFS1’, where two LoxP sites flank a section of the gene, and another expressing Cre 
recombinase. Hybrid descendants containing both LoxP sites and the Cre recombinase 
consequently have gene inactivation. 
For future use in these murine model systems, a selection of mutations corresponding to 
those we have characterised in human cells have been introduced in the mouse wfs1 gene 
using site-directed mutagenesis (appendix 6).  
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6.1.2  Testing the model 
Once a suitable level of knock-down can be confirmed, the effects of such a reduction in 
gene expression must be demonstrable on the phenotypic level to provide a negative 
control against which to measure ‘normal’ unaltered systems and experimental samples. 
Furthermore the successful delivery of replacement gene copies must also be tested and 
verified with wild-type genes before considering the consequences of introducing ‘mutant’ 
copies. 
Depletion of WFS1 is associated with increased ER stress and apoptosis (Fonseca, 2005; 
Riggs, 2005; Yamada, 2006), perturbation of calcium homeostasis (Takei, 2006; Zatyka, 
2008b) and decreases in glucose stimulated insulin secretion (Zatyka, 2008b). Confirming 
the suitability of knock-down models can be tested by comparatively measuring these 
pathways in wild-type and WFS1-depleted cells. Once the effects of depletion have been 
verified, ‘rescue’ experiments can be performed to reintroduce wild-type WFS1 into 
depleted cells as a positive control to confirm successful delivery of the gene and 
restoration of a normal phenotype. An established knock-down model with all the necessary 
controls completed will then be taken forward to the experimental stage where the 
mutated versions of WFS1 can be re-introduced into depleted cells and the phenotype can 
be observed. 
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6.1.3  Wolframin functional assays 
A top down approach could be taken for examining the overall functional effects selected 
WFS1 missense variants have on ER stress and apoptosis, before considering more specific 
pathways in detail.  
ER stress and apoptosis 
Comparing efficiency of the UPR between wild-type cells and those harbouring mutations 
can be achieved by treating cells with chemical stress inducers, then probing for biomarkers 
of ER stress such as upregulation of UPR target genes XBP1, BiP, and CHOP (Samali, 2010). A 
number of reagents can be used to disrupt parts of the protein metabolism pathway causing 
accumulation of unfolded proteins; A23187 and thapsigargin disturb calcium homeostasis, 
tunicamycin suppresses glycosylation, and brefeldin A inhibits transport of proteins to the 
golgi complex (Ding, 2007).  The relative survival rates of normal and mutant cells under 
conditions of cellular stress would also reveal information about the ability of these cells to 
cope with, or resolve such stimulus before making a ‘switch’ to apoptotic pathways. 
Following up on previous evidence we could also examine how WFS1 mutations affect 
distinct pathways known to be perturbed by loss of wolframin function such as insulin 
secretion and calcium signalling/homeostasis (Ishihara, 2004; Zatyka, 2008b). We anticipate 
some possible limitations in WFS1-H611 function in relation to insulin secretion pathways 
and hope to shed some light on the role of this allele in type 2 diabetes susceptibility.  
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Chaperone activity 
Several lines of evidence suggest wolframin may act as a chemical chaperone (Hofmann, 
2003; Zatyka, 2008b). This function can be tested using unique biosensors that enable 
measurement of chaperone activity, such as cdYFP (chaperone-dependent yellow 
fluorescent protein). CdYFP is a chromophore with low fluorescence intensity as a result of a 
single point-mutation that prevents the correct folding of the protein (Liman, 2005). This 
construct has been developed in such a way that in the presence of chaperone activity, 
correction to the folding defects enables an increase in fluorescent signal intensity. Applying 
this technology to the study of wolframin may provide some solid evidence about the ability 
of this protein to assist in protein folding, and could provide some interesting clues about 
the role of wolframin in the UPR. If chaperone activity can be demonstrated, we may take 
this line of study further by examining the relative ability of our WF-mutants to perform this 
function. 
 
The effects of WFS1 mutation on protein interactions 
Testing the ability of selected wolframin variants to interact with known molecular partners 
may enable us to pinpoint a more clearly defined area hampered by loss of function.  
ATF6α 
A recent report detailed the negative regulation of ATF6α by wolframin (Fonseca, 2010). 
Wolframin was shown to stabilise HRD1, an E3 ligase for ATF6α and enhance the 
ubiquitination and proteasomal degradation of ATF6α. In stress conditions ATF6α is thought 
to be released from wolframin to initiate the UPR. Some WFS1 mutations (G695V and 
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P742L) previously shown to induce insoluble protein aggregates in the ER, result in loss of 
interaction with HRD1. Consequently ATF6α is hyper-activated leading to an uncontrolled 
UPR.   
Our data have shown that not all WS-associated missense mutations result in 
mislocalisation and aggregation of wolframin, even those corresponding to a severe 
phenotype (WFS1-G736A). We therefore propose that the loss of HRD1 binding and 
consequent effects on the UPR may also differ, dependent on mutation-type. We would like 
to investigate this possibility by looking more closely at ATF6α regulatory pathways in 
conjunction with our panel of selected variants to further define the importance of this link 
in WS pathogenesis. To this end, production of ATF6α expression constructs are currently in 
progress.  
The ability of wolframin variants to bind with other known partner-proteins can also be 
explored. We would like to concentrate our efforts primarily on interaction with the sodium-
potassium ATPase β1 subunit, which was first demonstrated in the Birmingham laboratory 
(Zatyka, 2008a). Following confirmation of our proposed molecular partners (chapter 5) we 
may also have one or more novel interactors to include in co-immunoprecipitation 
experiments with WFS1 mutants. 
 
6.2.0  Conclusions 
The heterogenic nature of WS can make accurate diagnosis difficult. This is exemplified in 
our study by the discovery of TRMA-associated mutations (in the SLC19A2 gene) in one of 
our probands who was initially thought to have Wolfram syndrome.  
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Mutational analysis of WS patients and compilation of clinical data continues to widen the 
spectrum of disease-associated WFS1 mutations and phenotypic variability. We have 
contributed to this end by expanding the mutational spectrum of WS with a number of 
novel WFS1 mutations and reporting the first case of WFS2-associated WS in a UK cohort. 
Larger data sets enable us to perform more detailed analysis so that we can uncover 
relationships between genetic anomalies and clinical manifestation. Our data concur with 
previous reported correlations between WS genotype and phenotype (Smith, 2004; Cano, 
2007; D’Annunzio, 2008) as we found that patients harbouring inactivating WFS1 mutations 
appeared susceptible to a relatively more severe phenotype than those with at least one 
missense mutation. In our cohort, patients with inactivating mutations presented with 
diabetes mellitus at an earlier median age and a higher proportion of these individuals also 
developed additional clinical features compared to patients carrying missense mutations.  
Several previous studies have reported ‘mild’ cases of WS where individuals presented with 
a relatively late onset of disease (Van Den Ouweland, 2003; Cano, 2007; Gasparin, 2009). In 
each of these cases, the affected individuals carried at least one missense mutation, which 
suggests that perhaps some WFS1 mutations allow partial protein function (wolframin). Our 
data support this hypothesis by providing evidence that some WFS1 missense mutations 
allow expression of WFS1 RNA and stable wolframin protein, which is localised correctly to 
the endoplasmic reticulum membrane. This provides the basis and rationale for further 
investigation of the ability of these ‘mutated’ proteins to function in various capacities 
known to be disrupted by depletion of WFS1 such as glucose-stimulated insulin secretion, 
calcium homeostasis and mediation of the UPR (Ishihara, 2004; Zatyka, 2008b; Fonseca, 
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2005). Selected variants with residual function may potentially be enhanced or restored by 
chemical chaperones, offering new perspectives for pharmacologic intervention. 
The inclusion and molecular characterisation of the WFS1-H611 allele, associated with type 
2 diabetes mellitus, also provides a foundation for studying the role of this variant in a more 
prevalent disease. To our knowledge, no functional analyses have yet been conducted on 
this diabetes ‘risk-gene’, therefore we intend to investigate the impact this WFS1 allele has 
on glucose-stimulated insulin secretion and the ability of pancreatic β-cells to effectively 
cope with ER-stress conditions. We hope to shed some light on this aspect of type 2 
diabetes pathogenesis and β-cell function. 
Any verifiable wolframin partner-proteins from our panel of candidates will also be included 
in our future work. Our evidence that WFS1 is expressed in the exocrine pancreas, together 
with identification of a number of pancreatic digestive enzymes as potential novel 
wolframin molecular-partners gives us grounds to examine the function of wolframin from a 
new perspective. Given the localisation to insulin secretory granules (Hatanaka, 2011), we 
speculate that wolframin may also have a role in the exocrine pancreas, possibly in the 
exocytotic secretory pathway. Possible association between wolframin and lipase/colipase 
perhaps suggests that wolframin could be an important link between lipid toxicity 
(hyperlipidemia) and type 2 diabetes mellitus?  
As a clearer picture of WS natural history emerges we may be able to relate genetic 
mutations more effectively to phenotypic outcomes enabling more accurate prognoses to 
be made, perhaps opening up the catchment for identifying affected individuals who may 
not present with the classical complement of WS features. The increasingly diverse range of 
clinical manifestations associated with WFS1 mutations raises an important question about 
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the stringency of current diagnostic criteria, principally juvenile-onset diabetes mellitus and 
optic atrophy.  
Our study of specific missense mutation of WFS1 relating to phenotype provides a 
complementary and novel approach to the classical study of wolframin mutation, which has 
previously been thought to cause loss of function.  We contend that WS may be a disease 
characterised by loss of protein function to different degrees, which could in part explain 
the extreme phenotypic variability associated with mutation of this gene. 
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Appendix 3. West Midlands Regional Wolfram syndrome patient database clinical information. Reported age of onset of all primary Wolfram syndrome features. 
KEY: DM – diabetes mellitus, OA – optic atrophy, DI – diabetes insipidus. 
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Appendix 4.  Genetic data (where available) for individuals listed on the West Midlands Regional Genetics 
WS database.  
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Appendix 4. Genetic data (where available) for individuals listed on the West Midlands Regional Genetics 
WS database.  
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Appendix 6. Site-directed mutagenesis of mouse wfs1. 
Appendix 5. Comparative haplotype analysis of individuals with WFS2-associated Wolfram syndrome. 
Microsatellite markers across a critical region of chromosome 4q22-24 analysed on an automated ABI3730 
sequencer using GeneScan Analysis software. Data contains the estimated size (base pairs) of detected 
fragments, confirming a shared haplotype between patient D01.11844 in this study and an affected 
individual from a previously described cohort of Jordanian-Bedouin descent (Amr, 2000). 
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Appendix 7. Clone set 1 harvested in RIPA buffer. Raw data figures for expression of WFS1 variants in HEK293 cells normalised to β-actin. 
Measurements are calculated in arbitrary units of absorbance (Gel.Doc). T= transfection replicate.     
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Appendix 8 Clone set 1 harvested in RIPA buffer. Steady-state expression in arbitrary units (AU) of WFS1 variants relative 
to wild-type over four repeat experiments (T=transfection replicate), and mean values for each variant. P.values are 
generated from two-tailed students T-test comparing relative expression of each variant to wild-type. 
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Appendix 9 Clone set 2 harvested in RIPA buffer. Raw data figures for expression of WFS1 variants in HEK293 cells normalised to β-actin. 
Measurements are calculated in arbitrary units of absorbance (Gel.Doc). T= transfection replicate.     
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Appendix 10 Clone set 2 harvested in RIPA buffer. Steady-state expression in arbitrary units (AU) of WFS1 variants relative to 
wild-type over three repeat experiments (T=transfection replicate), and mean values for each variant. P.values are generated from 
two-tailed students T-test comparing relative expression of each variant to wild-type. 
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Appendix 11 WFS1 measurements in supernatant harvested in RIPA buffer. Raw data figures for expression of WFS1 variants in HEK293 cells 
normalised to β-actin. Measurements are calculated in arbitrary units of absorbance (Gel.Doc). T= transfection replicate.     
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Appendix 12 WFS1 measurements in pellets harvested in RIPA buffer. Raw data figures for expression of WFS1 variants in HEK293 cells 
normalised to β-actin. Measurements are calculated in arbitrary units of absorbance (Gel.Doc). T= transfection replicate.     
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Appendix 13 Mean steady-state expression WFS1 variants relative to wild-type in both soluble and 
insoluble fractions of RIPA buffer lysates (n=3).  
T-Tests comparing differences between relative expression of WFS1 variants to wild-type in the 
soluble and insoluble fractions of RIPA lysates.  
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Appendix 14 Raw data figures for expression of WFS1 variants harvested from HEK293 cells in Laemmli buffer normalised to β-actin. 
Measurements are calculated in arbitrary units of absorbance (Gel.Doc). T= transfection replicate.     
APPEN
D
ICES 
 
    
 
Appendix 15 WFS1 variants harvested in Laemmli buffer. Steady-state expression in arbitrary units (AU) of WFS1 variants relative to wild-
type over three repeat experiments (set=transfection replicate), and mean values for each variant. P.values are generated from two-tailed 
students T-test comparing relative expression of each variant to wild-type. 
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Appendix 16A. Pilot data (n=2/3) showing relative stability of WFS1 variants over 48 hours. HEK293 cells 
transfected with WFS1 constructs were treated with 100µM cyclohexamide and harvested at time intervals of 
0, 6, 24 and 48 hours. Following SDS-PAGE and western blot analysis the relative stability of each variant was 
calculated by comparing protein levels (measured in arbitrary units) at each time interval relative to 0 hours.   
Marked inconsistencies (see standard error) in results suggested that extended chase-periods following 
cyclohexamide treatment was unsuitable for our system.  
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Appendix 16B. Graphical representation of pilot data (n=2/3) showing relative stability of WFS1 variants 
over 48 hours (see appendix 15A for details). 
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Appendix 17 Pilot data (n=2/3) showing relative stability measurements of WFS1 variants 6 hours 
following 100µM cyclohexamide treatment. 
Appendix 19 Two-tailed students T-test results comparing the 
differences in relative expression of variants 6 hours after 
cyclohexamide treatment. 
Appendix 18 Expression of WFS1 variants 6 hours following cyclohexamide treatment. Measured in 
arbitrary units relative to expression at 0 hours. 
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Appendix 20 Raw data for WFS1 expression following 100µM cyclohexamide treatment normalised with β-actin measurements. Figures are arbitrary units 
of absorbance (Gel.Doc). 
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Appendix 21 Raw data for WFS1 expression following 100µM cyclohexamide treatment normalised with β-actin measurements. Figures are 
arbitrary units of absorbance (Gel.Doc). 
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Appendix 22 Raw data for WFS1 expression following 100µM cyclohexamide treatment normalised with β-actin measurements. Figures are arbitrary 
units of absorbance (Gel.Doc). 
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Appendix 23 Average relative expression of WFS1 variants following 100µM cyclohexamide treatment 
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Appendix 24  Del-del-Ct and fold-change calculations from Taqman real-time PCR measurements of wild-type and mutant WFS1. 
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Appendix 25  Del-del-Ct and fold-change calculations from Taqman real-time PCR measurements of wild-type and mutant WFS1. 
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Appendix 26  Del-del-Ct and fold-change calculations from Taqman real-time PCR measurements of wild-type and mutant WFS1. 
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Appendix 27 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-WFS1 Ig (x40 mag). WFS1 Ig 1:50     
Appendix 27 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-WFS1 Ig (x40 mag). WFS1-Ig 1:100 
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Appendix 27 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-WFS1 Ig (x40 mag).  WFS1 Ig 1:200 
Appendix 28 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-PDI Ig (x40 mag).  PDI Ig 1:200 
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Appendix 28 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-PDI Ig (x40 mag).  PDI Ig 1:350 
Appendix 28 Antibody optimisation. COS7 cells fixed and stained with a dilution series of 
anti-PDI Ig (x40 mag).  PDI Ig 1:500 
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Appendix 29 COS7 cells fixed and stained for markers of the ER and presence of WFS1 (x100), contrast adjusted. (A 
and B) Examples of over-expressed WFS1-L511P. (C) Similar patterns of WFS1-P742L expression reported in 
previous study (From Fonseca, 2005).  
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Appendix 30 COS7 cells fixed and stained with anti-WFS1 Ig (x100), contrast adjusted. Further examples of over-expressed WFS1-L511P which produces a 
reticular, punctuate pattern of staining.  
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Appendix 31 Antibody optimisation for immunohistochemistry of rat pancreas (x100mag).  No primary controls with 
increasing RED channel exposure settings.  
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Appendix 32 Antibody optimisation for immunohistochemistry of rat pancreas (x100mag). No primary controls with 
increasing GREEN channel exposure settings.  
APPEN
D
ICES 
 
     
Appendix 33 Antibody optimisation for immunohistochemistry of rat pancreas (x100mag).  Anti-insulin antibody 
dilution series, exposure red 1 sec.  
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Appendix 34 Antibody optimisation for immunohistochemistry of rat pancreas (x100mag). Anti-WFS1 antibody 
dilution series, exposure green 3 sec.  
